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9CHAPTER 1 The energy-less red blood cell is lost –
General introduction and outline of the
thesis
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The moment the mature red blood cell leaves the bone marrow, it is optimally adapted to
perform the binding and transport of oxygen, and its delivery to all tissues. This is the most
important task of the erythrocyte during its estimated 120-day journey in the blood stream.
The membrane, hemoglobin, and proteins involved in metabolic pathways of the red blood
cell interact to modulate oxygen transport, protect hemoglobin from oxidant-induced
damage, and maintain the osmotic environment of the cell. The biconcave shape of the red
blood cell provides an optimal area for respiratory exchange. The latter requires passage
through microcapillaries, which is achieved by a drastic modification of its biconcave shape,
made possible only by the loss of the nucleus and cytoplasmic organelles and, consequently,
the ability to synthesize proteins.1
During their intravascular lifespan, erythrocytes require energy to maintain a number of vital
cell functions. These include (1) maintenance of glycolysis; (2) maintenance of the
electrolyte gradient between plasma and red cell cytoplasm through the activity of adenosine
triphosphate (ATP)-driven membrane pumps; (3) synthesis of glutathione and other
metabolites; (4) purine and pyrimidine metabolism; (5) maintenance of hemoglobin’s iron in
its functional, reduced, ferrous state; (6) protection of metabolic enzymes, hemoglobin, and
membrane proteins from oxidative denaturation; and (7) preservation of membrane
phospholipid asymmetry. Because of the lack of nuclei and mitochondria, mature red blood
cells are incapable of generating energy via the (oxidative) Krebs cycle. Instead, erythrocytes
depend on the anaerobic conversion of glucose by the Embden-Meyerhof Pathway and the
oxidative Hexose Monophosphate Shunt for the generation and storage of high-energy
phosphates (in particular ATP) and reductive potential in the form of glutathione and purine
nucleotides: reduced nicotinamide adenine dinucleotide (NADH), and nicotinamide adenine
dinucleotide phosphate (NADPH) (Figure 1).
In addition, erythrocytes possess a unique glycolytic bypass for the production of 2,3-
diphosphoglycerate (2,3-DPG): the Rapoport-Luebering Shunt. This shunt circumvents the
phosphoglycerate kinase (PGK) step and accounts for the synthesis and regulation of 2,3-
diphosphoglycerate (2,3-DPG) levels that decreases hemoglobin’s affinity for oxygen.2 In
addition, 2,3-DPG constitutes an energy buffer. 
Numerous enzymes are involved in the above-mentioned pathways and many red blood cell
enzymopathies have been described in the Embden-Meyerhof Pathway, the Hexose
Monophosphate Shunt, the Rapoport-Luebering Shunt, the glutathione pathway,
purine–pyrimidine metabolism and methemoglobin reduction.3-14 These enzymopathies
disturb the erythrocyte’s integrity and shorten its cellular survival, resulting in hemolytic
anemia.15 According to their clinical consequences, two groups of enzymopathies can be
distinguished. The first concerns deficiencies in enzymes involved in the Embden-Meyerhof
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Pathway and purine–pyrimidine metabolism. Ultimately, these deficiencies impair ATP
production, leading to chronic nonspherocytic hemolytic anemia (CNSHA). The most
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Figure 1. Schematic overview of the Embden-Meyerhof Pathway, the Hexose Monophosphate Shunt,
the Rapoport-Luebering Shunt, and the Glutathione Pathway.
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common cause of CNSHA is pyruvate kinase (PK) deficieny. Second, disorders concerning
the Hexose Monophosphate Shunt, which maintains adequate levels of reduced glutathione
(GSH). This group of disorders is associated with hemolytic episodes, induced by oxidative
stress, drugs, or infections. Deficiency of glucose-6-phosphate dehydrogenase (G6PD) is the
most frequently encountered enzymopathy in this group. In general, the degree of hemolysis
is dependent on the relative importance of the affected enzyme and the properties of the
mutant enzyme with regard to functional abnormalities or instability, or both. The ability to
compensate for the enzyme deficiency by overexpressing isozymes or using alternative
pathways contribute to the clinical picture of patients with red blood cell enzymopathies. A
frequently observed response to compensate for anemia is increased erythrocyte production
(reticulocytosis). Reticulocytosis (reticulocytes normally comprise 0.5 to 2.5% of total
erythrocytes) is an important sign of hemolysis. Reticulocytes still preserve cytoplasmic
organelles, including ribosomes and mitochondria, and are thus capable of protein synthesis
and the production of ATP by oxidative phosphorylation. Several enzymes including
hexokinase (HK), PK, G6PD, aldolase, and pyrimidine 5’-nucleotidase (P5’N) display much
higher activity in reticulocytes and are often referred to as the age-related enzymes.16
A number of red blood cell enzymopathies concern enzymes expressed in other tissues as
well. The deficiency is, however, more pronounced in red blood cells, when compared to
other cells, because of the long life span of the mature erythrocyte after the loss of protein
synthesis.17 Therefore, once an enzyme in red blood cells is degraded or has otherwise
become nonfunctional, it cannot be replaced by newly synthesized proteins. Some enzyme
deficiencies (e.g. triosephosphate isomerase deficiency) may involve cells other than the red
blood cell as well. By far the majority of red cell enzymopathies are hereditary in nature,
although acquired deficiencies have also been described, mainly in malignant hematological
disorders.18-21
In this chapter, a summary is made of the major features regarding the biochemical,
structural and genetic basis of clinically relevant red blood cell enzymopathies involved in
the Embden-Meyerhof Pathway, the Rapoport-Luebering Shunt, the Hexose Monophosphate
Shunt, and the Glutathione Pathway.
The Embden-Meyerhof Pathway
Glucose is the energy source of the red blood cell. Under normal physiological
circumstances (i.e no excessive oxidative stress), 90% of glucose is catabolized
anaerobically to pyruvate or lactate by the Embden-Meyerhof Pathway, or glycolysis (Figure
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1). Although one mole of ATP is used by HK, and an additional mole of ATP by
phosphofructokinase (PFK), the net gain is two moles of ATP per mole of glucose, because
a total of four moles of ATP are generated by PGK and PK. In addition, reductive potential
is generated in the form of NADH, in the step catalyzed by glyceraldehyde-3-phosphate
dehydrogenase (GA3PD). This reducing energy can be used to reduce methemoglobin to
hemoglobin by NADH-cytochrome b5 reductase (cytb5r). If this reaction takes place, the end
product of the glycolysis is pyruvate. However, if NADH is not reoxidized here, it is used in
reducing pyruvate to lactate by lactate dehydrogenase (LD) in the last step of the glycolysis. 
The Embden-Meyerhof Pathway is subjected to a complex mechanism of inhibiting and
stimulating factors. The overall velocity of red blood cell glycolysis is regulated by three
rate-limiting enzymes, HK, PFK, and PK, and by the availability of nicotinamide adenine
dinucleotide (NAD) and ATP. Some glycolytic enzymes are allosterically stimulated (e.g.
fructose-1,6-diphosphate (FBP) for PK) or inhibited (e.g. glucose-6-phosphate (G6P) for
HK) by intermediate products of the pathway.
In general, enzymopathies of the Embden-Meyerhof Pathway cause CNSHA. The continous
lack of sufficient energy and other metabolic impairments results in a shortened lifespan of
the mature red blood cell, albeit with variable clinical severity. The chronic nature of
hemolysis contrasts with the periodic hemolytic episodes that characterize most cases of
G6PD deficiency (see below). The lack of characteristic changes in red blood cell
morphology differentiates the glycolytic enzymopathies from erythrocyte membrane defects
and most hemoglobinopathies. 
Hexokinase
Hexokinase catalyzes the phosphorylation of glucose to G6P, using ATP as a phosphoryl
donor (Figure 1). As the initial step of glycolysis, HK is one of the rate-limiting enzymes of
this pathway. The activity of hexokinase is significantly higher in reticulocytes compared to
mature red cells, in which it is very low. In fact, of all glycolytic enzymes, HK has the lowest
enzymatic activity in vitro.14
In mammalian tissues four isozymes of HK with different enzymatic properties exist, HK-I
to III, with a molecular mass of 100 kDa, and HK-IV (or glucokinase), with a molecular
mass of 50 kDa. HK-I to III are considered to be evolved from an ancestral 50 kDa HK by
gene duplication and fusion.22 Consequently, both the C- and N-terminal halves of HK-I to
III show extensive internal sequence similarity but only in case of HK-II is catalytic function
maintained in both the C- and N-terminal halves. HK-I and HK-III have further evolved into
enzymes with catalytic (C-terminal) and regulatory (N-terminal) halves, respectively. HK-I
is the predominant isozyme in human tissues that depend strongly on glucose utilisation for
Chapter 1
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their physiological functioning, such as brain, muscle and erythrocytes. HK-I displays
unique regulatory properties in its sensitivity to inhibition by physiological levels of the
product G6P and, moreover, relief of this inhibition by inorganic phosphate (Pi).23,24
The recent determination of the structures of the human and rat HK-I isozymes have
provided substantial insight into ligand binding sites and subsequent modes of interaction of
these ligands (Figure 2).25-28 The mode of inhibition by G6P remains subject to debate.25-34
Erythrocytes contain a specific subtype of HK (HK-R)35 that is encoded by the HK-I gene
(HK1), localized on chromosome 10q2236 and spanning more than 100 kb.37 The structure
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Figure 2. Hexokinase I monomer in complex with glucose, phosphate, and ADP. The C- and N-
terminal halves are colored blue and red, respectively.
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of HK1 is complex. It encompasses 25 exons, which, by tissue-specific transcription,
generate multiple transcripts by alternative splicing of different 5’ exons.37 Erythroid-
specific transcriptional control results in a unique red blood cell-specific mRNA that differs
from HK-I transcripts at the 5’ untranslated region (5’-UTR) and at the first 63 nucleotides
of the coding region.38-40 Consequently, HK-R lacks the porin-binding domain that mediates
HK-I binding to mitochondria.38
Hexokinase deficiency (MIM 235700) is a rare autosomal, recessively inherited disease with
CNSHA as the predominant clinical feature. As with most glycolytic red cell enzyme
deficiencies the severity of hemolysis is variable, ranging from severe neonatal hemolysis
and death to a fully compensated chronic hemolytic anemia. Splenectomy is in general
beneficial. Seventeen families with hexokinase deficiency have been described to date41 and
only three patients have been characterized at the molecular level.42-45 One compound
heterozygous patient carried a missense mutation that encoded a leucine to serine
substitution at residue 529. An as yet unidentified mutation on the other allele caused
skipping of the sixth exon, as detected in this patient’s cDNA.42,43 One other patient was
homozygous for a missense mutation that predicted the substitution of a highly conserved
threonine by serine at residue 680 in the enzyme’s active site, where it interacted with
phosphate moieties of adenosine diphosphate (ADP), ATP and G6P.45 The last case
constituted a lethal out-of-frame deletion of  exons 5 to 8 of HK1. This deletion was
identified in the homozygous state in a fetus who died in utero.44
Glucose-6-Phosphate Isomerase
Glucose 6-phosphate isomerase (GPI) catalyzes the interconversion of G6P into fructose-6-
phosphate (F6P) in the second step of the Embden-Meyerhof Pathway (Figure 1). As a result
of this reversible reaction, products of the Hexose Monophosphate Shunt can be recycled to
G6P. Unlike HK and other age-related enzymes, the GPI activity in reticulocytes is only
slightly higher than that of mature erythrocytes. Apart from its role in glycolysis, GPI exerts
cytokine properties outside the cell and is involved in several extracellular processes.46
Because GPI knock-out mice die in the embryological state, GPI is considered to be a crucial
enzyme.47,48
Recently, the crystal structure of human GPI was resolved. The enzyme is a homodimer,
composed of two 63-kDa subunits of 558 amino acids each. The active site is composed of
polypeptide chains from both subunits. Thus, formation of the dimer is a prerequisite for
catalytic activity.49,50 The structural gene coding for GPI (GPI) is located on chromosome
19q13.1.51 GPI spans at least 50 kb and consists of 18 exons that are transcribed into a cDNA
of 1.9 kb in length.52
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GPI deficiency (MIM 172400) is an autosomal recessive disease and is second to PK
deficiency in frequency. Approximately 50 families with GPI deficiency have been described
worldwide.53 Homozygous or compound heterozygous patients have chronic hemolytic
anemia of variable severity and display enzymatic activities of less than 25% of normal.
Splenectomy is often beneficial. Hemolytic crises may be triggered by viral or bacterial
infections but, in contrast to G6PD deficieny, drug-induced hemolysis is rare.54,55 A few
patients displayed hemolytic crises after oxidative stress.56-59 Hydrops fetalis appears more
common in GPI deficiency than in other enzyme deficiencies.58,59 In rare cases, GPI
deficiency also affected non-erythroid tissues, causing neurological symptoms and
granulocyte dysfunction.60 Normally, GPI is very stable but a striking feature of nearly all
GPI mutants is their thermolability, whereas kinetic properties are more or less unaffected.
Twenty-nine mutations have been detected in GPI, 24 of which were missense mutations,
three were nonsense mutations, and two mutations affected splice sites.53 Mapping of these
mutations to the crystal structure of human GPI has provided insight in the molecular
mechanisms causing hemolytic anemia in this disorder. In accordance with the three-
dimensional structure, mutations could be categorized into three distinct groups that affected
(1) the overall structure, (2) the dimer interface and (3) the active site.50
Phosphofructokinase
Phosphofructokinase catalyzes the, rate-limiting, ATP-mediated phosphorylation of F6P to
FBP (Figure 1). PFK is a homo- or heterotetramer with a molecular mass of approximately
380 kDa, and the enzyme is allosterically regulated, among other metabolites, by 2,3-DPG.61
Three different subunits have been identified in humans: PFK-M (muscle), PFK-L (liver) and
PFK-P (platelet).62 The subunits are expressed in a tissue-specific manner and, in
erythrocytes, five isoenzymes of varying subunit composition (M4, M3L1, M2L2, ML3, and
L4) can be identified.63 The cDNAs for all three subunits have been cloned.64-66 The gene
encoding the M subunit (PFKM) has been reassigned to chromosome 12q13.367 and spans
30 kb. It contains 24 exons and contains at least two promoter regions.68 The L-subunit
encoding gene (PFKL) contains 22 exons and spans more than 28 kb.69 It is located on
chromosome 21q22.3.70
PFK deficiency (MIM 171850) is a rare autosomal, recessively inherited disorder. Because
red blood cells contain both M- and L-subunits, mutations affecting either of both genes will
affect enzyme activity. Thus, mutations concerning the L subunit will render red blood cells
that contain only M4 and, consequently, they are PFK deficient. In such cases, patients
display a mild hemolytic disorder without myopathy. Alternatively, a deficiency of the M
subunit results in the absence of muscle PFK and, in addition, causes a partial PFK
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deficiency in erythrocytes. Accordingly, deficiency of the M subunit causes myopathy and a
mild hemolytic disorder. Erythrocytes that express only the L4 PFK also show a metabolic
block at the PFK step in glycolysis and lowered 2,3-DPG levels. To date, 15 PFK deficient
PFKM alleles from more than 30 families have been characterized.71 One-third of the
reported patients are of Jewish origin and in this population an intronic splice site mutation,
IVS5+1G>A,72 and a single base-pair deletion in exon 22, c.2003delC,73 are among the most
frequently encountered mutations. Patients usually have only a mild, well compensated
hemolytic anemia with an enzyme activity of approximately half normal. 
Aldolase
Aldolase catalyzes the reversible conversion of fructose-1,6-biphosphate to glyceraldehyde-
3-phosphate (GA3P) and dihydroxyacetone phosphate (DHAP) (Figure 1). Aldolase is a
tetramer of identical subunits of 40 kDa each, and three distinct isoenzymes have been
identified, aldolase A, B and C. Erythrocytes, muscle and brain express the 364 amino acids
long aldolase A subunits. The gene for aldolase A (ALDOA) is located on chromosome
16q22–q24.74 It spans 7.5 kb and consists of 12 exons. Multiple transcription-initiation sites
have been determined and ALDOA pre-mRNA is spliced in a tissue-specific manner.75
Aldolase deficiency (MIM 103850) is a very rare disorder and only five patients from four
families have been described.76-79 They all displayed moderate chronic hemolytic anemia.
Enzyme stability was decreased in a boy described by Beutler et al. In addition to hemolytic
anemia, this patient also displayed mental retardation and dysmorphic features.76 The two
patients reported by Miwa et al.77 suffered from severe hemolytic anemia, exacerbated by
infection, but none of the features described by Beutler et al. In one of these patients the
causative mutation concerned a homozygous substitution of aspartic acid to glycine at
residue 128.80 The patient reported by Kreuder et al. suffered from hemolytic anemia,
myopathy and psychomotor retardation. In this case, aldolase deficiency was caused by an
ALDOA missense mutation that predicted a glutamate to lysine substitution at residue 206.78
Recently, a patient was described with CNSHA and severe rhabdomyolysis but normal
cognitive function. This patient showed severe clinical symptoms and, ultimately, died at the
age of four years. She was compound heterozygous for a null mutation, Arg303Stop, and a
missense mutation, Cys338Tyr, near a critical region in aldolase A.79
Triosephosphate Isomerase
Triosephosphate isomerase (TPI) is the glycolytic enzyme with the highest activity in vitro.14
TPI catalyzes the interconversion of GA3P and DHAP. It consists of a dimer with two
identical subunits of 248 amino acids (27 kDa).81 No TPI isozymes are known but three
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distinct electrophoretic forms can be distinguished as a result of post-translational
modifications.82,83 In red blood cells, TPI activity is not maturation dependent.
TPI deficiency (MIM 190450) is a rare autosomal recessive disorder, characterized by
hemolytic anemia at onset, often accompanied by neonatal hyperbilirubinemia requiring
exchange transfusion. In addition, patients display progressive neurological dysfunction,
increased susceptibility to infection, and cardiomyopathy. Affected individuals often die in
childhood.84 Patients show an 20- to 60-fold increased DHAP concentration in their
erythrocytes,85 consistent with a metabolic block at the TPI step.
TPI is transcribed from a single gene (TPI1) on chromosome 12p1386 that consists of seven
exons and spans 3.5 kb.87 Three processed pseudogenes have been identified.87 Fourteen
mutations have been described in TPI1 and the most frequently ocurring mutation (74%)
causes a glutamine to aspartic acid change at residue 104.88 This substitution likely perturbs
the local structure of the active site.81 Haplotype analysis strongly suggested a single origin
for this mutation whereby the common ancestor originated from Northern Europe.89 This is
in agreement with the European origin of almost all TPI-deficient individuals.
Phosphoglycerate Kinase
Phosphoglycerate kinase generates one molecule of ATP by catalyzing the reversible
conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate (Figure 1). This reaction can be
bypassed by the Rapoport-Luebering shunt (see below) with the consequent loss of one ATP
molecule. Two isozymes of PGK exist, PGK-1, ubiquitously expressed in all somatic cells,
and PGK-2, expressed only in spermatozoa.90 PGK-1 is a 48-kDa monomer consisting of
417 amino acids.91,92 The three-dimensional structure of horse muscle PGK, highly
homologous to the human enzyme, revealed that PGK consists of two domains. These
domains are connected by a conserved hinge, allowing for conformational freedom.93 The
ADP/ATP binding site is located on the C-terminal domain while phosphoglycerates bind the
N-terminal domain. A conformational rearrangement involving bending of the hinge occurs
upon binding of both substrates, bringing them in position for phosphate transfer.94
The gene encoding PGK-1 (PGK1) is located on Xq13.3,95 thereby rendering PGK
deficiency an X-linked disorder. PGK1 spans 23 kb and is composed of 11 exons.96
PGK deficiency (MIM 311800) is characterized by chronic hemolytic anemia (often fully
compensated), dysfunction of the central nervous system, and myopathy. However, the
phenotype of PGK-1 deficiency is highly variable because patients usually do not display all
three clinical features.97 PGK activity varies between 0 and 20% of normal but there is no
correlation of residual enzymatic activity with clinical severity. Fourteen different mutations
in PGK1 have been described in association with PGK deficiency.71 Most of these mutations
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are missense mutants of which one, in addition to encoding a non-conserved Glu252Ala
substitution, resulted in aberrant splicing with a consequent 90% reduction in mRNA
levels.98
Pyruvate Kinase
Pyruvate kinase catalyzes the irreversible phosphorylgroup transfer from
phosphoenolpyruvate (PEP) to ADP, yielding pyruvate and the second mole of ATP in
glycolysis (Figure 1). PK is a key regulatory enzyme of glycolysis, and pyruvate is crucial
for several metabolic pathways. The enzyme is active as a tetramer, and four different
isozymes are expressed in mammals. The M1 isozyme is expressed in skeletal muscle, heart,
and brain. It is the only isozyme that is not subjected to allosteric regulation. The M2
isozyme is expressed in early fetal tissues, but also in most adult tissues, including
leucocytes and platelets. L-type PK is predominately expressed in the liver whereas R-type
PK expression is confined to the red blood cell.99-101 In basophilic erythroblasts, both PK-R
and PK-M2 are expressed. During further erythroid differentiation and maturation, a switch
in isozymes occurs whereby progressively increased PK-R expression gradually replaces
PK-M2.102-105 This is in part due to changes in protein synthesis and degradation rates.106
Human red blood cell PK consists of two distinct species, R1 and R2. R1 PK predominates
in reticulocytes and young erythrocytes, whereas mature red blood cells mainly possess R2
PK.107-109 R1 PK is a homotetramer composed of four PK-R, also called L’, subunits (L’4).
Limited proteolytic degradation of the 63 kDa PK-R subunit renders a 57-58 kDa PK-L
subunit that is incorporated in the heterotetramer R2 PK (L2L’2).108,110,111 The enzymatic
activity of PK decreases with increasing cell age of the erythrocyte. PK is allosterically
activated by PEP and FBP, and negatively regulated by its product ATP.112,113 Furthermore,
PK has an absolute requirement for cations, normally Mg2+ and K+.114,115
Recently, the three-dimensional structure of human erythrocyte PK was elucidated.116 Each
PK-R subunit can be divided into four domains (Figure 3), the N domain (residues 1 to 84),
A domain (residues 85–159 and 263–431), B domain (residues 160–262) and C domain
(residues 432–574).116 Domain A is the most highly conserved whereas the B and C domain
are more variable.117 The active site lies in a cleft between the A domain and the flexible B
domain. The B domain is capable of rotating away from the A domain generating either the
‘open’ or ‘closed’ conformation. The C domain contains the binding site for FBP. The
allosteric transition from the inactive T-state to the active R-state involves the simultaneous
and concerted rotations of entire domains of each subunit, in such a way that all subunit and
domain interfaces are modified.118,119 The allosteric and catalytic sites are able to
communicate with each other across the relatively long distance that separates the FBP
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binding site from the catalytic center. The A/A’ and C/C’ subunit interface interactions and
the A/B interdomain interactions are considered key determinants of the allosteric
response.116,119-124
The gene encoding the PK-M1 and PK-M2 subunits is located on chromosome 15q22125 and
the respective subunits of 531 amino acids each are produced by alternative splicing.126,127 The
PK-R and PK-L subunits are transcribed from a single gene (PKLR), located on chromosome
1q21,128,129 by the use of alternative promoters.99,130-133 The gene consists of 12 exons and
spans 9.5 kb.134,135 Exon 1 is erythroid-specific and exon 2 is liver specific. Exons 3 to 12 are
20
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Figure 3. Pyruvate kinase monomer, The A, B, C, and N domains are colored blue, purple, green, and
red, respectively. The position of bound phosphoenolpyruvate is indicated by a red sphere.
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included in both mRNAs and encode a PK-R subunit of 574 amino acids, whereas the PK-L
subunit comprises 531 amino acids.
PK deficiency (MIM 266200) is the most common cause of nonspherocytic hemolytic anemia
due to defective glycolysis and is inherited in an autosomal recessive manner. The estimated
prevalence is 51 cases (i.e. homozygous or compound heterozygous patients) per million in the
white population.136 The continous lack of sufficient energy for normal functioning shortens
the life-span of the mature PK-deficient erythrocyte and results in non-spherocytic hemolytic
anemia. 2,3-DPG levels are generally increased, thus ameliorating the anemia by lowering the
oxygen-affinity of hemoglobin.137 Phenotypically, the clinical picture varies from severe
hemolysis causing neonatal death to a well compensated hemolytic anemia. Some PK-deficient
patients present with hydrops fetalis.138 Reticulocytosis is almost always observed.
Splenectomy often ameliorates the hemolysis, especially in severe cases, and increases the
reticulocyte counts even further. To date, more than 150 mutations in PKLR have been reported
to be associated with pyruvate kinase deficiency.139,140 A schematic overview is presented in
Figure 4. Most (70%) mutations in PKLR are missense mutations concerning conserved
residues in structurally and functionally important domains of PK. In the European and North-
American population, the most frequently detected mutations are missense mutants c.1456C>T
(Arg486Trp),141 c.1529G>A (Arg510Gln),141 c.994G>A (Gly332Ser),142 and nonsense
mutant c.721G>T (Glu241Stop).141 One large, in-frame deletion, has been described in
PKLR.143 There appears to be no direct relationship between the nature and location of the
substituted amino acid and the type of molecular perturbation.116,144 One transcriptional
mutant is of particular interest because it silences erythroid-specific PKLR transcription
completely.145 The causative single-base change disrupts a putative binding domain for an as
yet unidentified trans-acting factor that mediates the effects of factors necessary for regulation
of PK gene expression during red cell differentation and maturation.145
Glyceraldehyde-3-phosphate Dehydrogenase, Monophosphoglycerate Mutase, Enolase,
and Lactate Dehydrogenase
Red blood cell deficiencies of glyceraldehyde-3-phosphate dehydrogenase146,147 and
enolase148 have been described in association with hemolytic anemia but a causal
relationship was not established.
Monophosphoglycerate mutase (MPGM) in erythrocytes is a homodimer, composed of two
subunits BB. Deficiency of this subunit, that is expressed in many other tissues as well, has
not been reported.
Deficiencies of either the H (B) or M (A) subunits of lactate dehydrogenase have been
reported. However, neither defiency causes hemolytic anemia, despite strongly reduced
22
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enzymatic activity.149 Interestingly, homozygous LDH M subunit deficiency in mice is
associated with chronic hemolytic anemia.150
Rapoport-Luebering Shunt
In the erythrocyte, 2,3-DPG is synthesized and dephosphorylated in the Rapoport-Luebering
Shunt. Both reactions are catalyzed by one multifunctional protein that posesses
diphosphoglycerate mutase (DPGM) and diphosphoglycerate phosphatase (DPGP)
enzymatic activities (Figure 1).151,152 This erythroid-specific enzyme153 regulates 2,3-DPG
levels in the red blood cell and is very important in regulating the oxygen affinity of
hemoglobin. DPGM is a homodimer, with 30-kDa subunits consisting of 258 amino acids.
The Rapoport-Luebering Shunt is unique to mammalian red blood cells and represents the
principal physiological means to regulate oxygen affinity of hemoglobin.154-156 From an
oxygen-transport point of view, the Embden-Meyerhof pathway serves mainly the generation
of 2,3-DPG because this is quantitatively the major glycolytic intermediate in the red blood
cell and its levels are about equal to the sum of the other glycolytic intermediates. The
oxygen affinity of hemoglobin is also influenced by slight changes of blood pH, and a
corresponding sensitivity for the pH exists in the Rapoport-Luebering Shunt that, again,
permits changes in 2,3-DPG contents to fine-tune the oxygen affinity of hemoglobin. In PK
deficiency 2,3-DPG is increased as a result of the metabolic block at the PK step and of a
retrograde accumulation of products of glycolysis. The increased 2,3-DPG levels result in a
decreased oxygen affinity of hemoglobin so that oxygen is more readily transferred to tissue.
This beneficial circumstance is absent in those glycolytic enzyme defects that cause a
decrease in 2,3-DPG levels, e.g. HK and GPI deficiency. 
The gene for DPGM (DPGM) has been mapped to chromosome 7q31-34157 and it consists
of three exons, spanning more than 22 kb.158 DPGM deficiency (MIM 222800) is a very rare
autosomal recessive disorder and only a few cases have been described, all belonging to one
French family.159 Patients had severely reduced 2,3-DPG levels and increased ATP levels.
They were clinically normal and displayed no hemolytic anemia. Instead, they presented
with erythrocytosis that likely resulted from the reduced 2,3-DPG levels and, consequently,
the increased oxygen affinity of hemoglobin. These patients were compound heterozygous
for a single-nucleotide change in DPGM that predicted the replacement of the highly
conserved arginine at residue 89 by cysteine (DPGM Créteil I), and a single-nucleotide
deletion that introduces a premature stopcodon and, consequently, encodes a truncated
peptide (DPGM Créteil II).160
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Hexose Monophosphate Shunt (Pentose Phosphate Shunt)
Approximately 10% of glucose in red blood cells is normally catabolized by the Hexose
Monophosphate Shunt (or Pentose Phosphate Shunt). However, in case of oxidative stress,
e.g. during infection or evoked by the use of certain drugs, this fraction may be markedly
increased. The principal function of the Hexose Monophosphate Shunt is to produce two
NADPH molecules from NADP via the oxidation of G6P. NADPH is required for a variety
of biosynthetic pathways, for the stability of catalase, and the regeneration and preservation
of the reduced form of glutathione (Figure 1). These processes are crucial to protect the cell
against oxidative stress. Because of the lack of other sources of NADPH, the erythrocyte
relies strongly on the key enzyme of this reaction, glucose-6-phosphate dehydrogenase.
Each of two enzymes, G6PD (see below) and 6-phosphogluconate dehydrogenase (6PGD),
generate one molecule of NADPH in the Hexose Monophosphate Shunt (Figure 1). In
contrast to G6PD deficiency, hereditary 6PGD deficiency does not cause hemolytic anemia,
even in the homozygous condition.161
Glucose-6-Phosphate Dehydrogenase
Glucose-6-phosphate dehydrogenase is expressed in all cells and catalyzes the first step in
the Hexose Monophosphate Shunt that involves the conversion of glucose-6-phosphate to 6-
phosphogluconate (Figure 1). This step generates one mole of NADPH. G6PD is an essential
enzyme because total lack of G6PD has been shown to be a lethal condition at an early stage
The energy-less red blood cell is lost 
Figure 5. A dimer of human glucose-6-phosphate deydrogenase. Subunits A and B are colored red and
blue. Structural NADP+ molecules are drawn in ball-and-stick mode and colored dark blue.
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in embryonic development.162 G6PD activity is higher in reticulocytes than in mature
erythrocytes. Under physiological conditions, the active human enzyme exists in a dimer-
tetramer equilibrium. Lowering the pH causes a shift towards the tetrameric form.163
The crystal structure of human G6PD was recently elucidated.164 G6PD consists of
identical 59 kDa subunits of 515 amino acids long. Each subunit is comprised of two
domains, an N-terminal domain and a large β/α domain with an antiparallel nine-stranded
sheet (Figure 5).  The extensive interface between the two monomers is of crucial
importance for enzymatic stability and activity.164
The gene encoding G6PD (G6PD) is located on the X-chromosome (Xq28),165 spans 18 kb
and consists of 13 exons of which exon 1 is noncoding. The promoter shares many features
common to other housekeeping genes.166
G6PD deficiency (MIM 305900) is the most common enzymopathy, affecting more than
400 million people worldwide. Five different syndromes can be distinguished: (1) drug-
induced hemolysis, (2) infection-induced hemolysis, (3) favism, (4) neonatal jaundice, and
(5) CNSHA. The majority of G6PD-deficient individuals develop hemolysis only in
response to oxidative stress, after intake of certains drugs, during infections, or after
consumption of fava beans. Apart from these acute hemolytic episodes these patients are
usually asymptomatic. In contrast, the most severe form of G6PD deficiency causes mild to
severe chronic hemolysis, exacerbated by oxidative stress. More than 400 different G6PD
variants have been described, associated with a wide range of biochemical characteristics
and phenotypes.167 Accordingly, five classes of G6PD-deficient variants can be
distinguished.168
Class I severe deficiency, associated with CNSHA
Class II severe  deficiency (< 10% residual activity) but no CNSHA
Class III moderate to mild deficiency (10–60% residual activity) (e.g. G6PD A–)
Class IV very mild or no deficiency (e.g. G6PD A)
Class V increased enzymatic activity (only one known variant, G6PD Hektoen)  
Nearly half of the mutations encoding class I G6PD variants directly affect the subunit
interface of the G6PD dimer.164,169,170 However, identical variants may still lead to different
phenotypes.171,172 One well-established genetic determinant accounting for the phenotypic
variability in G6PD deficiency, in particular with regard to neonatal jaundice, is represented
by the co-inheritance of Gilbert’s syndrome.173,174 The genetic basis of Gilbert’s syndrome
constitutes a polymorphic dinucleotide insertion repeat in the promoter of UGT1, the gene
that codes for UDP glucuronosyltransferase 1. This enzyme catalyzes bilirubin conjugation
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by the liver and the presence of a variant promoter is actively involved in the pathogenesis
of G6PD deficiency-associated hyperbilirubinemia.175,176
For further reading regarding G6PD (deficiency) we refer to excellent reviews by Beutler,177
Dacie,178 Luzzatto,179 and Vulliamy.167
The Glutathione Pathway
The sulfhydryl-containing tripeptide reduced glutathione protects hemoglobin and other
essential proteins in the red blood cell from peroxidative injury. In this process, which
involves the reduction of peroxides or oxidized protein sulfhydryl groups, GSH is converted
to oxidized glutathione (GSSG). 
GSH synthesis – γ-Glutamylcysteine Synthetase, and Glutathione Synthetase
The first step in glutathione biosynthesis involves the synthesis of glutamylcysteine from L-
glutamate, L-cysteine, and ATP. This rate-limiting step in glutathione synthesis is ATP-
dependent and catalyzed by γ-glutamylcysteine synthetase (GC-S). There is a feedback
inhibition by reduced glutathione. GC-S is a heterodimer composed of a catalytic 73 kDa
heavy chain (GC-Sh) and a regulatory 31 kDa light chain (GC-Sl).180,181 These subunits are
encoded by separate genes, located on chromosome 6p12 (GCLC)182 and 1p21 (GCLM),183
respectively.
Hereditary GC-S deficiency (MIM 606857) is a very rare autosomal recessive disorder. It is
associated with mild CNSHA that may be fully compensated. Drug- and infection-induced
hemolytic crises may occur. Only 10 patients have been described, five of which were
characterized at the molecular level.184-186 One mutation predicted the substitution of
histidine by leucine at residue 370 of GC-Sh, probably resulting in an unstable protein.184
Two other, related, patients were homozygous for a GC-Sh variant that harboured a leucine
instead of proline at residue 158.185 Recently, two other related patients were reported that
carried a missense mutation, coding for arginine instead of cysteine at residue 127 of GC-Sh.
This variant was associated with decreased GSH production and markedly decreased
enzymatic activity.186
The second step in GSH synthesis involves the addition of glycine to the dipeptide γ-
glutamylcysteine. This irreversible and ATP-dependent reaction is mediated by glutathione
synthetase (GSH-S). GSH-S is a homodimer of 52 kDa187 and the 23 kb gene coding for
GSH-S (GSS) is located on chromosome 20q11.2.188
Only a few cases of GSH-S deficiency (MIM 601002) have been reported and these were
The energy-less red blood cell is lost 
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associated with mild chronic hemolytic anemia.188,189 GSH-S deficiency is inherited in an
autosomal recessive manner and patients may be susceptible to more severe, acute hemolytic
crises when exposed to ‘oxidant’ substances. Two distinct types of GSH-S deficiency can be
distinguished. Both types share the existence of mild chronic hemolysis and this is the
predominant clinical feature of the first type of GSH-S deficiency. However, in patients with
the second and more severe form, the major features are mental retardation, severe
generalized muscle weakness, tremors, incoordination, hemolytic anemia, and metabolic
acidosis. This type of GSH-S deficiency is also known as 5-oxoprolinuria or pyroglutamic
aciduria.190 The difference in severity reflects the fact that in the mild form, GSH-S
deficiency is confined to the red blood cells. GSH-S activity is present in adequate amounts
in young erythrocytes but because of unstable GSH-S variants, enzymatic activity declines
rapidly when the cell ages, due to the lack of protein synthesis. Other cells of the body that
contain nuclei and ribosomes are capable of compensating for the loss of GSH-S by
increasing protein synthesis capacity. With regard to the severe type of GSH-S deficiency, all
cells of the body have low GSH-S enzymatic activity because no functional enzyme can be
produced in adequate amounts. In both types of GSH-S deficiency, the red blood cell exhibits
markedly reduced GSH levels. Several causative mutations have been identified, associated
with the disease.188,189,191
Generating oxidized glutathione – Glutathione Reductase and Glutathione Peroxidase
Glutathione reductase (GSR) links the glutathione pathway to the Hexose Monophophate
Shunt by means of the reversible oxidation and reduction of NADP (Figure 1). Thereby, GSR
maintains high levels of reduced glutathione in the red blood cell. GSR requires flavin
adenine dinucleotide (FAD) as a cofactor. A mitochondrial and a cytoplasmic GSR isozyme
are both produced from the same mRNA, most likely by alternative initiation of
translation.192 The enzyme is a homodimer, linked by a disulfide bridge. Each 56-kDa
subunit contains four domains, of which domains 1 and 2 bind FAD and NADPH,
respectively. Domain 4 constitutes the interface.193,194 The subunit is encoded by the GSR
gene (GSR), located on chromosome 8p21.1.195 GSR spans 50 kb and contains 13 exons.192
GSR deficiency (MIM 138300) is an autosomal recessive disease. Because of the extremely
large GSR pool in human erythrocytes,196 even the almost complete absence of GSR is
associated with relatively mild clinical expression, without chronic hemolysis.197
Glutathione peroxidase (GSH-Px) is a homotetrameric enzym, consisting of 21-kDa subunits.
The enzyme converts hydrogen peroxide to water, thus reducing the peroxidative stress for
cellular proteins. Several GSH-Px isozymes are known but only GSH-Px1 is active in the
erythrocytes. Red blood cells also display high catalase activity. Catalase also converts hydrogen
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peroxide to water, rendering GSH-Px activity redundant. Therefore, deficiencies of either
catalase or GSH-Px are without significant consequences for the red blood cell. GSH-Px activity
shows ethnic variation198 and although a partial GSH-Px deficiency has been documented in
association with hemolytic anemia,199 a clear causal relationship has not been established.
Outline of the thesis
The phenotype of hereditary red blood cell enzymopathies is highly variable. One of the
important frontiers in the interaction between laboratory medicine and clinical practice is to
establish the correlation between a patient’s genotype and his phenotype. The phenotype,
however, does not depend solely on the molecular properties of mutant proteins but, rather,
reflects a complex interplay between physiological, environmental, and other (genetic)
factors. Moreover, the ultimate outcome of (mutant) gene expression is subjected to several
control mechanisms during transcription, pre-mRNA processing, and translation (Figure 6).
Therefore, the obligatory first step towards a comprehensive understanding of the disease
phenotype in red blood cell enzymopathies comprises the elucidation of its molecular
mechanisms of disease. It is evident that this requires not only the identification of the
causative mutation on the DNA level but, instead, the combination of genetic information
with clinical, biochemical and structural data. In this way, the identified mutation on the
DNA level and the mechanisms via which these mutations exert their effects render a causal
relationship that, ultimately, may answer the question: “Why is the patient ill?”
In chapter 2 we describe how a single-base change in the erythroid-specific promoter of
PKLR silenced expression of this otherwise normal allele completely and, ultimately, led to
the identification of a novel transcriptional regulatory element in PKLR gene.
In chapter 3, a novel approach, using RNA from ex vivo produced nucleated erythroid cells
from the patient, was employed to study the effects of two splice site mutations, encountered
in one compound heterozygous patient with severe PK deficiency. The spectrum of identified
aberrant transcripts was correlated to the PK-deficient phenotype.
Chapter 4 describes the molecular diagnosis of PK deficiency in a large group of patients.
To better understand the mechanisms by which the novel amino acid substitutions could
impair enzymatic function and lead to PK deficiency, we evaluated their position and the
nature of substitution in the three-dimensional model of the recently elucidated crystal
structure of human erythrocyte PK.
Due to an irony of fate, a Danish mother gave birth to two patients with severe PK deficiency,
each from a different father. One of the children was homozygous for a novel missense
29
Chapter 1
mutation and this proved to be fatal. In chapter 5 we describe the effect of these mutations
by molecular modeling of the two mutated residues.
Chapter 6 describes two patients with severe glucose-6-phosphate dehydrogenase
deficiency. Two de novo mutations were identified, one of which was novel. The predicted
amino acid substitutions both affected the same crucial region in the enzyme and although
perturbation of this region is usually associated with severe clinical features, both patients
displayed distinct clinical symptoms.
In chapter 7 we have established the molecular basis of hexokinase deficiency in a patient
who was diagnosed more than 20 years ago. Previously determined biochemical data could
now be attributed to the obtained genetic and structural data of this rare glycolytic enzyme
defect.
Finally, in chapter 8 the combined findings of these investigations are discussed and placed
into a broader perpsective. Possible aims for further research are discussed. 
Figure 6. Schematic representation of human gene expression.
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Abstract
We established the molecular basis for pyruvate kinase (PK) deficiency in a white male
patient with severe nonspherocytic hemolytic anemia. The paternal allele exhibited the
common PKLR cDNA sequence (c.) 1529G>A mutation, known to be associated with PK-
deficiency. On the maternal allele, three in cis mutations were identified in the erythroid-
specific promoter region of the gene: one deletion of thymine –248 and two single nucleotide
substitutions, nucleotide  (nt) –324T>A and nt –83G>C. Analysis of the patient’s RNA
demonstrated the presence of only the 1529A allele, indicating severely reduced
transcription from the allele linked to the mutated promoter region. Transfection of promoter
constructs into erythroleukemic K562 cells showed that the most upstream –324T>A and
–248delT mutations were non-functional polymorphisms. In contrast, the –83G>C mutation
strongly reduced promoter activity. Site directed mutagenesis of the promoter region
revealed the presence of a putative regulatory element (PKR-RE1) whose core binding motif,
CTCTG, is located between nt –87 and –83. Electrophoretic mobility shift assay using K562
nuclear extracts indicated binding of an, as-yet-unidentified trans-acting factor. This novel
element mediates the effects of factors necessary for regulation of pyruvate kinase gene
expression during red cell differentiation and maturation.
Introduction
Pyruvate kinase (PK) catalyzes the final step of glycolysis in which phosphoenolpyruvate is
converted to pyruvate with the concomitant generation of adenosine triphosphate (ATP).
Pyruvate kinase deficiency is the most common cause of nonspherocytic hemolytic anemia
due to defective glycolysis. The consequent lack of sufficient energy, which is required for
normal functioning and cellular survival, shortens the life span of the mature PK-deficient
erythrocyte. Consequently, PK deficient patients display a phenotype of non-spherocytic
hemolytic anemia albeit with variable clinical severity.1 PK deficiency is transmitted as an
autosomal recessive disease and to date, more than 130 mutations in PKLR have been
reported to be associated with pyruvate kinase deficiency.2 Most (70%) of these mutations
are missense mutations affecting conserved residues in structurally and functionally
important domains of PK.
The human gene for liver and red blood cell-specific PK (PKLR) is located on chromosome
1q213 where it directs tissue-specific transcription for both the liver-specific isozymes PK-L
and the red blood cell-specific isozyme PK-R4-6 by the use of alternate promoters.7-9
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Functional analysis of the rat PK erythroid-specific promoter has indicated that nucleotides
(nts) from –870 to +54, relative to the cap site, confer erythroid specificity to a reporter
gene.10 Within this region, a minimal promoter (nts –62 to +54), including a putative –50
CCACC/Sp1 element and a –20 GATA element, displayed erythroid-specific activity.10
Studies on the human promoter have, moreover, indicated that a region from –120 to –270,
relative to the translational initiation codon, functions as a powerful enhancer.9 DNA
sequence comparison between the rat and human erythroid-specific promoter of PKLR
reveals four well-conserved elements, indicated in Figure 1. Furthermore, two CAC boxes
GATA-1CAC/Sp1CAC/Sp1
GATA-1
GATA-1
-469   aggttacagagtggtgaaggcactctgcatttcttggttgagacagagaa
-419   aaaaagtggtcagaactgggtaaccctccccccaccatattatcacagtg
-369   atcccttttgtctttcttcaggctccagccccaccctacagccccTgctc
  -19   ccaggcccacactgaaagc
-319   cctggattcactagagctaacttcagtaaagtacaaagaaaatggggcca
-269   tatgactggccaaaaaaaaaaTatctattcacgtggatgaccagatagta
-219   tgaatggattgaaaatttatcaggaaaaaaggatgagaggaaatgccagg
-169   agatgagggcagagagcaggccgttctgggggagggattctgtggggaca
               -119 gggtggcctactgggtgtgccccttttctcttctctGtctcccttagata
   -69   agaccagcagttttgtcatcctctccctctcattccatggtcccgcagcc
  -324T>A
 
 -248delT
PKR-RE
-83G>C
GATA-1
Figure 1. Partial DNA sequence of the erythroid-specific promoter of PKLR. A 469-bp region
comprising the upstream regulatory domain and exon 1 down to the ATG codon as used in this study.
Conserved elements (from Kanno et al.9) between the human and rat PK-R promoter are depicted by
dotted lines. The cytosine identified as the PK-R transcriptional start site5 is underlined. GATA-1,
CAC/Sp1 motifs, and the novel regulatory element PKR-RE1, as reported in this study, in the upstream
270-bp region are shown in boxes (orientation indicated by arrows). The three in cis mutations, as
identified in our patient, are indicated above their corresponding nucleotides (in capital letters) in the
promoter sequence. 
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and four GATA motifs are present within the first 250 bp upstream region.9 So far only one
mutation in the PK-R promoter has proven to be associated with pyruvate kinase deficiency
– a single-base substitution at nt –72 (–72A>G). The downregulation of expression by this
mutated promoter has been attributed to disruption of the consensus binding motif for
GATA-1 at nts –69 to –74.11
Previously, we reported two in cis mutations in a severely PK deficient Danish patient.12 We
now report on the functional analysis of these mutations and show that the most proximal
one, –83G>C, constitutes part of a core binding motif of a novel regulatory element (PKR-
RE1) in the erythroid-specific promoter of PKLR, in close proximity to a regulatory GATA-
1 binding site. 
Patient, materials, and methods
The patient is a six-year-old Danish boy suffering from severe, transfusion-dependent
hemolytic anemia since birth. PK deficiency was diagnosed at the age of 1 year. Because of
the continuous presence of transfused donor erythrocytes, we used a density gradient to
separate reticulocytes from mature erythrocytes, in order to obtain an as-representative-as-
possible patient-specific red cell population.13 PK activity and activity measurements of the
red blood cell age-related enzymes glucose-6-phosphate dehydrogenase (G6PD) and
hexokinase (HK), were determined according to standardized procedures.14
DNA sequence analysis of PKLR
The coding region of PKLR was amplified using primers as previously described.15
Additional primers were used for part of the putative erythroid-specific promoter (GenBank
accession number AB015984 D13232) and 3’-untranslated region (3’-UTR; GenBank
accession number D13243). Sense primer PKRP-ESF 5’-AGGTTACAGAGTGGTGAAGGC-
3’ (nts –469 to –449, relative to the start codon) and antisense primer PKRP-ESR: 5’-
GCTTTCAGTGTGGGCCTGG-3’ (nts –20 to –1) amplify a 469 bp region immediately
upstream of the initiator methionine. Sense primer PKRU-F: 5’-
TCTACGTTCTCCAGCCCACAC-3’ (nts + 58 to +78, relative to the termination codon) and
antisense primer PKRU-R: 5’-GAGTGGGAAGGAATTTCTGGG-3’ (nts +689 to +669)
amplify a 669 bp region of the 3’-UTR. Polymerase chain reactions (PCRs) were carried out
with 200 ng DNA in 50-µL volumes containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5
mM MgCl2, 0.01% (wt/vol) gelatin, 0.2 mM of each deoxynucleotide triphosphate (dNTP),
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0.3 µM of each primer, and 2.5 U AmpliTaq Gold DNA polymerase. All reagents were
obtained from Applied Biosystems (Roche Molecular Systems, Branchburg, NJ). After
initial incubation for 10 minutes at 95°C, samples were subjected to 35 cycles of
amplification with denaturation at 94°C for 30 seconds, annealing for 30 seconds at 64°C
(60°C for exon 9 and 3’-UTR), and extension at 72°C for 45 seconds, followed by an
elongated extension time of 10 minutes after the last cycle. Automated DNA sequence
analysis was performed with the ABI Prism dRhodamine Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA), according to the manufacturer’s
instructions. Sequencing reactions were all carried out in forward and reverse direction, and
samples were analyzed on an ABI 310 Genetic Analyzer (Applied Biosystems). The PCR
products were purified prior to DNA sequence analysis using the QIAquick PCR purification
kit (Qiagen, Valencia, CA).
Restriction enzyme analysis
Mutations were confirmed by restriction enzyme analysis on newly amplified PCR product. The
cDNA sequence (c.) 1529G>A mutation in exon 11 was confirmed by StyI digestion as
described.15 The two promoter mutations, –324T>A and –83G>C, were confirmed by digestion
of the PCR product with BstXI and BsmAI, respectively. The 469-bp PCR product from the
wild-type allele, as amplified with PKRP-ESF and PKRP-ESR, contains one recognition site for
BstXI that yields fragments of 206 bp and 263 bp after digestion. The –324T>A mutation creates
a second recognition sequence for this enzyme, resulting in additional fragments of 152 bp and
54 bp. The –83G>C mutation abolishes one of two recognition sequences for BsmAI normally
present in this PCR product. Consequently, fragments of 35 bp and 434 bp are produced after
digestion of the mutant allele with BsmAI whereas 35-bp, 357-bp, and 77-bp fragments are the
result of digestion of the wild-type allele with this restriction enzyme. All enzymes were
purchased from New England Biolabs, Beverly, MA.
Reverse transcription-PCR
Reverse transcription-PCR (RT-PCR) to detect the c.1529G>A mutation was performed
using the GeneAmp RNA PCR Core Kit from Applied Biosystems (Roche Molecular
Systems) according to the instructions of the manufacturer. 
Briefly, 1.0 µg of the patient’s reticulocyte RNA was reverse transcribed using random
hexamers as primers. After addition of 30 pmol of primers CDPK-11 (5’-
CTCAGCCCAGCTTCTGTCTCG-3’, exon 11 nts 1437 to 1457) and PKr-6 (5’-
GTGTGGGCTGGAGAACGTAGA-3’, exon 12 nts +78 to +58), the samples were subjected
to 35 cycles of amplification with denaturation at 94°C for 30 seconds (5 minutes at 95°C
50
Novel trans-acting factor binding motif in PKLR 
prior to the first cycle), annealing at 58°C for 30 seconds, and extension at 72°C for 30
seconds, followed by an elongated extension time of 10 minutes after the last cycle. Total
liver RNA was used as a positive control and controls without RNA as well as controls in
which the reverse transcription step was omitted were included.
Allelic frequency determination
Allelic frequency of –248delT and population evidence regarding its physiologic effect were
obtained by screening the DNA of 241 anonymized white control subjects and heterozygotes for
the c.1529G>A mutation, respectively, for the –248delT mutation by allele-specific
oligonucleotide hybridization (ASOH). Genomic DNA (100 ng) was amplified in the region of
nt –248T in the PK-R promoter by PCR. The 25-µL system contained 34 mM Tris-HCl, pH 8.8,
8.3 mM NH4SO4, 1.5 mM MgCl2, 85 g/mL bovine serum albumin, 0.2 mM of each dNTP, 100
ng of sense (5’-CTCCCTGGATTCACTAGAGC-3’, nts –322 to –303) and antisense (5’-
AGGATGGACTTTGCTAAGT-3’, nts 65 to 83) primers, and 1.5 U Taq DNA polymerase. After
a 5-minute denaturation step at 98°C, 30 cycles of 93°C for 30 seconds, 58°C for 30 seconds,
and 72°C for 30 seconds were performed followed by a 7-minute 72°C  incubation. The 405-bp
PCR product (4 µL) was then spotted on Nytran SuPerCharge membranes (Schleicher and
Schuell, Keene, NH). The membranes were denatured, neutralized, and UV-crosslinked prior to
hybridization. The membranes were hybridized with wild-type (5’-AAATATCTATTCACGTG-
3’) and mutant (5’-AAAAATCTATTCACGTG-3’) 32P-labeled oligonucleotide probes for the
–248T position of the PK-R promoter. After hybridization the membranes were washed in 6 ×
SSC, 0.1% sodium dodecyl sulphate (SDS) at 50°C and developed with a Cyclone storage
phosphor autoradiography system (Packard Instrument, Meriden, CT).
Promoter constructs and site-directed mutagenesis
The human PK promoter constructs from the patient and healthy controls were generated
from a 469-bp PCR fragment comprising the upstream regulatory domain and exon 1, down
to the ATG codon (Figure 1). The blunt-end PCR fragment was cloned into the pCR-Blunt
vector (Invitrogen, Paisley, United Kingdom) before it was excised and inserted into the MluI
and XhoI sites of pGL3-Basic (Promega, Madison, WI). Site-directed mutagenesis was
performed with splicing by overlap extension as described.16 Using PK-R promoter reporter
plasmid pGL3_PKRWT as the wild-type template, we generated the following mutants:
pGL3_PKR91A (nt –91T>A), pGL3_PKR90T (nt –90C>T), pGL3_PKR89G (nt –89T>G),
pGL3_PKR88G (nt –88T>G), pGL3_PKR87A (nt –87C>A), pGL3_PKR86G (nt –86T>G),
pGL3_PKR85A (nt –85C>A), pGL3_PKR84G (nt –84T>G), pGL3_PKR83C (nt –83G>C),
pGL3_PKR82G (nt –82T>G), pGL3_PKR81A (nt –81C>A), pGL3_PKR80G (nt –80T>G),
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pGL3_PKR79T (nt –79C>T), and pGL3_PKR78T (nt –78C>T). Briefly, two PCR products
were generated that harbored the desired mutation using primers PKRP-ESF and PKRP-ESR
in combination with the applicable mutant antisense primers and sense primers, respectively
(primer sequences are available on request). Fragments were electrophoresed and purified
from the agarose gel using the QIAquick Gel Extraction Kit (Qiagen). Subsequently, for each
mutant promoter construct 12.5 µL of each of both fragments obtained by the first PCR
reaction were combined and subjected to a second round of amplification with primers
PKRP-ESF and PKRP-ESR. Finally, the blunt-end mutated PCR fragment was cloned into
the pCR-Blunt vector (Invitrogen), and subcloned into the XhoI and MluI sites of the pGL3-
Basic vector, as described above. All constructs were verified by DNA sequence analysis.
There were three additional mutant promoter constructs prepared as described that harbored
the –248delT polymorphism (pGL3_PKR248delT), the –324T>A mutation
(pGL3_PKR324A) and, by using the patient’s DNA as a template, both the –324T>A and
–83G>C mutations in cis (pGL3_PKR324A/83C).  
Cell culture and transient DNA transfections 
K562 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal calf serum, 1% streptomycin, and 1% penicillin in 10% CO2 at 37C. Cells were
transiently transfected with Lipofectamine (Life Technologies, Paisley, United Kingdom)
according to the manufacturer’s instructions. Briefly, 30,000 cells/cm2 were seeded in 24-
well plates 24 hours prior to transfection. The cells were transfected with 2 µg reporter
plasmid DNA and 100 ng RL-SV40 plasmid (Promega) that was used as internal control.
After 48 hours, luciferase activity was measured with the Dual Luciferase Assay kit
(Promega) and normalized to renilla luciferase activity. The promoterless pGL3-Basic
Luciferase Reporter Vector (Promega) was used as a negative control.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were performed essentially as described17 with
K562 nuclear extracts, prepared according to Dignam.18 Wild-type and mutant double-
stranded oligonucleotide probes were obtained by annealing the following single-stranded
primers: PKWT: sense 5’-TTCTCTTCTCTGTCTCCCTT-3’ and antisense
5’AAGGGAGACAGAGAAGAGAA-3’; and PKmut: sense 5’-TTCTCTTCTCgGTC-
TCCCTT-3’ and antisense 5’-AAGGGAGACcGAGAAGAGAA-3’, respectively. PKmut
contains the –84T>G mutation (in lower case). Competitors (excess of unlabelled probe
oligonucleotide or corresponding mutant oligonucleotide) were included as described in the
figure legends.
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Results
Glycolytic enzyme activities
The results from the measurement of peripheral blood glycolytic enzyme activities in the
patient and his parents are summarized in Table 1. In the patient, PK activity was only just
below the lower reference value, whereas the HK and G6PD values were high, indicating
that the red cell population was relatively young. Consequently, we interpreted the PK
activity as too low. To exclude the interference of donor cells, we isolated the low-density,
reticulocyte-rich fraction of the patient by Percoll-density centrifugation. Subsequent
glycolytic enzyme activity measurements in this fraction showed an even lower PK activity.
In contrast, the G6PD and HK activity remained unaltered, thus underscoring the presence
of PK deficiency in the patient’s red blood cells. The PK activity measured in peripheral
blood of the father was normal, whereas the erythrocyte PK activity of the mother was low,
relative to that of G6PD and HK. 
DNA sequence analysis of PKLR
By DNA sequence analysis of PKLR, the patient was found to be heterozygous for the
common c.1529G>A mutation in exon 11 (Figure 2A). This mutation was confirmed by StyI
digestion and subsequent restriction enzyme analysis of his parents revealed that the patient
had inherited this allele from his father (data not shown). Apart from heterozygosity for the
well established polymorphisms2 c.1705A>C, c.1738C>T, and c.1992T>C in exon 12, no
Table 1. Glycolytic enzyme activities in the patient and his parents
PK G6PD HK
(U/gHb) (U/gHb) (U/gHb)
Peripheral blood
Control 8.4–14.4 9.5–15.0 1.05–1.81
Patient 7.1 21.4 4.30
Father 14.2 21.0 1.90
Mother 8.3 18.0 2.30
Reticulocyte-rich fraction
Patient 3.8 21.7 4.22
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other mutations were detected in PKLR exons and splice junctions. However, three
previously undescribed base alterations were indentified in the PK-R promoter compared
with the healthy control individual. Of these, two were single nucleotide substitutions of,
respectively, thymine to adenine at nt –324 (–324T>A) and guanine to cytosine at nt –83
(–83G>C). Both mutations were confirmed in the patient by BstXI and BsmAI digestion,
respectively, and also found to be present in the patient’s mother, whereas they were absent
in the patient’s father (Figure 3), thereby demonstrating that both mutations were present in
cis. Neither allele was detected in a healthy control population (n = 100). A third sequence
variation was observed around nt –248 in both the patient and his mother but not in the
patient’s father and the control. Its characterization, however, was hampered because of an
apparent concomitant variation in the number of adenines between nts –249 and –258 in all
subjects. Since the latter was likely to be a PCR artifact due to slippage of Taq DNA
Figure 2. Heterozygous PKLR c.1529G>A missense mutation and sole expression of the 1529A
allele in the patient. (A) PKLR DNA sequence analysis of exon 11 in the patient shows a heterozygous
G>A substitution (arrow). The splice donor site of intron 11 is indicated. (B) RT-PCR analysis of the
patient’s RNA yielded only one transcript that contained the 1529A mutation (arrow), thereby
indicating a severely reduced transcription of the in trans 1529G allele. Double horizontal arrows
denote boundaries between exons.
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polymerase at this homonucleotide run,19 we cloned this promoter fragment and
characterized its DNA sequence context (see “Polymorphic deletion of thymine –248”).
Polymorphic deletion of thymine –248
DNA sequence analysis of a number of cloned promoter fragments from the patient and the
control confirmed the presence of the –324T>A and –83G>C mutations in cis in the patient.
The third mutation in the patient constituted the deletion of thymine –248 (–248delT). 
Since nt –248T constitutes part of an inverted consensus binding site for GATA-1,
(A/T)GATA(A/G),20 the –248delT mutation potentially disrupts binding of GATA-1 (Figure
1). Therefore, constructs containing the wild-type (pGL3_PKRWT) and the –248delT
polymorphic allele (pGL3_PKR248delT) were transiently transfected in K562 cells to
determine the effect of the –248delT mutation on promoter activity. A comparison between
the two alleles showed a statistically significant (P < .05) increase in promoter activity upon
–248delT (Figure 4A).
In vivo evidence regarding the functional consequences on transcriptional activity of the
–248delT deletion was obtained from a study of carriers of c.1529G>A and –248delT in
trans. If the –248T mutation abolished or severely impaired transcription, such compound
heterozygous patients should be PK-deficient and anemic or at least have macrocytosis
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Figure 3. Heterozygosity for two novel mutations in the PK-R promoter at nt –83 (–83G>C) and
nt –324 (–324T>A) in the patient and his mother. A 469-bp fragment was amplified as described and
subjected to restriction enzyme digestion. The obtained pattern for each reaction is indicated by arrows
(see “Patient, materials, and methods”). Heterozygosity for both the –83G>C mutation (BsmAI
digestion) and the –324T>A mutation (BstXI digestion) was confirmed in the patient (PAT) and also
detected in his mother (M), whereas they were absent in the patient’s father (F).
P indicates uncut PCR product; and C, healthy control.
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because of increased erythropoiesis. In a previous study,21 several thousand DNA samples
from a general population were screened for the c.1529G>A mutation and 11 heterozygotes
were detected. Among these, four individuals also carried the –248delT mutation. Since 37
out of 37 c.1529G>A alleles carried the wild-type promoter (data not shown), it is reasonable
to assume that these individuals were compound heterozygotes for c.1529G>A and
–248delT. If the –248delT mutation prevented transcription, then the patient should be PK
deficient. Enzyme activities were not available, but we compared the average hemoglobin of
three female compound heterozygotes (12.6 g/dL), which was no different than the 12.1 g/dL
of the three female single heterozygotes for c.1529G>A. The male patient had a hemoglobin
of 15.2 g/dL. All had normal mean corpuscular volume (MCV) values. We infer that the
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Figure 4. The –83G>C mutation in the PK-R promoter strongly down-regulates promoter
activity in vitro. Luciferase reporter gene constructs containing 469 bp of the wild-type or mutated PK-
R promoter were transiently transfected in K562 erythroleukemic cells. Luciferase activities were
expressed relative to control pGL3-SV40 and pGL3-Basic was included as a negative (promoterless)
control. (A) Constructs pGL3_PKRWT and pGL3_PKR248delT contained the wild-type or
polymorphic –248delT allele, respectively. The latter mutation disrupts an inverted GATA-1 binding
site (arrow) but no down-regulation of promoter strength is observed. In contrast, an increase in
promoter activity was observed upon removal of thymine –248. (B) Individual and combined effects of
the –83G>C and –324T>A missense mutations were studied using constructs that contained only the
–83G>C mutation (pGL3_PKR83C) or the –324T>A mutation (pGL3_PKR324A), or both mutations
in cis (pGL3_PKR324A/83C). The –324T>A mutation had no effect on promoter activity as compared
to the wild-type (pGL3_PKRWT). In contrast, the –83G>C mutation is capable of strongly reducing in
vitro promoter activity and is unaffected by the concomitant presence of the –324T>A substitution in
cis. *Statistically significant (P < .05).
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–248delT mutation is a benign polymorphism and is not associated with reduced promoter
activity and, consequently, with PK-deficiency. Subsequent determination of the allelic
frequency of this mutation was performed by screening 241 control subjects of a general
white population for this mutation by allele-specific oligonucleotide hybridization. There
were 206 wild-type subjects (–248T/T), 34 heterozygous subjects (–248T/delT), and one
homozygous control (–248delT/delT). Consequently, the allelic frequency for this novel
polymorphism in the PK-R promoter is 0.075.
Functional characterization of nt –324T>A and nt –83G>C  promoter mutations
To asses the functional consequences of the mutated PK-R promoter region, we first
performed RT-PCR analysis on the patient’s RNA with primers spanning exons 11 and 12 to
determine the relative expression of the two alleles. As shown in Figure 2B, only the 1529A
allele could be detected in the patient, strongly indicating that transcription is severely
reduced by the mutated promoter.
To study the individual and combined effects of the –324T>A and –83G>C mutations on
PK-R promoter activity, we transfected constructs pGL3_PKRWT (wild-type),
pGL3_PKR324A (nt –324T>A), pGL3_PKR83C (nt -83G>C) and pGL3_PKR324A/83C
(nt –324T>A and nt –83G>C in cis) in K562 cells and compared their relative luciferase
activities. Figure 4B shows that the –83G>C substitution is capable of down-regulating
promoter activity (pGL3_PKR83C and pGL3_PKR324A/83C). This effect was achieved
either with (pGL3_PKR324A/83C) or without (pGL3_PKR83C) the concomitant presence
of the –324T>A mutation. In contrast, promoter activity was not altered, with regard to the
wild-type promoter, in case only the –324T>A mutation was present (pGL3_PKR324A). We
infer that the –83G>C mutation disrupts transcription.
Delineation of a putative regulatory element comprising the nt –83G>C mutation
Since the proximal erythroid-specific promoter region of PKLR previously was reported to
dictate basal promoter activity9, we hypothesized nt –83 to be part of a previously
unrecognized trans-acting factor binding element. To unravel the sequence of the putative
cis-element we generated a series of consecutive promoter mutants  from nts –91 to –78 and
determined their activity in K562 cells. Figure 5 shows that substitution of nts –87 to –83
leads to a decreased promoter activity. In particular, the –84T>G mutation exhibited a
profound reduction in transcription. Substitutions further upstream (nts –88 to –91) or
downstream (nts –82 to –78) did not significantly alter promoter activity. Thus, we defined the
existence of a novel regulatory element in the PK-R promoter PKR-RE1 whose core binding
motif is confined to nts –87 to –83.
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To further explore the involvement of PKR-RE1 in binding trans-acting factors, we
performed EMSA with K562 nuclear extract and oligonucleotide probes designed according
to the native core binding motif (PKWT) and mutated PKR-RE1 (Pkmut; –84T>G). Figure
6 demonstrates the formation of three distinct DNA-protein complexes upon incubation with
labeled PKWT (lane 1). 
One of these bands (arrow) could be competed off succesfully by increasing amounts of
excess unlabeled PKWT (lanes 2-4), but remained unaffected by the addition of increasing
amounts of excess unlabeled PKmut as a competitor (lanes 5-7), thereby establishing its
specificity. This band was absent when lysates were incubated with radiolabeled PKmut
(lane 8), thereby suggesting that the particular protein-DNA interaction was abolished in
Figure 5. Site-directed mutagenesis of a region of the PK-R promoter spanning nts –91 to –78
identifies the core motif CTCTG of a novel PK-R regulatory element (PKR-RE1). PK-R promoter
reporter gene constructs harboring mutations from nts –91 to –78 were expressed in K562 cells. The
applicable mutation is depicted in the lower part of the figure. Luciferase activities were calculated
relative to control pGL3-SV40. pGL3-Basic was included as a negative (promoterless) control. The
decreased promoter activity as a result of the introduced mutations at nts –87 to –83 revealed a single
pentanucleotide motif CTCTG. *Statistically significant (P < .05).
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case PKR-RE1 was disrupted. Instead, another band appeared that could, however, be
competed off succesfully by increasing amounts of both unlabeled PKWT and  PKmut (lanes
9-11 and 12-14, respectively). We infer that the –83C is part of a putative trans-acting factor
binding element, characterized by a CTCTG core motif.
Discussion
We established the molecular basis for PK deficiency in a six-year-old boy of Danish
ancestry who suffered from severe hemolytic anemia. On the paternal allele of this patient
we detected a guanine-to-adenine substitution at nt 1529 in PKLR. The Arg510Gln encoded
by this frequently occuring mutation and the consequent structural changes in PK that lead
1    2   3   4    5   6   7    8    9  10  11  12 13 14
Figure 6. PKR-RE1 is involved in DNA-protein interaction. Electrophoretic mobility shift assay
was performed with K562 nuclear extract and oligonucleotide probes designed according to the native
core binding motif (PKWT; lanes 1-7) and mutated PKR-RE1 (PKmut; lanes 8-14). Absence (–) and
increasing amounts of unlabeled wild-type and mutant competitor is indicated. The figure shows three
distinct DNA-protein complexes upon incubation with labeled PKWT (lane 1). One of these bands
(arrow) could be competed off succesfully by increasing amounts of excess unlabeled PKWT (lanes 2-
4), but remained unaffected by the addition of increasing amounts of excess unlabeled PKmut as a
competitor (lanes 5-7). In contrast, this band was absent when lysates were incubated with radiolabeled
PKmut (lane 8), whereas the extra band that appeared upon incubation with PKmut could be competed
off succesfully by increasing amounts of both unlabeled PKWT and PKmut (lanes 9-11 and 12-14,
respectively)
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to PK deficiency have been well documented.15,22 The fact that the father had normal PK
activity (Table 1), in spite of being heterozygous, emphasizes the difficulty of accurately
identifying heterozygotes based on enzyme activity alone. On the maternal allele of the
patient, we detected three novel mutations in the erythroid-specific promoter of PKLR. Two
of these mutations were single-base substitutions, –324T>A and –83G>C, relative to the
initiator adenine. The third change consisted of the deletion of thymine at nt –248.
RT-PCR analysis of the patient’s RNA demonstrated sole expression of the 1529A allele
(Figure 2B). Therefore, it was conceivable that the mutated promoter caused effective
downregulation of transcription from the affected allele. Analysis of the various promoter
mutations in K562 cells showed that –83G>C alone was capable of inducing a drastically
reduced promoter activity in vitro, whereas the –324T>A and –248delT mutations exerted no
such effect (Figure 4). The latter mutation represents a nonfunctional polymorphic
substitution (allele frequency 0.075), whereas –324T>A is a nonfunctional mutation. 
In vivo evidence regarding the lack of functional consequences on transcriptional activity of
the –248delT deletion came from a study among individuals who were compound
heterozygous for the c.1529G>A and –248delT in trans. If transcription was hampered by
the –248delT mutation, such patients should be PK deficient and anemic or at least have
macrocytosis because of increased erythropoiesis. However, the average hemoglobin level of
three female compound heterozygotes (12.6 g/dL) showed no differences when compared
with the average hemoglobin level of three female single heterozygotes for c.1529G>A (12.1
g/dL). One male patient had a hemoglobin level of 15.2 g/dL and all individuals had normal
MCV values.
Because –248delT disrupts the GATA-1 binding motif at nts –244 to –249, we also
investigated whether this mutation was able to influence promoter activity in vitro.
Luciferase activities reflecting the relative promoter strength of these constructs showed no
decline in promoter activity as a result of –248delT (Figure 4A). As this would have been
suggestive of a functional stimulatory GATA-1 binding site in vitro, it is unlikely that the
latter is the case. Thus, both in vitro and in vivo evidence support the presence of a non-
functional GATA-1 binding site at nts –244 to –249 in the erythroid-specific promoter of
PKLR. Interestingly, we found that the wild-type allele confered an approximately two-fold
increase in promoter activity upon deletion of thymine –248 (Figure 4A). Although the effect
is relatively small, it is possible that –248delT modulates the phenotypic expression of
pyruvate kinase deficiency, as previously shown for a polymorphic dinucleotide repeat at the
UDP-glucuronosyltransferase 1 promoter23 that contributes to the clinical phenotype in
G6PD deficient neonates.24
Only one mutation in PKLR is known to date that is associated with a reduced transcription
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from its erythroid-specific promoter and consequent quantitative reduction in PK-R. A
markedly reduced amount of PK-R mRNA was detected, 20% by semi-quantitative RT-PCR
analysis, as a result of a single nucleotide substitution at nt –72.11 The involvement of
GATA-1 was presumed since the mutation was located in the core of the binding motif of
this erythroid-specific transcription factor.20,25,26 Initially, a –249delA mutation in the PK-R
promoter was reported in association with PK deficiency.27 However, re-investigation of the
patient’s DNA revealed the presence of the same three in cis mutations we report here.27
Kugler has allowed us to examine a DNA sample from his patient, and we have confirmed
his results (data not shown).
Most current data on the function of the PKLR gene indicate that the proximal promotor
region is essential for transcriptional initiation. The distal region upstream position –300,
where nucleotide –324T is located, appears to be dispensable for transcriptional regulation
as shown by Kanno et al., who found that removal of nts –513 to –304, had no effect on
promoter activity.9 In the same study, the proximal 120 bp, containing two CAC boxes and
one GATA binding motif, were shown to direct a basal promoter activity, whereas the 150
bp upstream acted as an enhancer.9 From studies on the rat PK-R promoter, this region was
also found to be functionally important.10,28,29 Lacronique et al. demonstrated that a
proximal 320-bp PK-R promoter fragment is able to direct erythroid-specific transcription in
a rat fetal liver cell-free transcription system and interacts both in vitro and in vivo in a
erythroid-specific manner with GATA-1, CACC-binding proteins, and unidentified factors
recognizing G/C-rich motifs.28 Furthermore, Max-Audit et al. demonstrated the specific
binding of GATA-1 and members of the CACC/Sp1 family to the proximal GATA binding
site of a minimal promoter spanning nts –62 to +54.10 GATA-1 and Sp1, two factors known
to physically interact,30 have also been shown to cooperatively activate transcription from a
minimal (nts –62 to +43) rat PK-R promoter in Drosophila S2 cells.29
Because of the effect of the –83G>C mutation and its location in a well conserved region
between rat and humans (Figure 1), we anticipated that nt –83G was an essential part of a
trans-acting factor binding element. Systematic mutagenesis of the region disclosed the
presence of a cis-element, whose core CTCTG extents from nts –87 to –83 (Figure 5). We
designated this novel regulatory element in the PK-R promoter, PKR-RE1. Subsequent
EMSA using K562 nuclear extract demonstrated in vitro DNA-protein interaction at the core
of PKR-RE1 involving an as-yet-unidentified protein (Figure 6). In agreement with these
data, Lacronique et al. previously showed by in vitro DNAse I footprinting that the
corresponding conserved sequence in the rat PK-R promoter encompassing nts –64 to –58
was involved in DNA-protein interaction.28 In gel shift assays, the labeled probe containing
the CTCTG sequence and spanning nts –80 to –57 formed two retarded complexes which,
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on the basis of mobility shift assays, were suggested to correspond to GATA-1-containing
complexes, although GATA-1 later proved to bind more upstream.28 Since the CTCTG motif
is located just 10 bp upstream of the GATA-1 binding site, an appealing model would be that
GATA-1 formed a complex with the trans-acting factor binding to PKR-RE1, similar to the
previously described erythroid ternary complex between GATA-1, the helix-loop-helix factor
TAL1, and the bridging LIM-only protein Lmo2.31 Although, PKR-RE1 does not constitute an
E-box, we tested whether GATA-1- and FOG-mediated trans-activation of the PK-R promotor
was affected by the –83G>C mutation, but have so far not observed any difference between the
wild-type sequence and the mutant (R.v.W., W.W.v.S., C.N., and F.C.N., unpublished results,
November 2000). Based on the current knowledge, we therefore propose that the PKR-RE1
functions independently of GATA-1. 
Since the CTCTG motif resembles no known transcription factor elements,32 PKR-RE1 may
be involved in a novel mechanism of erythroid-specific trans-activation. Future identification
of the putative trans-acting factor(s) may provide important leads to our understanding of
erythroid-specific transcriptional regulation involved in red cell differentiation and maturation. 
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Abstract
Two single-nucleotide substitutions in PKLR constituted the molecular basis underlying
pyruvate kinase (PK) deficiency in a patient with severe haemolytic anaemia. One novel
mutation, IVS5+1G>A, abolished the intron 5 donor splice site. The other mutation,
c.1436G>A, altered the intron 10 donor splice site consensus sequence and, moreover,
encoded an R479H substitution. We studied the effects on PKLR pre-mRNA processing,
using ex vivo produced nucleated erythroid cells from the patient. Abolition of the intron 5
splice site initiated two events in the majority of transcripts: skipping of exon 5 or,
surprisingly, simultaneous skipping of exon 5 and 6 (∆5,6). Subcellular localization of
transcripts suggested that no functional protein was produced by the IVS5+1A allele. The
unusual ∆5,6 transcript suggests that efficient inclusion of exon 6 in wild-type PKLR mRNA
depends on the presence of splice enhancing elements in exon 5. The c.1436G>A mutation
caused skipping of exon 10 but was mainly associated with a severe reduction in transcripts
although these were, in general, normally processed. Accordingly, low amounts of PK were
detected in nucleated erythroid cells of the patient, thus correlating with the patient’s PK-
deficient phenotype. Finally, several low-abundant transcripts were detected that represent
the first examples of ‘leaky-splicing’ in PKLR.
Introduction
The enucleated mature red blood cell depends solely on anaerobic glycolysis for the constant
generation of ATP in order to maintain cellular integrity and function. Disturbances in
glycolysis shorten its cellular survival and frequently result in nonspherocytic haemolytic
anaemia of variable severity. The most common cause of chronic nonspherocytic haemolytic
anaemia is pyruvate kinase (PK) deficiency1 (MIM 266200). PK catalyses the final step of
glycolysis, converting phosphoenolpyruvate to pyruvate with the concomitant generation of
ATP. PK deficiency is transmitted as an autosomal recessive disease, and molecular analysis
has identified more than 130 mutations in the structural gene (PKLR) in association with PK
deficiency.2 The majority of these mutations constitute single-base substitutions, predicting
amino acid changes of conserved residues in structurally and functionally important domains
of PK. In contrast, mutations that affect PKLR transcription,3,4 or processing of its pre-
mRNA5-11 are less frequently encountered.
Pre-mRNA processing12-14 is a critical aspect of gene expression and comprises the precise
removal of introns in such a way that the exons are joined to form mature mRNAs with intact
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translational reading frames. The splicing reaction is carried out by the spliceosome which
consists of five small ribonucleoprotein complexes U1, U2, U4, U5, and U6 snRNPs15 and
a large number of non-snRNP proteins.16 The spliceosome is assembled in vivo onto the pre-
mRNA as it is being synthesized, thus providing an intimate relationship between
transcription and pre-mRNA processing.17,18 Changes in splice site choice, e.g. as result of
mutation, arise from changes in the assembly of the spliceosome and are thought to be
regulated by altered binding of the initial factors to the pre-mRNA and the formation of early
spliceosome complexes.19 Fifteen percent of point mutations in human genes, associated
with disease, affect the conserved splice site signals.20 However, mutations can affect pre-
mRNA processing in a multitude of ways.21 Therefore, in order to fully comprehend the
contribution of any specific mutation on disease, it is important to consider mRNA
biogenesis, quality control, and metabolic fate.22
In this study we report on the identification of two single-base substitutions in PKLR of a
patient with severe PK deficiency. A novel G>A substitution at the invariant GT dinucleotide
of intron 5 and a similar substitution concerning the last nucleotide of exon 10, both affected
the 5’ splice site. Since pre-mRNA processing is a nuclear event and the reticulocyte is
devoid of RNA synthesis,23 we studied the effects of these mutations on PKLR pre-mRNA
processing using ex vivo produced nucleated erythroid cells from the patient. Multiple
aberrant transcripts were identified and characterized. Subsequent subcellular localization of
mRNAs and Western Blot analysis established the relevance of each transcript with regard
to the PK-deficient phenotype of the patient. In addition, the characterization of one unusual
transcript which lacked both exon 5 and 6 as a result of the intron 5 donor site mutation,
suggests that efficient inclusion of exon 6 in wild-type PKLR mRNA depends on the
presence of splice enhancer elements in exon 5 in the primary transcript.
Subjects and methods
Patient
The patient is a 31 year old Dutch woman, diagnosed at birth with severe, transfusion-
dependent haemolytic anaemia due to PK deficiency. Other causes of anaemia were ruled
out. Splenectomy, performed at the age of four years, improved her condition only slightly.
From age 15 years on, the transfusion dependency has gradually decreased and is, to date,
limited to periods of infection or during pregnancy, in general when blood hemoglobin falls
below 6.4 g/dL. Throughout her life she has displayed a remarkable heat-sensitivity which
led to haemolytic crises not only during febrile episodes but also as a result of prolonged
68
Aberrant processing of PKLR pre-mRNA 
exposure to sunlight. Her heterozygous parents were asymptomatic.
Appropriate informed consent was obtained from the patient and the normal control
individual, a healthy female with no haemolysis and normal glycolytic enzyme activities.
Biochemical analysis
PK and hexokinase (HK) enzyme activities were measured according to standard methods.24
Thermal stability of PK was determined by the PK heat stability test.25
Molecular analysis of PKLR
Genomic DNA was isolated by standard methods. The erythroid-specific promoter and
individual exons of PKLR, including flanking intronic regions, were amplified by PCR as
described4 and sequenced with the BigDye Terminator Cycle Sequencing Kit v3.1 (Applied
Biosystems, Foster City, CA). The IVS5+1G>A and c.1436G>A mutations were confirmed
by HphI and MscI (New England Biolabs, Beverly, MA) digestion of independently
amplified PCR products.
In vitro production of human nucleated erythroid cells
Nucleated erythroid cells from the patient and a normal control individual were produced
from light-density cells as described.26 Briefly, light-density cells were collected from 50 mL
venous blood by Ficoll-Paque Plus (Amersham-Pharmacia Biotec, Uppsala, Sweden)
density centrifugation. Cells were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM), containing 20% fetal bovine serum and supplemented with human stem cell factor
(10 ng/mL) (a gift from dr. H. Lokhorst), erythropoietin (1 U/mL) (Janssen Cilag, Tilburg,
The Netherlands), interleukin-3 (1 ng/mL) (Biosource Europe, Bruxelles, Belgium),
dexamethasone (10-6 M), and β-estradiol (10-6 M) (both from Sigma, St Louis, MI). Cells
were grown at 37C at 5% CO2 and maintained at 1–2×106 cells/mL. Proliferation and
cellular morphology was monitored every other day by May-Grünwald-Giemsa stained
cytocentrifuged smears. Cells were harvested after 10 days and at that moment the culture
consisted of more than 95% (pro-)erythroblasts. Subsequently, RNA was isolated or cells
were used for polysome profile analysis. The transcriptional and translational active state of
the cells with regard to PK was verified by polysome analysis and Western Blot (see
‘Discussion’).
RT-PCR and estimation of allelic differences in transcript levels
Total RNA was isolated from nucleated erythroid cells using RNABee reagent (Campro
Scientific, Veenendaal, The Netherlands), according to instructions of the manufacturer. RT-
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PCR was performed using the GeneAmp RNA PCR Core Kit (Roche, Branchburg, NJ). 1.0
µg total RNA was reverse transcribed using random hexamers as primers. Because aberrant
splicing events may not be confined to the immediate proximity of the location of both
mutations, an extensive region was amplified from PKLR cDNA. In case of the IVS5+1G>A
mutation, a region encompassing exons 4 to 7 was amplified with 30 pmol of primers PK-
C4F: 5’-ACATTGCGCGACTCAACTTCTCC-3’ (exon 4, nts 338–360) and PK-C7R: 5’-
TGATCTTGATGCCGTGTCCTTCC-3’ (exon 7, nts 931–909). The effects of the
c.1436G>A mutation were studied by amplification of exons 9 to 12 with primers PK-C9F:
5’-GGGCAACTTCCCTGTGGAAGC-3’ (exon 9, nts 1230–1250) and PK-C12R: 5’-
GATGGGGTACAAGGGTAGGCTGG-3’ (exon 12, nts +44 to +22, relative to the
termination codon). In both cases, the reverse primer was 6-FAM labeled. Samples were
heated for 5 minutes at 95C and subjected to 35 cycles of amplification (denaturation at
94C for 30 seconds, annealing at 64C for 30 seconds, and extension at 72C for 60
seconds), followed by an elongated extension step of 10 minutes after the last cycle. Controls
without RNA as well as controls in which the reverse transcription step was omitted were
included. Labeled fragments were separated on an ABI 310 Genetic Analyzer (Applied
Biosystems). Sizing (bp) and peak areas of fragments were calculated using GeneScan
Analysis Software (Applied Biosystems).
In order to estimate relative transcript levels from both alleles of the patient, RT-PCR
product, encompassing exons 9 to 12, was digested by MscI and subjected to agarose gel
electrophoresis. The c.1436G>A mutation in exon 10 creates a unique recognition site for
this enzyme and RT-PCR product from the 1436A allele renders fragments of 204 and 336
bp after digestion. The product from the other allele remains uncut (540 bp). Equal allelic
amounts of exon 10 as amplified from the patient’s genomic DNA served as a control,
yielding digestion fragments of 212 and 50 bp in case of the 1436A allele whereas the DNA-
PCR product from the other allele is uncut (262 bp).
Subcloning of RT-PCR products
RT-PCR products were cloned using the pGEM-T Easy Vector System Kit (Promega,
Madison, WI). Plasmid DNA was isolated (Qiaprep Spin Miniprep Kit, Qiagen, Hilden,
Germany) and 50 to 65 inserts were sequenced with the vector-derived T7 primer.
Polysome profile analysis and ∆5 transcript instability
Ten minutes before harvesting the cultured nucleated erythroid cells, cycloheximide was
added to a concentration of 100 g/mL. Cells were washed three times with ice-cold PBS
containing 1 g of cycloheximide per mL and lysed in 200 L of 20 mM Tris-HCl (pH 7.6),
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15 mM KCl, 1.5 mM Mg-acetate, 0.1 mM EDTA, 0.1% Triton X-100, and 7 mM -
mercaptoethanol. Cells were kept on ice for 1 minute and Na-desoxycholate and Igepal
(Sigma) were added to a final concentration of 0.5%. The suspension was incubated for 30
minutes on ice. Cell debris and nuclei were removed by a 5 minute centrifugation at 4°C at
10,000 rpm. The supernatant was immediately layered onto isokinetic 15-32% (w/w) sucrose
gradients in 20 mM Tris-HCl pH 7.6, 100 mM K-acetate, 3 mM Mg-acetate, 0.1 mM EDTA,
and 7 mM -mercaptoethanol. Gradients were centrifuged for 45 minutes at 50,000 rpm in
a SW55 Beckman rotor, and harvested by upward displacement through a
spectrophotometer, set at 260 nm. Ten fractions of 0.25 mL were collected into tubes
containing 0.125 mL phenol/chloroform. RNA was isolated and 0.15 g RNA of each
fraction was used for RT-PCR and subsequent fragment analysis. 
To study the ∆5 transcript (i.e. the transcript lacking exon 5) instability, cells were isolated,
lysed, and kept on ice. Aliquots of lysates were taken at 0, 10, 30, and 60 minutes and RNA
was isolated for RT-PCR (primers PK-C4F and PK-C7R) and subsequent fragment analysis.
SDS-PAGE and Western Blot analysis
107 cultured nucleated erythroid cells of the patient and control were lysed in 100 L buffer
containing 10 mM Tris-HCl, pH 7.5, 100 mM KCl, 2 mM -mercaptoethanol, 10 mM 
ε-aminocaproic acid, 10 mM EDTA, 1 mM PMSF. Samples were adjusted for protein
content, subjected to 10% SDS-PAGE and transferred onto a PVDF membrane. Membranes
were blocked for 1 hour at room temperature in 5% BSA, 0.1% Tween-20 in phosphate
buffered saline (PBST) and incubated overnight with a polyclonal anti-PK antibody27 in 1%
BSA, PBST. The membrane was washed 3 times with PBST and incubated for 2 hours with
1:10,000 diluted anti-rabbit IgG-HRP-linked antibody (Cell Signaling Technology, Beverly,
MA) in 1% BSA, PBST. Bands were visualized by Enhanced Chemiluminescence
(PerkinElmer, Boston, MA), according to instructions of the manufacturer. 
Results
Glycolytic enzyme activities
Typical haematological parameters of the patient are displayed in Table 1. Despite a
reticulocytosis of 638‰, the patient was severely anaemic. The PK activity was in the
normal range but was very low considering the massive reticulocytosis, illustrated by the
strongly elevated HK activity. Furthermore, PK from the patient showed reduced thermal
stability, indicated by the 90% decrease in PK activity in the heat stability test (Figure 1).
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PKLR sequence analysis
DNA sequence analysis of the patient’s PKLR gene revealed compound heterozygosity for
two single base substitutions. The first mutation, on the paternal allele, concerned a guanine
to adenine change at nt +1 of intron 5: IVS5+1G>A. This novel mutation abolishes the
invariant GT dinucleotide of the intron 5 donor splice site. On the maternal allele we detected
a previously reported guanine to adenine change at the last nt of exon 10 (c.1436G>A).5,28
Apart from encoding an arginine to histidine change at residue 479, this mutation disrupts
the consensus sequence of the intron 10 donor splice site. No other mutations were detected
Table 1. Haematological parameters and glycolytic enzyme activities of the patient.
patient reference value
haemoglobin (g/dL) 7.1 11.8–14.4
RBC (1012/L) 1.94 3.7–5.0
MCV (fL) 118 80–97
reticulocytes (‰) 638 5–25
PK (U/gHb) 9.0 6.9–14.5
HK (U/gHb) 8.90 1.02–1.58
0
20
40
60
80
100
Figure 1. Thermal stability of PK. Thermal stability of PK in erythrocyte lysates from a normal control
and the patient, was determined according to standard methods. Residual enzyme activity is expressed
as percentage of the initial activity (set to 100%)
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in coding region, flanking intronic sequences or the erythroid-specific promoter. Because
both mutations were likely to affect correct PKLR pre-mRNA processing, we studied the
effects of these mutations using erythroid cells, actively involved in RNA synthesis. For this,
we cultured nucleated erythroid cells from the light-density fraction of venous blood of the
patient and a control subject. After 10 days of culture, the initial 108 light-density cells of the
patient rendered a culture consisting of 9.5×107 cells. More than 95% of these cells were
morphologically identified as (pro-)erythroblasts. Total RNA was isolated from these cells.
The IVS5+1G>A mutation leads to skipping of exon 5 or simultaneous skipping of exon
5 and 6
For comprehensive analysis of aberrant processing induced by the IVS5+1G>A mutation,
fluorescent RT-PCR products encompassing PKLR cDNA exons 4 to 7 were separated by
capillary electrophoresis, cloned and evaluated. DNA sequence analysis of the cloned RT-
PCR product of the control confirmed normal processing of wild-type PKLR transcripts as
reflected by the majority of inserts (Figure 2A, transcript 1). 
In agreement with this, one major 586 bp fragment was detected by fragment analysis
(Figure 3A). In addition, clonal analysis revealed two rare inserts that reflected low level,
alternative processing of wild-type PKLR pre-mRNA. One of these transcripts lacked exon
6 (∆6) whereas the other transcript lacked 95 bp of the 3’-end of exon 6 due to processing at
a cryptic donor site at nt 600 in exon 6. (Figure 2A, transcripts 2 and 3). These transcripts
were, likely, represented by the 411 and 493 bp fragments, as detected by fragment analysis
(Figure 3A).
DNA sequence analysis of cloned RT-PCR product of the patient revealed six distinct inserts.
Three of these reflected the same transcripts as detected in the control, i.e. normally
processed with regard to exon 5 (Figure 2A, transcripts 1 to 3; Figure 3B, 411, 493, and 586
bp fragments). We postulate that these transcripts were not associated with the IVS5+1G>A
mutation because donor site mutations abolish normal splicing completely20 and, moreover,
Figure 2. Aberrant splicing induced by the IVS5+1G>A and c.1436G>A mutation. Schematic
representation (not drawn to scale) of the region of PKLR flanking the IVS5+1G>A (panel A) and
c.1436G>A (panel B) mutation. Location and direction of primers used for RT-PCR are indicated by
arrows. Exons are numbered and depicted as solid black boxes connected by intronic sequences,
relevant sizes (in bp) are indicated. The mutations and the location of cryptic splice donor (gt) and
acceptor sites (ag) are depicted above the exons. Normal and aberrant processing of wild-type (WT)
and patient (P) pre-mRNA is reflected by solid and dashed lines, respectively. The respective wild-type
and mutant nucleotide is indicated for each transcript. Transcripts were characterized by DNA
sequence analysis of cloned RT-PCR products and the fragment size (in bp) is indicated for each
transcript. Note that software-calculated fragment sizes (in bp) were used throughout ‘Results’. For
completeness, the actual size is displayed in brackets, directly below the calculated size. Relative
frequencies (%) of each transcript were derived from fragment analysis data. ND: Not Detected.
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the transcripts were detected in both the patient and the control. Consequently, they were
derived from the other allele of the patient. The three other inserts encountered in the cloned
RT-PCR product of the patient reflected transcripts aberrantly processed with regard to exon
5. They were not detected in the control (see above) and, thus, likely associated with the
IVS5+1G>A mutation. Of these three transcripts, two were abundant. They lacked either
exon 5 (∆5) or both exon 5 and 6 (∆5,6) (Figure 2A, transcripts 4 and 5), and corresponded
to fragments of 461 and 273 bp, as detected by fragment analysis (Figure 3B). The third,
Figure 3. Detection of aberrant transcripts associated with the IVS5+1G>A mutation. Fluorescent-dye
labeled RT-PCR products of total RNA from nucleated erythroid cells of a control subject (panel A)
and the patient (panel B) were separated by capillary electrophoresis. Primers amplified a region of
PKLR cDNA encompassing exons 4 to 7 and RT-PCR products are indicated by arrows. Peak heights
reflect the fluorescence signal of the individual fragments.
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low-abundant, transcript contained the first 51 nt of intron 5 due to the use of a cryptic donor
site at nt +52 in intron 5 (Figure 2A, transcript 6) and, likely, corresponded to the 635 bp
fragment, as detected by fragment analysis (Figure 3B). No clones were encountered that
could match the minor 374 bp fragment, detected by fragment analysis (Figure 3B). When
reviewing the different transcripts identified in the patient and control, we speculate that the
corresponding transcript lacks exon 5 and the 95 bp from the 3’-end of exon 6. 
The c.1436G>A mutation causes skipping of exon 10 and is associated with strongly
reduced transcript levels
Using primers spanning exons 9 to 12, we studied the effect of the c.1436G>A mutation on
pre-mRNA processing. Fragment analysis (data not shown), and DNA sequence analysis of the
cloned RT-PCR product of the control confirmed normal pre-mRNA processing in the majority
of transcripts (Figure 2B, transcript 7). In addition, two minor transcripts were detected that
lacked either exon 11 (∆11) or 67 bp of the 5’-end of exon 11 due to alternative processing at
a cryptic splice acceptor site at nt 1502 in exon 11 (Figure 2B, transcripts 8 and 9).
The cloned RT-PCR product of the patient revealed four distinct transcripts associated with
the c.1436G>A mutation. Three of these were low-abundant transcripts that had the absence
of exon 10 in common. They lacked exon 10 itself (∆10), exon 10 and 11 together (∆10,11),
or exon 10 and 67 bp of the 5’-end of exon 11. (Figure 2B, transcripts 10 to 12). The majority
of c.1436G>A associated transcripts was normally processed and, consequently, contained
an adenine at nt 1436 (Figure 2B, transcript 13). Three transcripts were not associated with
the c.1436G>A mutation and, thus, originated from the IVS5+1A allele. As in the control,
the majority of these transcripts was normally processed whereas a minority resulted from
alternative processing with regard to exon 11 (Figure 2B, transcripts 8 and 9). 
Remarkably, when comparing the composition of clones from the patient, only 12 of the 63
clones represented transcripts derived from the 1436A allele. A similar asymmetrical clonal
distribution was observed in the before-mentioned experiments regarding the IVS5+1G>A
mutation: of the 56 selected clones, only six clones represented transcripts from the 1436A
allele. This prompted us to estimate the relative amounts of transcripts from each allele of
the patient. Therefore, we compared MscI digestion fragments of exon 10-containing RT-
PCR and DNA-PCR products. The c.1436G>A mutation in this exon introduces a unique
recognition sequence for MscI. Agarose gel electrophoresis of digested DNA-PCR product
showed that half the amount of this 262 bp PCR product was cut into 212 and 50 bp fragments
(Figure 4, the 50 bp fragment is not shown). In contrast, the two RT-PCR product digestion
fragments (336 and 204 bp), representing the 1436A allele, were considerably less in amount
than the undigested product (540 bp) which represented the 1436G allele (Figure 4).
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The ∆5,6 nonsense transcript is, in part, associated with polysomes whereas the ∆5
transcript is unstable 
To examine whether the identified transcripts were translationally active, cell-extracts were
fractionated on sucrose gradients. Absorbance profiles of samples of the control and patient
indicated the presence of polysomes in fractions 4 to 10 (Figure 5A and 5B).
RNA obtained from each fraction was amplified by RT-PCR using primers PK-C4F and PK-
C7R, and PCR products were analyzed by fragment analysis. As depicted in Figure 5C, the
majority of wild-type mRNA was associated with polysomes. Low levels of the two other
transcripts were present in all fractions, although we note that the mRNA alternatively
spliced at the cryptic donor site in exon 6, appeared to accumulate in the lighter fractions,
containing inactive ribosomes. 
With regard to the patient, a substantial amount of ∆5,6 transcripts accumulated in the lighter
fractions. Only part of this mRNA was polysome-associated (Figure 5D). The other
transcripts were present in low amounts. Although there appeared to be a tendency for the
normally processed 1436A mRNA to associate with polysomes (Figure 5D), levels were too
low for accurate interpretation. The finding that the ∆5 mRNA was also present in low
amounts was surprising because, thus far, this transcript had been the most abundant one. A
possible explanation can be that the transcript was degraded during sample handling time
(approximately one hour), prior to performing polysome analysis. Therefore, we performed
a time-stability assay (see ‘Methods’). The results confirmed that once the cells were lysed,
the ∆5 transcript was rapidly degraded (Figure 6).
Figure 4. Association of the c.1436G>A mutation with strongly reduced transcript levels. Exon 10 was
amplified from total RNA of the patient with primers spanning exons 9 to 12, and digested with MscI.
Equal allelic amounts of exon 10 as amplified from the patient’s genomic DNA served as a control.
One of the two fragments after MscI digestion of genomic PCR product is not shown (50 bp fragment).
M: molecular mass marker.
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Figure 5. Subcellular localization of PKLR transcripts by RT-PCR analysis of polysomal fractions. (A,
B) Polysome profile analysis of nucleated erythroid cellular extracts of the control and the patient.
Polysomes were in gradient fractions 4 to 10. 40S, 60S, and 80S (monosomes) peaks are indicated by
arrows. (C, D) Distribution of mRNAs from the control and the patient as determined by RT-PCR and
subsequent fragment analysis. Primers amplified exons 4 to 7 from PKLR cDNA. For each transcript,
the amount of RT-PCR product is plotted against the fraction numbers. Transcript composition is
indicated as follows: n, normally processed; ∆6, deletion of exon 6; cryp6, spliced at the cryptic donor
site in exon 6; ∆5,6, deletion of exon 5 and 6; ∆5, deletion of exon 5.
Figure 6. Instability of the exon 5 deleted transcript. Nucleated erythroid cell lysate from the patient
was placed on ice and RNA was isolated at the indicated time intervals. RNA stability was analyzed
by RT-PCR with primers spanning exons 4 to 7, and agarose gel electrophoresis.  M: molecular mass
marker.
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Low amounts of PK monomers are synthesized by the cultured nucleated erythroid cells
of the patient
Normally processed PKLR 1436A missense mRNA, albeit present at low levels, might direct
active translation of R479H PK monomers. Using a polyclonal anti-PK antibody, a distinct
band of the expected 63 kDa29 was detected by Western Blot in the nucleated erythroid cells
of the normal control, corresponding to (erythroid-specific) PK monomers (Figure 7). The
smaller, faint band most likely corresponded to the partially proteolysed form of 57–58
kDa.29,30 The same amount of total protein from nucleated erythroid cells of the patient
displayed one faint, but distinct band of 63 kDa (Figure 7), indicative of low amounts of PK
monomers.    
Discussion
Severe pyruvate kinase deficiency in a Dutch patient with haemolytic anaemia was
associated with two single nucleotide substitutions in the PKLR gene. One novel mutation,
IVS5+1G>A, abolished the invariant dinucleotide at the donor splice site of intron 5. On the
other allele, the previously reported c.1436G>A (R479H) missense mutation was detected
which, additionally, altered the exonic consensus sequence of the intron 10 donor splice site.
Both mutations were expected to exert their principal effect at the RNA level by interfering
with correct processing of PKLR pre-mRNA. To study these effects, we used ex vivo
produced nucleated erythroid cells from the patient. Both mutations induced aberrant
processing of PKLR transcripts, and multiple mRNAs were identified. Subcellular
localization of transcripts and Western Blot analysis established the relevance of each
Figure 7. Detection of PK monomers in nucleated erythroid cells. Extracts of nucleated erythroid cells
of the control and the patient were adjusted for protein content and separated by SDS-PAGE. Proteins
were transferred to blot and PK monomers (63 kDa) were visualized by Western Blot, using a
polyclonal anti-PK antibody.
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transcript with regard to the PK-deficient phenotype of the patient. The transcript lacking
exon 5 and 6 in particular was unusual which suggests the presence of a splice enhancer
element in PKLR exon 5.
The recognition of the exon is, in general, invoked by the pairing between the 3’ and 5’ splice
site across an exon in a process called exon definition.31 Inactivation of the 5’ splice site
involves disruption of U1 snRNP binding to the donor site during early spliceosome
assembly.13 Consequently, the predominant effect of 5’ splice site mutations is skipping of
the upstream exon or the use of cryptic splice sites, when present in the vicinity of the wild-
type site.20,32 Indeed, the two major transcripts derived from the allele with the IVS5+1G>A
mutation lacked exon 5: ∆5 and ∆5,6. In addition, we detected small amounts of a transcript
with an in-frame insertion of 51 nt, resulting from processing at the cryptic donor site at nt
+52 in intron 5. The fact that this cryptic site was used at such low frequency is likely the
reflection of its markedly low 5’ splice site score33 of 63.0. The 132-bp deleted ∆5 transcript
maintains the open reading frame, encoding a PK monomer (estimated mass 58 kDa) that
lacks amino acids 126 to 169. In contrast, the 319 bp deleted ∆5,6 transcript contains a
premature stopcodon at nt 710 in exon 7. Thus, if synthesized, this monomer (estimated mass
14 kDa) would be severely truncated, lacking approximately 75% of its peptide chain.
Considering the abundance of ∆5 and ∆5,6 transcripts and their putative involvement in
protein synthesis, we determined the subcellular localization of the respective mRNAs by
polysome analysis. First, we  established the transcriptional and translational activity of the
cultured nucleated erythroid cells with regard to PK, using blood from a normal control
individual. Wild-type PKLR mRNA was associated with polysomes, and PK monomers were
detected by Western Blot, confirming the translationally active state of the cultured cells.
With regard to the ∆5,6 transcript, a substantial amount accumulated in the lighter fractions
and only part of the mRNA was polysome-associated. Thus, translation of ∆5,6 mRNA was
inefficient. Moreover, it is most likely that such a severely truncated protein, if stable, would
be non-functional.
The ∆5 transcript was unstable during polysome analysis. Western Blot analysis failed to
identify any PK of the predicted size (Figure 7) which may be directly related to this
instability or, alternatively, the mutant protein encoded by the ∆5 mRNA may be unstable. If
translated, a nonfunctional protein is to be expected since the deletion of residues 126 to 169
includes a number of amino acids essential for the enzyme’s function.28,34-37
For two reasons, the detection of the ∆5,6 mRNA was noteworthy. Firstly, this mRNA
examplifies another nonsense transcript insensitive to nonsense mediated mRNA decay
(NMD).38-40 This surveillance mechanism rapidly degrades mRNAs with premature
translation termination codons, thereby preventing the potentially deleterious effects of
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truncated proteins.41 The relative abundance of ∆5,6 mRNA suggests that this nonsense
transcript bypasses NMD, similar to recently reported fibrinogen Aα42 and β-globin43
nonsense mRNAs. Secondly, simultaneous skipping of exon 5 and 6 is unusual by itself.
Splice site mutations are rarely associated with multiple exon skipping20,32 and only a few
examples are available.44,45 Our results suggest that the IVS5+1G>A mutation-induced
skipping of exon 5 enhanced skipping of exon 6. Additional downstream (exon 7) or
upstream (exon 4) skipping events were excluded (data not shown). We hypothesize that, in
wild-type PKLR pre-mRNA, efficient inclusion of exon 6 depends on the presence in the
primary transcript of, yet undefined, splice enhancing elements in exon 5. Likely candidates
are exonic splice enhancers (ESEs).46,47 ESEs are cis-acting exonic sequence motifs that
promote exon definition by serving as RNA binding sites for specific serine/arginine-rich
(SR) proteins.48 The role of ESEs in constitutive splicing is now appreciated49,50 and binding
of SR proteins to constitutive exons plays an important role in the splicing reaction.48 ESEs
are very common in human genes and might be present in most, if not all, human exons.51,52
Interference with the function of exonic cis-elements has been shown to be a common
mechanism for inappropriate exon skipping.53 The effects of ESE-disrupting mutations have,
to our knowledge, thus far been limited to the ESE-containing exon. Recently, however,
ESEs were found to be capable of activating not only weak splice sites within the same exon,
but also weak splice sites of flanking adjacent exons, across a 430 bp intron.54 These in vitro
results, combined with the small size of PKLR intron 5 (134 bp), the weak splice sites
flanking exon 6 (3’ splice site score intron 5, 82.1; 5’ splice site score intron 6, 72.4), and the
fact that exon 6 is aberrantly processed in wild-type pre-mRNA (Figure 2A), strengthen our
hypothesis regarding the requirement of upstream exonic splice enhancing elements for
efficient inclusion of PKLR exon 6. Such a regulatory mechanism may also explain why
point mutations in an upstream exon can cause skipping of only the downstream exon.55
It is noteworthy to realize that the observation of splice site mutations leading to multiple
exon skipping can easily been obscured by the frequently applied investigative approaches
to study such mutations that involve the use of primers located only in the immediate
upstream and downstream exons. Consequently, multiple exon skipping events will go by
undetected.
Although not invariant, the guanine at the –1 nt of the 5’ splice site is very common in
primates (78%).33 The predominant feature of mutating the –1 nt is skipping of the upstream
exon. Normal processing of pre-mRNA may be observed, albeit usually at low levels.
Previous studies regarding the c.1436G>A mutation were unable to demonstrate aberrant
splicing induced by this mutation.5,28 Instead, low levels of normally processed transcript
were detected.28 Our results confirmed the association of the c.1436G>A mutation with a
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strong reduction in transcript levels. Furthermore, we demonstrate here that this mutation
does effect pre-mRNA processing by the characterization of three aberrant transcripts that
lacked exon 10. The majority of 1436A transcripts, however, was normally processed which
may be a reflection of the modest decrease in 5’ splice site score of the mutated donor site
(71.5), compared to the wild type donor site (83.9). Of interest was the presence of the
∆10,11 transcript. The equal amounts of transcripts lacking exon 11 detected in control and
patient’s RNA suggests, however, that simultaneous skipping of exon 10 and 11 in this case
more likely reflects ‘leaky splicing’ (see below) that led to skipping of exon 11 on transcripts
that had already skipped exon 10 due to the c.1436G>A mutation.
During this study we identified low-abundant alternative transcripts, not associated with
mutation. They likely resulted from inefficient processing or ‘leaky splicing’ events as has
been reported for other genes.56,57 We report here for the first time alternative processing of
wild-type PKLR pre-mRNA. Correct processing of exon 6 and 11 appeared to be inefficient
and in both cases the exons were either skipped or alternatively processed at exonic cryptic
splice sites. Although such low-abundant transcripts are not likely to result in clinical
expression, their characterization may render employable knowledge. For example, the
identification of a PKLR splice site mutation (IVS6–2A>T),10 prompted the investigators to
analyze the patient’s cDNA. This revealed no abnormalities other than a 67-bp deletion of
the 5’ end of exon 11 which, in turn, led the authors to conclude that this aberrant transcript
was related to the intron 6 acceptor site mutation.10 Figure 2B clearly shows that the 67-bp
deletion from exon 11 was a result of inefficient processing of this exon in wild-type PKLR
pre-mRNA. We propose that the actual effect of the IVS6–2A>T mutation has escaped
detection and remains to be established. 
No functional PK monomers were produced from the patient’s IVS5+1A allele. However, we
detected low amounts of PK monomers in nucleated erythroid cells of the patient which is
in agreement with the low levels of normally processed 1436A missense mRNA. Hence, the
patient can be regarded as pseudo-homozygous for R479H PK. Recently, Valentini et al.
characterized recombinant wild type and R479H mutant PK, expressed in Escherichia coli.58
Structural data concerning this mutant showed that the His479 side chain was fully solvent-
exposed and that the crystal structure of R479H PK was identical to that of the wild-type
(recombinant) protein.58 Thus, structural perturbations induced by the R479H substitution
are likely to be limited. Furthermore, kinetic parameters of the catalytically active tetrameric
mutant enzyme appeared to be essentially unaffected.58 Altogether, we postulate that the PK-
deficient phenotype of the patient is directly related to strongly reduced amounts of R479H
PK tetramers. The only discrepancy comes from the patient’s heat-sensitivity (see ‘Subjects’)
which suggests decreased stability of the R479H PK tetramer during febrile episodes or even
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prolonged exposure to sunlight. This is in agreement with reduced thermal stability of the
patient’s PK in vitro (Figure 1) but contrasts with the nearly unaffected thermal stability of
recombinant R479H PK,58 thereby underscoring the differences in fate and function of
mutant enzymes in vivo and in vitro.59
Insight into the basic mechanisms of PKLR pre-mRNA processing and the factors that
influence splice site selection may eventually result in therapeutic possibilities designed to
target the splicing pathway. Such approaches have been shown to be feasible by the
successful treatment of nucleated erythroid cells from thalassemic patients using antisense
oligonucleotides that restored correct splicing60,61 and may well be applied to other human
diseases like PK deficiency.
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Abstract
Erythrocyte pyruvate kinase (PK-R) deficiency is the most frequent cause of hereditary
hemolytic anemia due to defective glycolysis. We report the molecular basis underlying PK-
R deficiency in 28 patients from 26 unrelated families. Twenty-four different point mutations
were detected in PKLR, 14 of which are reported here for the first time. Of these novel
mutations, 12 encoded an amino acid substitution: Ile90Asn, Gly95Arg, Gly111Arg,
Ala154Thr, Gly165Val, Leu272Val, Ile310Asn, Arg337Trp, Gly358Glu, Leu374Pro,
Arg385Lys, and Arg569Gln. Two novel mutations are postulated to either affect correct
splicing (IVS4–2A>C) or to result in a truncated PK-R monomer (Arg488Stop). The
c.331G>A mutation (Gly111Arg, PK Utrecht) was one of the most frequently detected
mutant PKLR alleles and is restricted to the Dutch population. To better understand the
mechanisms by which the novel amino acid substitutions could impair enzymatic function
and lead to PK-R deficiency, we evaluated their position and the nature of substitution in the
three-dimensional model of the recently elucidated crystal structure of human erythrocyte
PK. The predicted arginine side chain at residue 111 in PK Utrecht causes severe sterical
hindrance and unfavorable charge interactions. Residues Arg337, Gly358, Arg385, and
Arg569 are located at the subunit interfaces, and allosteric interactions are likely to be
disrupted upon mutation. In particular, mutations Arg337Trp and Arg385Lys disrupt salt
bridges crucial for the T- and R-state transition. Gly95Arg and Gly165Val disrupt the
functionally important ATP binding site and B domain. Amino acid changes Leu374Pro,
Ile90Asn, Ala154Thr, and Ile310Asn perturb the hydrophobic core. Leu272Val, identified in
an asymptomatic individual with normal enzymatic activity, causes minimal structural
perturbation and may be a nonfunctional amino acid substitution.
Introduction
Defective glycolysis is an important cause of hereditary non-spherocytic hemolytic anemia
and can frequently be attributed to a deficiency of pyruvate kinase (PK). PK is a key
regulatory enzyme of glycolysis and catalyzes the irreversible phosphoryl group transfer
from phosphoenolpyruvate (PEP) to ADP, yielding pyruvate and ATP. The enzyme is
allosterically activated by PEP and fructose-1,6-diphosphate (FDP) and has an absolute
requirement for cations, normally Mg2+ and K+. Of the four PK isozymes in mammals, red-
blood cell PK (PK-R) is exclusively expressed in erythroid cells. Together with the liver-
specific isozyme PK-L, PK-R is transcribed from the PKLR gene by means of tissue-specific
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expression.1,2 The PK-M1 (expressed in skeletal muscle) and PK-M2 (expressed in fetal and
most other adult tissues) isozymes are also produced from one gene (PKM2) but from
distinct mRNAs, generated by alternative splicing.3 Because the mature enucleated
erythrocyte is totally dependent on glycolysis, a deficiency of PK-R results in a continuous
lack of ATP. This shortens the life span of the red blood cell, leading to non-spherocytic
hemolytic anemia.4 PK deficiency is inherited in an autosomal recessive manner with an
estimated prevalence of 51 cases (i.e. homozygous or compound heterozygous patients) per
million in the white population.5 The clinical symptoms are variable, ranging from
pronounced neonatal jaundice requiring multiple transfusions to a fully compensated
hemolytic anemia.6 To date, more than 150 mutations in PKLR have been associated with PK
deficiency (reference 7, and this study). The vast majority of these mutations are missense
mutations that affect residues that are important for the enzyme’s stability and function.
Parameters of PK are so finely tuned that even moderate molecular alterations may
significantly perturb cell metabolism.8
Human red blood cell PK (PK-R) is a homotetramer and each subunit can be divided into
four domains: the N domain (residues 1–84), A domain (residues 85–159 and 263–431), B
domain (residues 160–262), and C domain (residues 432–574) (Figure 1).8 Domain A is the
most highly conserved whereas the B and C domain are more variable.9 The active site lies
in a cleft between the A domain and the flexible B domain. The B domain is capable of
rotating away from the A domain generating either the ‘open’ or ‘closed’ conformation. The
C domain contains the binding site for FDP. The allosteric transition from the inactive T-state
to the active R-state results in a catalytically active PK tetramer, consisting of an assembly
of domains and subunits in which allosteric and catalytic sites are able to communicate with
each other across the relatively long distance that separates the FDP binding site from the
catalytic center. Tetrameric interactions at the interfaces between the A domains (A/A’
subunit interface) and the C domains (C/C’ subunit interface), as well as A/B and A/C
interdomain interactions are considered to be key determinants of the allosteric response.8,10-
15 However, a comprehensive analysis of the allosteric transition awaits the direct
comparison of crystal structures from the T- and R-state enzymes from the same species.
We established the molecular defect underlying PK deficiency in a group of 28 different
patients from 26 unrelated families. Twenty-four different mutations were detected in PKLR,
associated with PK deficiency. Twenty of these mutations, including 14 novel ones, encoded
a single amino acid substitution. The structural perturbation predicted by the novel missense
mutations may lead to severe impairment of enzymatic function. The mechanism by which
this occurs can be quite diverse, affecting, for instance, allosteric properties, substrate
binding, effector binding, or overall protein stability. The recently elucidated crystal
92
Fourteen novel mutations in PKLR 
Ta
bl
e 
1.
 C
lin
ic
al
 c
la
ss
ifi
ca
tio
n 
of
 P
K
 d
efi
ci
en
t p
at
ie
nt
s i
nv
es
tig
at
ed
 in
 th
is 
st
ud
y
Pa
tie
nt
o
ri
gi
n
PK
LR
 m
ut
at
io
n
ef
fe
ct
a
ge
 o
f
PK
 a
ct
iv
ity
H
K
 a
ct
iv
ity
sp
le
ne
ct
om
y
re
gu
la
r
H
b
re
tic
ul
o
ph
en
ot
yp
e
M
/F
cD
N
A
 n
t
di
ag
no
sis
V
m
a
x
in
 IU
/g
H
b
V
m
a
x
in
 IU
/g
H
b
tr
an
sf
us
io
ns
g/
dL
‰
D
P8
7 
(F
)
D
ut
ch
28
3G
>A
/4
01
T>
A
G
95
R
/V
13
4D
bi
rth
3.
5
6.
7
ye
s
ye
s
9.
1
19
3
se
v
er
e
M
E7
2 
(F
)
D
ut
ch
26
9T
>A
/3
31
G
>A
I9
0N
/G
11
1R
bi
rth
<
1.
0
6.
9
ye
s
ye
s
6.
4
70
0
se
v
er
e
M
E7
4a
(F
)
D
ut
ch
26
9T
>A
/3
31
G
>A
I9
0N
/G
11
1R
bi
rth
<
1.
0
7.
6
ye
s
ye
s
6.
9
49
8
se
v
er
e
A
C7
6 
(F
)
A
m
er
ic
an
 B
la
ck
32
0T
>C
/1
52
9G
>A
M
10
7T
/R
51
0Q
2 
ye
ar
s
N
A
N
A
ye
s
ye
s
8.
6
27
0
se
v
er
e
SS
95
 (F
)
D
ut
ch
33
1G
>A
/9
29
T>
A
G
11
1R
/I3
10
N
bi
rth
6.
4
1.
10
n
o
ye
s
7.
2
33
se
v
er
e
A
B6
6 
(M
)
D
ut
ch
33
1G
>A
/1
49
2C
>T
G
11
1R
/R
49
8C
18
 y
ea
rs
1.
3
4.
67
ye
s
n
o
9.
6
18
7
se
v
er
e
SB
02
b
(M
)
D
ut
ch
IV
S4
–2
A
>C
/4
94
G
>T
sp
lic
in
g/
G
16
5V
bi
rth
1.
5
N
A
-
-
N
A
N
A
se
v
er
e
SN
99
 (F
)
D
an
ish
40
1T
>A
/1
52
9G
>A
V
13
4D
/R
51
0Q
2 
m
on
th
s
4.
7
1.
48
n
o
ye
s
9.
3
14
se
v
er
e
CM
99
 (F
)
Fi
nn
ish
40
1T
>A
/1
52
9G
>A
V
13
4D
/R
51
0Q
3 
m
on
th
s
4.
7
2.
11
n
o
ye
s
7.
5
12
6
se
v
er
e
CB
93
 (M
)
D
ut
ch
72
1G
>T
/1
52
9G
>A
E2
41
X
/R
51
0Q
bi
rth
<
1.
0
3.
80
n
o
ye
s
7.
5
70
se
v
er
e
B
F9
8 
(M
)
D
an
ish
10
09
C
>T
/1
45
6C
>T
R
33
7W
/R
48
6W
bi
rth
3.
8
7.
10
n
o
ye
s
8.
6
46
se
v
er
e
U
S0
2 
 (M
)
D
an
ish
10
09
C
>T
/1
45
6C
>T
R
33
7W
/R
48
6W
5 
m
on
th
s
6.
4
4.
24
n
o
ye
s
6.
7
13
se
v
er
e
Y
I9
0 
(M
)
Sy
ria
n
10
73
G
>A
/1
07
3G
>A
G
35
8E
/G
35
8E
10
 y
ea
rs
1.
4
8.
24
ye
s
ye
s
7.
8
N
A
se
v
er
e
JW
65
 (M
)
D
ut
ch
11
78
A
>G
/1
45
6C
>T
N
39
3S
/R
48
6W
32
 y
ea
rs
17
%
d
N
A
ye
s
n
o
9.
6
55
6
se
v
er
e
D
H
95
 (M
)
D
ut
ch
12
69
G
>A
/1
65
4G
>A
sp
lic
in
g/
V
55
2M
6 
m
on
th
s
5.
1
N
A
n
o
ye
s
5.
6
44
se
v
er
e
D
M
96
 (M
)
A
lb
an
ia
n
13
73
G
>A
/1
37
3G
>A
G
45
8D
/G
45
8D
1 
ye
ar
10
0%
d
50
0%
d
n
o
ye
s
5.
9
45
0
se
v
er
e
G
H
92
 (F
)
D
ut
ch
14
62
C
>T
/1
52
9G
>A
R
48
8X
/R
51
0Q
bi
rth
1.
5
8.
10
n
o
ye
s
5.
8
14
7
se
v
er
e
EV
70
 (F
)
D
ut
ch
14
62
C
>T
/1
52
9G
>A
R
48
8X
/R
51
0Q
3 
ye
ar
s
0.
8
N
A
ye
s
n
o
6.
1
85
1
se
v
er
e
JR
63
 (M
)
D
ut
ch
33
1G
>A
/1
45
6C
>T
G
11
1R
/R
48
6W
33
 y
ea
rs
4.
2
2.
64
n
o
n
o
10
.7
43
m
ild
SH
68
 (F
)
D
ut
ch
33
1G
>A
/1
45
6C
>T
G
11
1R
/R
48
6W
30
 y
ea
rs
5.
0
N
A
n
o
n
o
11
.7
31
m
ild
CC
78
 (F
)
D
ut
ch
11
21
T>
C
/1
70
6G
>A
L3
74
P/
R
56
9Q
21
 y
ea
rs
1.
9
1.
94
n
o
n
o
10
.9
71
m
ild
R
C7
3c
(M
)
D
ut
ch
11
21
T>
C
/1
70
6G
>A
L3
74
P/
R
56
9Q
26
 y
ea
rs
1.
4
1.
45
n
o
n
o
12
.2
61
m
ild
K
L7
0 
(M
)
D
ut
ch
11
54
G
>A
/1
52
9G
>A
R
38
5K
/R
51
0Q
7 
ye
ar
s
0.
9
1.
95
n
o
n
o
12
.2
48
m
ild
M
N
03
 (F
)
D
ut
ch
12
69
G
>A
/1
45
6C
>T
sp
lic
in
g/
R4
86
W
bi
rth
1.
3
N
A
n
o
n
o
8.
7
10
9
m
ild
M
D
00
 (M
)
D
ut
ch
14
56
C>
T/
15
29
G
>A
R
48
6W
/R
51
0Q
3 
m
on
th
s
1.
7
2.
54
n
o
n
o
9.
3
42
m
ild
M
B
86
 (M
)
D
ut
ch
15
29
G
>A
/1
52
9G
>A
R
51
0Q
/R
51
0Q
1 
ye
ar
N
A
N
A
n
o
n
o
9.
6
70
m
ild
IM
60
 (F
)
Ch
ec
h
46
0G
>A
/N
A
15
4T
/N
43
 y
ea
rs
4.
8
1.
31
n
o
n
o
10
.6
12
as
ym
pt
om
at
ic
K
T9
3 
(M
)
G
ha
ne
se
81
4C
>G
/N
L2
72
V
/N
5 
ye
ar
s
8.
4
1.
51
n
o
n
o
12
.0
N
A
as
ym
pt
om
at
ic
R
ef
er
en
ce
-
-
-
-
6.
9–
14
.5
1.
02
–1
.5
8
-
-
13
.8
–1
7.
1 
(M
)
-
v
a
lu
es
11
.8
–1
5.
4 
(F
)
5-
25
Pa
tie
nt
s a
re
 c
at
eg
or
iz
ed
 a
cc
or
di
ng
 to
 th
e 
se
v
er
ity
 o
f t
he
 p
he
no
ty
pe
,16
m
u
ta
tio
ns
 re
po
rte
d 
he
re
 fo
r t
he
 fi
rs
t t
im
e 
ar
e 
in
 b
ol
d-
fa
ce
 ty
pi
ng
. a
 S
ist
er
 o
f M
E7
2,
b
th
is 
pa
tie
nt
 d
ie
d 
on
e 
da
y 
af
te
r b
irt
h 
du
e 
to
 se
v
er
e 
he
m
ol
yt
ic
 a
ne
m
ia
,c
 b
ro
th
er
 o
f C
C7
8,
d 
re
la
tiv
e 
to
 n
or
m
al
. N
A
,
N
ot
 a
v
ai
la
bl
e;
 N
,N
or
m
al
.
93
Chapter 4
structure of human erythrocyte PK8 has enabled the evaluation of amino acid substitutions
at the molecular level and this in turn may provide insight with respect to a genotype-
phenotype correlation. To gain insight into the mode of action of the here reported novel
amino acid substitutions, we evaluated the concerned residues and the predicted molecular
perturbation in the three-dimensional model of human erythrocyte PK. 
Patients, materials and methods
Patients
Twenty-eight patients were investigated. These were either newly identified patients or
previously diagnosed patients who were referred to our center for confirmation of the
diagnosis and to establish the molecular basis of PK deficiency. Other causes of (hemolytic)
anemia were ruled out. Table 1 lists the clinical data of these patients who belong to 26
unrelated families, mostly from Dutch origin. The age at which the diagnosis PK deficiency
was made, and PK and hexokinase (HK) enzyme activity measurements at the time of
diagnosis are listed. HK activity measurements were included to estimate the contribution of
the relatively young cell fraction (displaying much higher enzymatic activities of PK and
HK) to the total PK activity as measured. Furthermore, clinical data regarding splenectomy
and the need for regular transfusions are indicated for each patient as well as their most
recent Hb levels and reticulocyte counts. The patient’s phenotypes were classified according
to Zanella et al. (i.e. severe phenotype: pre-splenectomy Hb levels lower than 8 g/dL and/or
more than 50 transfusions and/or splenectomized; mild phenotype: Hb levels greater than 9
g/dL, fewer than five transfusions, non-splenectomized).16
Appropriate informed consent was obtained from all patients or their parents.
Biochemical and molecular analysis
Hematological parameters were measured on a Cell-Dyn 4000 hematology analyzer (Abbott
Diagnostics, Santa Clara, CA). PK and HK enzyme activities were measured according to
standard methods.17
Genomic DNA was isolated by standard methods. The erythroid-specific promoter and
individual exons of PKLR, including flanking intronic regions, were amplified by PCR as
described previously18 and sequenced with the BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) on an ABI 310 Genetic Analyzer (Applied
Biosystems). PKLR cDNA nucleotide and amino acid numbering starts at the initiator
methionine of reference sequence P30613 (GenBank) and mutations are described according
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to the mutation nomenclature system.19 Novel mutations were confirmed by restriction enzyme
digestion of independently amplified PCR products, except for the c.283G>A mutation, which
was confirmed by independent PCR and DNA sequence analysis. The following enzymes were
used ((+) or (–) indicates the presence or absence of a recognition sequence in case of presence
of the mutation): c.269T>A, SfaNI (–); c.331G>A, MspI (–); IVS4–2A>C, BsrI (–); c.460G>A,
HPY-CH4III (+); c.494G>T, BsrI (–); c.814C>G, BspMI (–); c.929T>A, DpnII (–); c.1009C>T,
NlaIII (+); c.1073G>A, AfeI (+); c.1121T>C, MspI (+); c.1154G>A, MnlI (–); c.1462C>T, BslI
(–); c.1706G>A, BspMI (+) (all enzymes obtained from New England Biolabs, Beverly, MA).
For detection of the c.460G>A mutation a single mismatch was introduced in the reverse primer
to create a recognition sequence for HPY-CH4III. Detection of the c.1706G>A mutation by
BspMI digestion requires the in cis presence of cytosine at the polymorphic nt 1705. 
None of the novel mutations were detected in DNA of a normal control population (n = 100),
screened for by the appropriate method.
Structural analysis and molecular modeling
Amino acid substitutions were evaluated using the three-dimensional structure of recombinant
human erythrocyte R-state tetrameric PK, cystallized in complex with FDP and
phosphoglycolate, a substrate analog (Protein Data Bank Entry 1LIU).8 Mutated residue Arg111
was modeled using the program O20 and coordinates from 1LIU. Figures were generated using
computer programs Molscript21 and Raster3D.22
Results and Discussion
Based on the clinical picture, 26 of 28 investigated patients were expected to be either compound
heterozygous or homozygous for a mutation in PKLR. One additional patient with anemia but
without hemolysis (IM60) was expected to be heterozygous whereas another asymptomatic
individual (KT93) was detected by chance. Table 1 shows that the molecular diagnosis was
complete in all patients. In total, 24 different single-base changes were identified in PKLR of
which 14 mutations have not been reported before. Twenty mutations, including 12 novel ones,
encoded an amino acid change whereas four mutations predicted either a truncated peptide
(mutations c.721G>T and c.1462C>T) or aberrant PKLR mRNA (IVS4–2A>C and
c.1269G>A). 
The structural effects of the 12 novel amino acid substitutions were evaluated in the three-
dimensional model of human erythrocyte PK. The location of the residues concerned is shown
in Figure 1. The results from structural analysis are summarized in Table 2.  
95
Chapter 4
Figure 1. PK monomer with depicted positions of the substituted amino acids described in this
study (color version, addendum page 164). The figure highlights one PK subunit in the tetrameric
structure. The residues affected by the novel missense mutations are shown as red spheres. The A
domain is colored blue. The B (top) and C domains (bottom) are colored green. The N-terminal domain
is colored light-blue. The substrate analog phosphoglycolate and the allosteric effector fructose-1,6-
diphosphate are colored purple and drawn in ball-and-stick mode in their binding pockets in the A and
C domains, respectively.
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The c.331G>A (Gly111Arg) mutation is a frequent mutation in the Dutch population
The c.331G>A mutation predicts the substitution of a highly conserved glycine by arginine
at residue 111 located at the end of helix Aα1. The introduction of an arginine side chain
causes severe sterical hindrance and unfavorable charge interactions with side chains of
Arg86, Ile90, Val418, and His422, thereby destabilizing helix Aα1 and its neighborhood
(Figure 2). 
The c.331G>A mutation was detected in five of the 27 unrelated families (Table 1). Because
all five families were of Dutch origin, the Gly111Arg PK-R variant represents an important
BH: buried hydrophobic, the original residue is buried in the hydrophobic core
SH: sterical hindrance, the new side chain needs more room than is available
LH: leaves a hole, a buried side chain is replaced by a smaller side chain – the resulting
hole must be filled up with water or a structural rearrangement must occur
AS: residue is located in the active site, including PEP binding site and metal ion
binding sites
NA: residue is located near or at the ATP binding site
SI: subunit interface, residue is located in either the A/A’, SI(A) or C/C’, SI(C)
interface of two subunits – mutation may disturb allosteric interactions
LC: loss of charged contact
UC: unfavorable charge interaction
DS: disrupts secondary structure (e.g. introduction of a proline residue in the middle of
a strand or helix)
Table 2. Structural implications of novel missense mutations in PKLR
PKLR allele amino acid change secondary role in structure /
structure likely effect of mutation
c.269T>A Ile90Asn Aβ1 BH, SH
c.283G>A Gly95Arg Aα1 BH, NA, SH
c.331G>A Gly111Arg Aα1 SH, UC
c.460G>A Ala154Thr Aβ3 BH, SH
c.494G>T Gly165Val Bβ1 SH
c.814C>G Leu272Val Aα3 BH
c.929T>A Ile310Asn Aβ5 BH
c.1009C>T Arg337Trp Aα6a AS, SH, SI(A), LC
c.1073G>A Gly358Glu Aα6 BH, SI(A), SH
c.1121T>C Leu374Pro Aα7a DS, BH, SH
c.1154G>A Arg385Lys Aα7 SI(A), HB
c.1706G>A Arg569Gln Cβ5 SI(C)
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cause of PK deficiency in The Netherlands. In fact, together with the common c.1529G>A
(12 out of 50 mutant PKLR alleles) and c.1456C>T (7 out of 50 alleles) mutations, the
c.331G>A allele (5 out of 50 alleles) underlies almost 50% of all cases of PK deficiency
reported in this study (Table 1). We designated this variant PK Utrecht. Haplotype analysis
using the recently reported erythroid-specific promoter polymorphism -248delT,18 and the
known polymorphisms in intron 5 (IVS5+51C/T), intron 11 (variable number of ATT-
repeats), and exon 12 (c.1705A/C, c.1738C/T, and +267T/C), showed an identical haplotype
in all families: T-T-16-C-T-C. This strongly suggests a single origin of PK Utrecht in the
Dutch population.  
All patients in which the c.331G>A mutation was encountered were compound
heterozygous, and four different mutations were detected in trans to the 331A allele:
c.269T>A (Ile90Asn) in the related patients ME72 and ME74, c.929T>A (Ile310Asn) in
patient SS95, c.1492C>T (Arg498Cys) in patient AB66, and c.1456C>T (Arg486Trp) in the
unrelated patients JR63 and SH68 (Table 1). The absence of homozygous patients limits the
evaluation of the Gly111Arg substitution with regard to its deleterious effect and the PK-
deficient phenotype. A comparison of the phenotypes of the six compound heterozygous
patients shows that four patients are severely affected whereas two patients display a mild
phenotype (Table 1). These latter two, unrelated, patients have co-inherited the c.1456C>T
mutation which likely accounts for their mild phenotype. The c.1456C>T mutation encodes
the substitution of Arg486 with tryptophan.23 Despite this drastic amino acid replacement at
Figure 2. Modeling of the Gly111Arg
substitution (color version,
addendum page 165). Ribbon drawing
of the neighborhood of the Gly111Arg
substitution with selected residues
shown in ball-and-stick. The modeled
conformation of Arg111 is depicted
with magenta carbon atoms. Arginine
side chains can adopt several
orientations, but only one is shown. In
all possible conformations of Arg111,
sterical clashes or unfavorable charge
interactions would occur between its
side chain and one or more of the
neighboring residues depicted.
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the A/C domain interface, the introduction of the tryptophan side chain causes little structural
perturbation and limited changes in biochemical parameters.8 Accordingly, its inheritance is
usually associated with mild clinical symptoms24 and even homozygous patients exhibit, in
general, a mild anemia.25
Amino acid substitutions in the A/A’ and C/C’ subunit interfaces: Arg337Trp, Gly358Glu,
Arg385Lys, and Arg569Gln
Arg337 and Arg385 are highly conserved residues located in the A/A’ subunit interface close
to the active site. In fact, Arg337 is one of three consecutive amino acids (337RGD339) that
are absolutely conserved among 50 PK sequences.9 A comparison between the T-state
structures of Leishmania mexicana12 and Escherichia coli,10 and the R-state structures of
PK-M1,26,27 yeast,11 and human PK-R,8 shows that Arg337 and Arg385 are involved in salt
bridge formation to the same residue in the R- and T-state, respectively. In the T-state
structures, Arg385 (human PK-R numbering) forms a salt bridge with Asp390 of the
opposing monomer. In the R-state structures, this inter-subunit salt bridge is lost and Asp390
Figure 3. Structural role of Arg337 and Arg385 (color version, addendum page 165). Arg337 is
located close to the substrate-binding site in the A domain (blue) and forms a salt bridge with Asp390
of the same subunit. Arg385, located in the A domain of an opposing subunit (gray), forms a salt bridge
with Asp221 of the B domain (green). In the crystal structure, the substrate binding site is occupied by
the substrate analog phosphoglycolate drawn in purple ball-and-stick representation. Mutation
Arg337Trp would cause severe sterical hindrance and abolish charge interactions. The more
conservative mutation of Arg385Lys would not cause sterical hindrance and would retain in part the
potential for hydrogen bonding and charge interactions. Due to their position close in domain and
subunit interfaces close to the active site these mutations will likely affect catalysis and allosteric
regulation.
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now forms a salt bridge with Arg337 of the same subunit, while Arg385 now establishes an
inter-subunit salt bridge near the active site with Asp221 of the B domain of the opposing
monomer (Figure 3). 
The Arg385–Asp221 salt bridge anchors the B domain in the ‘closed conformation’,
competent for PEP binding.10 In agreement with this, Wooll et al. have shown that the loss
of this salt bridge, brought about by a single amino acid substitution (Ser402Pro, i.e. Ser446
in PK-R) at the A/A’ subunit interface of the (R-like) PK-M1 isozyme, is accompanied by
increased rotational flexibility of the B domain.14 Furthermore, substitution of the residues
equivalent to Arg385 and Asp390 in Escherichia coli (i.e. Arg292 and Asp297) by aspartate
and arginine, respectively, rendered the enzyme totally inactive.13 Therefore, mutations
Arg337Trp and Arg385Lys appear to disturb interactions crucial to the T- to R-state allosteric
transition and, in the case of Arg385Lys, may affect the closure of the active site by the B
domain.
Patients BF98 and US02 were both compound heterozygous for the c.1009C>T (Arg337Trp)
and c.1456C>T (Arg486Trp) mutation (Table 1). Despite the co-inheritance of the mild
1456T allele (see above), they were both severely affected. Thus, the severe clinical
phenotype of patients BF98 and US02 may result from the detrimental effect of the
Arg337Trp substitution. Interestingly in this respect are the clinical features observed in a
heterozygous PK-deficient patient. In this patient heterozygosity for the c.1010G>A
missense mutation, which predicts the substitution of Arg337 by glutamine, was associated
with the existence of hemolysis.28 Similarly, DNA analysis of another, moderately affected,
patient displayed no other abnormality than heterozygosity for the c.1010G>C missense
mutation which encodes the substitution of Arg337 by proline.24 This suggests that PKLR
alleles encoding a substitution of residue 337 display a dominant mode of inheritance, as has
been suggested for certain other PK variants.29,30
Considering the important structural role for Arg385 in both the T- and R-state structures of
PK it was surprising that patient KL70, compound heterozygous for c.1154G>A
(Arg385Lys) and c.1529G>A (Arg510Gln) was only mildly affected (Table 1). In contrast,
another missense mutation affecting Arg385 (Arg385Trp) caused severe hemolysis in a 1-
year-old transfusion-dependent boy in spite of the in trans presence of the mild 1456T
allele.5 This apparent discrepancy may be explained by the fact that substitution of arginine
by lysine, which are both positively charged, is a more conservative change than substitution
of Arg385 with tryptophan and does not destroy the potential to form salt bridges.
Gly358 is completely buried in the A/A’ subunit interface. Introduction of a negatively
charged glutamate at position 358 perturbs this interface and causes severe PK deficiency as
illustrated by patient YI90 (Table 1). This patient was designated as homozygous for the
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causative c.1073G>A missense mutation that encodes Gly358Glu. He is a 10-year-old boy
from Syrian ancestry who suffered from hemolytic anemia since birth. He presented with
hyperbilirubinemia shortly after birth for which he received an exchange transfusion.
Thereafter, he required a blood transfusion every two to three weeks because of persistent
hemolysis. He underwent splenectomy at age four years after which transfusion dependency
decreased to once every four to six months. To date, he is a pale and icteric boy who is
otherwise doing well. Because his parents were not available for study, we cannot rule out
the possibility that the patient is in fact compound heterozygous for c.1073G>A and a
deletion spanning (part of) exon 8. Interestingly, Gly358 is the least conserved residue of all
amino acids described in this study (Figure 4 and reference 9) and the residue at the
equivalent position 265 in Escherichia coli is glutamate, like it is in our patient. This
illustrates that disease-causing mutations in humans may occur in other species (e.g. the
mouse31) without leading to disease32 because of the presence of other compensating
sequence variations.33
Arg569 is a solvent exposed residue, located five residues from the C terminal end of PK-R
Isozyme      species           Gly358
                                                                      ↓
  PK-R   Hs    (348) KVFLAQKMMIGRCNLAGKPVV
 PK-R   Mm    (348) KVFLAQKMMIGRCNLAGKPVV
 PK-R      Rn   (348) KVFLAQKMMIGRCNLAGKPVV
 PK-R      Cf   (348) KVFLAQKMMIGRCNLAGKPVV
 PK-M2     Hs   (305) KVFLAQKMMIGRCNRAGKPVI
 PK-M2     Mm   (305) KVFLAQKMMIGRCNRAGKPVI
 PK-M2     Rn   (305) KVFLAQKMMIGRCNRAGKPVI
 PK-M1     Oc   (305) KVFLAQKMIIGRCNRAGKPVI
 PK-M1     Fc   (305) KVFLAQKMMIGRCNRAGKPVI
 PK-M1     Gg   (305) KVFLAQKMMIGRCNRAGKPII
  PK       Dm   (308) KVFLAQKAMIARCNKAGKPVI
  PK       Ce   (374) KVFLAQKMLISKCNRAGKPVI
  PK       Lm   (273) KVVVAQKILISKCNVAGKPVI
  PK       Sc   (275) EVLAVQKKLIAKSNLAGKPVI
  PK       Ec   (255) EVIFAQKMMIEKCIRARKVVI
Figure 4. Amino acid conservation of Gly358. Neighbouring amino acids of PK-R residue Gly358
of different PKs among selected species shows that the conservation of Gly358 is limited to mammals.
Species are: Hs (Homo sapiens, human); Mm (Mus musculus, house mouse); Rn (Rattus norvegicus,
Norway rat); Cf (Canis familiaris, dog); Oc (Oryctolagus cuniculus, rabbit); Fc (Felis catus, cat); Gg
(Gallus gallus, chicken); Dm (Drosophila melanogaster, fruit fly); Ce (Caenorhabditis elegans,
worm); Lm (Leishmania mexicana, protozoan); Sc (Saccharomyces cerevisiae, yeast); Ec (Escherichia
coli, bacterium).
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in the C/C’ subunit interface. It is the most C-terminal mutation reported to date (reference
7, and this study). The arginine side chain is directed away from the interface and does not
make specific hydrogen bonds or charge interactions. At first sight introduction of a
glutamine side chain at this position would not seem to have any drastic effect. However,
because Arg569 residues from different subunits are located close together across the subunit
interface, substitution of Arg569 with glutamine involves the loss of two positive charges in
the C/C’ interface. This additive effect on the local electrostatic potential might be the basis
for adverse effects of this mutation.
The two related patients (CC78 and RC73) carrying the Arg569Gln PK-R variant both
showed a very mild phenotype (Table 1). The in trans inherited allele in both patients was
c.1121T>C which predicts the substitution of Leu374 by proline (see below). Patient CC78
was first diagnosed with PK deficiency at 21 years-of-age because of a life-long history of
mild anemia. Subsequent testing of her brother (RC73) revealed the same PKLR genotype.
Both patients have never received any blood transfusion nor suffered from hemolytic crises.
Amino acid substitutions in the active site and B domain: Gly95Arg and Gly165Val
Gly95 is a highly conserved residue in the ATP binding site and the introduction of valine is
likely to affect catalysis. On the DNA level, the c.283G>A mutation that encodes the
Gly95Arg substitution alters the last nucleotide of exon 3. Thereby, it disrupts the exonic
consensus sequence that constitutes the 5’ splice site of intron 3 and may affect correct
processing of PKLR pre-mRNA.34 A dual effect of this mutation is thus expected, similar to
a previously described case of severe PK deficiency.35
Amino acid substitutions in the B domain are relatively rare (reference 7, and this study). The
only B domain alteration identified in this study concerns the substitution of glycine by
valine at residue 165. The introduction of the valine side chain causes severe sterical
hindrance, in particular with Trp201. Gly165 resides in a critical region of PK, illustrated by
the importance of active site residue Arg16311,12,26,27,36 which links domains A and B, and
is involved in ‘closure’ of the B domain upon substrate binding. Substitution of Arg163 by
Cys (PK Linz) in a homozygous patient was associated with severe, transfusion-dependent
hemolytic anemia.37
Mutations c.283G>A (Gly95Arg) and c.494G>T (Gly165Val) were identified in two
severely affected patients (Table 1). The clinical picture of patient DP87 has been previously
reported.38 She is one of the most severely affected patients described in this study. To date,
at 16 years-of-age, this pale girl displays retarded growth and requires blood transfusions
every four to six weeks. The patient with the predicted Gly165Val PK-R variant (SB02) died
one day after birth due to severe hemolytic anemia (Table 1). The in-trans PKLR allele of
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this patient carried the IVS4–2A>C splice site mutation which, most likely, abolishes normal
splicing completely (see below). We postulate that because of the lethal combination of these
two mutations, the Gly165Val substitution leads to severely impaired enzyme function. 
Amino acid substitutions in the hydrophobic core: Ile90Asn, Ala154Thr, Ile310Asn, and
Leu374Pro
Residues Ile90, Ala154, Ile310, and Leu374 are completely buried inside the densely packed
hydrophobic core. Consequently, the introduction of proline instead of leucine in helix Aα7a,
and polar residues at positions 90 and 310 (asparagine) and position 154 (threonine), perturb
the hydrophobic interior of the protein, forcing the surrounding side chains to rearrange
(Table 2).
Although the Ala154Thr substitution represents the least dramatic amino acid replacement,
Ala154 is a highly conserved residue and close to active site residues Arg116 (substrate
binding8 and ATP/ADP binding12,26,27) and Asp156 (K+ binding11,12,14,27). The heterozygous
individual in which this mutation was identified (IM60) showed PK activity in the
heterozygous range (Table 1), thereby confirming the association of this mutation with PK
deficiency.
Leu272Val causes little structural perturbation and may represent a nonfunctional
substitution
The substitution of leucine at residue 272 by valine is a conservative amino acid replacement
of which the causative mutation (c.814C>G) was identified by chance in an asymptomatic
individual who was heterozygous for this mutation. This individual (KT93) displayed normal
PK activity in the absence of reticulocytosis (Table 1). It is of course possible that altered
enzymatic properties of the Leu272Val PK-R hetero- or homotetramer obscure the
interpretation of in vitro enzymatic activity of PK, as measured under optimized
experimental conditions. It is also conceivable, however, that the subtle alterations induced
by valine at residue 272 are without functional consequences. The c.814C>G mutation was
not detected in the normal control population but these results hold limited value because the
control individuals are of Caucasian origin whereas KT93 originates from Ghana.
Interestingly in this respect is the fact that PK deficiency is very rare in Africa. Hence,
screening of a representative African control population may resolve the question whether
the African PKLR c.814C>G allele is either very rare, or a polymorphic variant that has
remained undetected because of only subtle effects on enzymatic activity. More conclusive
evidence regarding the effects on PK enzymatic function awaits the biochemical
characterization of the Leu272Val PK-R homotetramer.
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Other mutations in PKLR identified in this study
Two other novel single-base substitutions identified in this study were associated with PK
deficiency. These constituted a nonsense mutation (c.1462C>T) and a splice-site mutation in
intron 4 (IVS4–2A>C). The novel c.1462C>T mutation predicts a truncated PK monomer,
which, if stable, would lack 86 amino acids from its C-terminal end, thereby disrupting the FDP
binding site. It is highly likely that such a drastic alteration causes severe impairment of
enzymatic function. The IVS4–2A>C mutation abolishes the invariant AG dinucleotide39 of the
IVS4 splice acceptor site and, most likely, abolishes normal processing of PKLR pre-mRNA
completely. 
The twelve novel missense mutations reported here concerned residues that are fully conserved
among mammals. In addition, most residues are also highly conserved among PK from 50
different species9 and, apart from Gly165Val and Arg569Gln, are confined to the highly
conserved A domain (Figure 1). The three-dimensional model of human erythrocyte PK enabled
a close evaluation of these newly identified missense mutations. The predicted induced
molecular perturbation was shown to affect structurally and functionally important residues in
PK in such a way that its enzymatic function is likely to be severely reduced. In all cases a causal
relationship could be substantiated between the amino acid substitution and PK deficiency. The
clinical pictures associated with PK deficiency in this study ranged from very mild (e.g. patient
RC73) to very severe (e.g. DP87), and even lethal (SB02). Most patients are compound
heterozygous. Hence, if stable, five different PK-R tetramers may be assembled from two
different PK monomers. This limits the genotype-phenotype correlation to homozygous
patients. However, even homozygous PK-deficient patients may display considerable variation
in their clinical picture as has been demonstrated for c.1529G>A homozygotes.40 In spite of
these difficulties it remains of great value to study PK-deficient patients. Ultimately, a more
general picture may emerge regarding the effects of specific mutations. A good example with
regard to the latter is the acceptance of the 1456T allele as a ‘mild’ PK-deficient allele. Also in
this study this common PKLR allele was more frequently associated with a mild phenotype,
allelic frequency 0.50 (n = 16), than with a severe phenotype, allelic frequency 0.06 (n = 32)
(Table 1).
In order to be able to establish a genotype-phenotype correlation in PK deficiency, which may
be of importance in counseling PK-deficient patients, a first prerequisite is the identification of
the molecular mechanism by which amino acid substitutions lead to impaired enzymatic
activity. Although the sophisticated mode of action of PK is finely tuned we have reason to
believe that nonfunctional amino acid substitutions, like Leu272Val, may be tolerable in PK. The
structural information as employed in this study has provided insight regarding the nature of
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mutation and its associated effects on protein structure and, hence, function. Thereby, it
contributes to a better understanding of disease-causing amino acid changes in PK and, vice
versa, provides knowledge about the enzyme’s structure and function.
Acknowledgements
The authors wish to sincerely thank the following clinicians for providing clinical data: P.
Joosten (Medical Center Leeuwarden, Leeuwarden), M. Karagiorga and V. Berdoukas
(‘Aghia Sophia’ Children’s Hospital, Athens), L.E. de Bruyne and R.J.Th. Ouwendijk (Ikazia
Hospital, Rotterdam), A.H.P.M. Essink, E. de Vries, T. van Ditzhuijsen, and N. Van
Widdershoven (Jeroen Bosch Hospital, ’s Hertogenbosch), K. Schmiegelow (Rigshospitalet,
Copenhagen), A.A. van Loosdrecht (VU Medical Center, Amsterdam), T. van Maanen
(Westfries Gasthuis, Hoorn), R. Tamminga (Academic Hospital Groningen, Groningen), G.
Van Waveren (Boven IJ Hospital, Amsterdam), and P. Wijermans (Leyenburg Hospital, Den
Haag).
References
1. Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L- and R-type isozymes
of rat pyruvate kinase are produced from a single gene by use of different promoters.
J Biol Chem. 1987;262:14366-14371.
2. Tani K, Fujii H, Nagata S, Miwa S. Human liver type pyruvate kinase: complete
amino acid sequence and the expression in mammalian cells. Proc Natl Acad Sci U
S A. 1988;85:1792-1795.
3. Noguchi T, Inoue H, Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase
are produced from the same gene by alternative RNA splicing. J Biol Chem.
1986;261:13807-13812.
4. Valentine WN, Paglia DE. The primary cause of hemolysis in enzymopathies of
anaerobic glycolysis: a viewpoint. Blood Cells. 1980;6:819-829.
5. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from
the gene frequency in the general white population. Blood. 2000;95:3585-3588.
6. Hirono A, Kanno H, Miwa S, Beutler E. Pyruvate kinase deficiency and other
enzymopathies of the erythrocyte. The Metabolic & Molecular Bases of Inherited
Disease. New York: McGraw-Hill; 2001:4637-4664.
105
Chapter 4
7. Bianchi P, Zanella A. Hematologically important mutations: red cell pyruvate kinase
(third update). Blood Cells Mol Dis. 2000;26:47-53.
8. Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human
erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia. J
Biol Chem. 2002;17:23807-23814.
9. Enriqueta Muñoz M, Ponce E. Pyruvate kinase: current status of regulatory and
functional properties. Comp Biochem Physiol B Biochem Mol Biol. 2003;135:197-
218.
10. Mattevi A, Valentini G, Rizzi M, Speranza ML, Bolognesi M, Coda A. Crystal structure
of Escherichia coli pyruvate kinase type I: molecular basis of the allosteric transition.
Structure. 1995;3:729-741.
11. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation
of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6:195-210.
12. Rigden DJ, Phillips SE, Michels PA, Fothergill-Gilmore LA. The structure of
pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition
and unusual effector specificity. J Mol Biol. 1999;291:615-635.
13. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A. The allosteric
regulation of pyruvate kinase. J Biol Chem. 2000;275:18145-18152.
14. Wooll JO, Friesen RHE, White MA, et al. Structural and functional linkages between
subunit interfaces in mammalian pyruvate kinase. J Mol Biol. 2001;312:525-540.
15. Fenton AW, Blair JB. Kinetic and allosteric consequences of mutations in the subunit
and domain interfaces and the allosteric site of yeast pyruvate kinase. Arch Biochem
Biophys. 2002;397:28-39.
16. Zanella A, Bianchi P, Fermo E, et al. Molecular characterization of the PK-LR gene
in sixteen pyruvate kinase-deficient patients. Br J Haematol. 2001;113:43-48.
17. Beutler E. Red Cell Metabolism: A Manual of Biochemical Methods. Orlando:
Grune & Stratton; 1984.
18. van Wijk R, van Solinge WW, Nerlov C, et al. Disruption of a novel regulatory
element in the erythroid-specific promoter of the human PKLR gene causes severe
pyruvate kinase deficiency. Blood. 2003;101:1596-1602.
19. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human
sequence variations. Hum Genet. 2001;109:121-124.
20. Jones TA, Kjeldgaard M. Electron-density map interpretation. Methods Enzymol.
1997;277:173-208.
21. Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots
of protein structures. J Appl Cryst. 1991;24:946-950.
106
Fourteen novel mutations in PKLR 
22. Merritt EA, Bacon DJ. Raster3D: photorealistic molecular graphics. Methods
Enzymol. 1997;277:505-524.
23. Baronciani L, Beutler E. Analysis of pyruvate kinase-deficiency mutations that
produce nonspherocytic hemolytic anemia. Proc Natl Acad Sci U S A.
1993;90:4324-4327
24. Pastore L, Della Morte R, Frisso G, et al. Novel mutations and structural
implications in R-type pyruvate kinase-deficient patients from Southern Italy. Hum
Mutat. 1998;11:127-134.
25. Zanella A, Bianchi P, Baronciani L, et al. Molecular characterization of PK-LR gene
in pyruvate kinase-deficient Italian patients. Blood. 1997;89:3847-3852.
26. Muirhead H, Clayden DA, Barford D, et al. The structure of cat muscle pyruvate
kinase. EMBO J. 1986;5:475-481.
27. Larsen TM, Laughlin LT, Holden HM, Rayment I, Reed GH. Structure of rabbit
muscle pyruvate kinase complexed with Mn2+, K+, and pyruvate. Biochemistry.
1994;33:6301-6309.
28. Zarza R, Alvarez R, Pujades A, et al. Molecular characterization of the PK-LR gene
in pyruvate kinase deficient Spanish patients. Red Cell Pathology Group of the
Spanish Society of Haematology (AEHH). Br J Haematol. 1998;103:377-382.
29. Kahn A, Marie J, Galand C, Boivin P. Chronic haemolytic anaemia in two patients
heterozygous for erythrocyte pyruvate kinase deficiency. Electrofocusing and
immunological studies of erythrocyte and liver pyruvate kinase. Scand J Haematol.
1976;16:250-257.
30. Etiemble J, Picat C, Dhermy D, Buc HA, Morin M, Boivin P. Erythrocytic pyruvate
kinase deficiency and hemolytic anemia inherited as a dominant trait. Am J
Hematol. 1984;17:251-260.
31. Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative
analysis of the mouse genome. Nature. 2002;420:520-562.
32. Ferrer-Costa C, Orozco M, de la Cruz X. Characterization of disease-associated
single amino acid polymorphisms in terms of sequence and structure properties. J
Mol Biol. 2002;315:771-786.
33. Steward RE, MacArthur MW, Laskowski RA, Thornton JM. Molecular basis of
inherited diseases: a structural perspective. Trends Genet. 2003;102:505-513.
34. Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes:
sequence statistics and functional implications in gene expression. Nucleic Acids
Res. 1987;15:7155-7174.
35. van Wijk R, van Wesel ACW, Thomas AAM, Rijksen G, van Solinge WW. Ex vivo
107
Chapter 4
analysis of aberrant splicing induced by two donor site mutations in PKLR of a
patient with severe pyruvate kinase deficiency. Br J Haematol, accepted for
publication.
36. Cheng X, Friesen RH, Lee JC. Effects of conserved residues on the regulation of
rabbit muscle pyruvate kinase. J Biol Chem. 1996;271:6313-6321.
37. Neubauer B, Lakomek M, Winkler H, Parke M, Hofferbert S, Schröter W. Point
mutations in the L-type pyruvate kinase gene of two children with hemolytic
anemia caused by pyruvate kinase deficiency. Blood. 1991;77:1871-1875
38. Rijksen G, Veerman AJ, Schipper-Kester GP, Staal GE. Diagnosis of pyruvate
kinase deficiency in a transfusion-dependent patient with severe hemolytic anemia.
Am J Hematol. 1990;35:187-193.
39. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair
substitutions in mRNA splice junctions of human genes: causes and consequences.
Hum Genet. 1992;90:41-54.
40. Lenzner C, Nurnberg P, Jacobasch G, Gerth C, Thiele BJ. Molecular analysis of 29
pyruvate kinase-deficient patients from central Europe with hereditary hemolytic
anemia. Blood. 1997;89:1793-1799.
108
109
CHAPTER 5 Molecular modelling of human red blood
cell pyruvate kinase: structural
implications of a novel G1091 to A
mutation causing severe nonspherocytic
hemolytic anemia
Wouter W. van Solinge1*, Rob J. Kraaijenhagen1, Gert
Rijksen2, Richard van Wijk1*, Bjarne B. Stoffer3, Michael
Gajhede3, and Finn C. Nielsen4
1Clinical Laboratory, Eemland Hospital, Amersfoort, The
Netherlands; 2Department of Hematology, University Hospital,
Utrecht, The Netherlands; 3Institute of Chemistry, University
of Copenhagen, Copenhagen, Denmark; 4Department of
Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
*present address: Department of Clinical Chemistry,
University Medical Center Utrecht, Utrecht, The Netherlands.
Blood (1997); 90: 4987-4995.
110
Molecular modelling of RBC pyruvate kinase
Abstract
We present a novel G1091 to A mutation in the human liver and red blood cell (RBC) pyruvate
kinase (PK) gene causing severe hemolytic anemia. In two families, three children were
severely PK-deficient compound heterozygotes exhibiting the G1091 to A mutation and a
common G1529 to A mutation on the other allele. In one family, the mother, a G1091 to A
heterozygote, later had a second baby with a new husband, also a G1091 to A carrier. The
baby was homozygous for the G1091 to A mutation and died 6 weeks after birth from severe
hemolysis. Both mutant alleles were expressed at the RNA level. The  G1091 to A mutation
results in the substitution of a conserved glycine by an aspartate in domain A of RBC PK,
whereas the G1529 to A mutation leads to the substitution of a conserved arginine residue
with glutamine in the C-domain. Molecular modelling of human RBC PK, based on the
crystal structure of cat muscle PK, shows that both mutations are located outside the catalytic
site at the interface of domains A and C. The mutations are likely to disrupt the critical
conformation of the interface by introducing alternative salt bridges. In this way the Gly364
to Asp and Arg510 to Gln substitutions may cause PK deficiency by influencing the allosteric
properties of the enzyme.
Introduction
Pyruvate kinase (PK) catalyses the conversion of phosphoenol pyruvate to pyruvate and is an
important regulator of glycolysis. Two different genes have been characterized in mammals.
One encodes the liver and red blood cell (RBC) isoenzymes (PKLR gene), whereas the other
generates the muscle isoenzymes M1 and M2.1-3 Mutations in the PKLR gene are associated
with PK deficiency, an important cause of nonspherocytic hemolytic anemia. The clinical
symptoms are variable, ranging from a mild, compensated hemolytic anemia to death in
early childhood.4
In the last few years a variety of different mutations in the PKLR gene have been identified,
facilitating the molecular diagnosis of PK deficiency.5,6 Because of the lack of structural and
functional information, it has been difficult to predict the phenotypic consequences of
specific mutations. PK forms tetramers and its catalytic activity is allosterically regulated by
phosphorylation and allosteric effectors. The tertiary structure of human R-type PK (HRPK)
has not been determined, but the primary sequence is homologous to cat and rabbit muscle
PK isoform M1 (MlPK),7-9 whose structures have been solved at 2.6 Å and 2.9 Å resolution,
respectively (Larsen et al.9; Brookhaven Data Bank, accession code 1PKM [Allen and
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Muirhead]). M1PK is composed of four domains: first, the N-terminal domain N, which is
involved in subunit contacts in the tetrameric molecule; second, domain A, a classic α/β-
barrel, that comprises the catalytic site; third, domain B, which loops out from the end of the
third β-strand in domain A (the functional role of domain B is unclear); and, finally, the C-
terminal domain C, which forms an open twisted αβ-type domain that may play an important
role for tetramerization. However, the M1 type PK is the only PK enzyme which is not
allosterically regulated and hence functionally different from the RBC type PK. Reflections
on the effect of mutations in the human RBC PK gene have so far been based on the three-
dimensional model of cat muscle, assuming that these conclusions were valid for the human
RBC gene.
In this study, we report the finding of a novel PK mutation in two Danish families that causes
severe nonspherocytic hemolytic anemia. We have examined the expression of the mutant
alleles at the RNA and protein level. Simulation of the effect of the mutations in a human
RBC PK model, based on the crystal structure of muscle PK, shows that none of the
mutations involves the catalytic site, but both are likely to disrupt the structure of the critical
interface between domains A and C. We postulate that the G1091 to A and common G1529 to
A mutation cause PK deficiency by disrupting the allosteric properties of PK.
Materials and methods 
Nomenclature
Nucleotides and amino acids are numbered according to Kanno et al.7 (GenBank D13232-
D13243).
Patients
The proband was an 11-year-old Danish boy. At birth he suffered from a severe hemolytic
crisis, with a hemoglobin concentration of 10.3 g/dL, reticulocytosis, and
hepatosplenomegaly. PK activity was undetectable, and other possible causes of hemolysis
were excluded. At present, he requires blood transfusions every three months. His parents do
not suffer from any clinically noticeable hemolysis. After the boy’s mother was divorced and
remarried, she and her new husband had a baby girl. At birth, she was severely anemic and
died after six weeks, despite blood transfusions. The PK-activity of the baby was
undetectable.
During the molecular investigations a second Danish family was referred to our laboratories
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for molecular analysis of the PKLR genes. Both parents were healthy adults of Danish origin
with no known relation to the first family. The clinical course of their first child (girl) at birth
was identical as described above for the proband. At present, she is three years old and
requires blood transfusions every three months. The second child in this family, a boy, was
also born with a hemoglobin concentration of 11.3 g/dL and reticulocytosis. His liver and
spleen were normal. PK-activity was low. Presently, he is one year old and receives
transfusions every three months. Informed consent was obtained from all subjects.
DNA and RNA isolation
DNA from EDTA-stabilized blood and parrafin-embedded liver coupes was isolated as
described.10,11 Total RNA was isolated from isolated blood reticulocytes as described.12
Polymerase chain reaction (PCR) procedures
To have high specificity and yield for sequencing purposes, the human PKLR gene was first
amplified with primers PKr-1 (exon 1: 5’-CCC AGG CCC ACA CTG AAA GC-3’) and Pkr-
6 (exon 12: 5’- GTG TGG GCT GGA GAA CGT AGA-3’) using the XL-PCR kit from
Perkin-Elmer (Norwalk, CT) according to the manufacturer’s instructions, with
modifications.13 Briefly, components were mixed using 0.2 mmol/L of each dNTP, 50 pmol
of each primer, and 1.1 mmol/L Mg (OAc)2. After 4 minutes of denaturation at 95°C, 4 U of
Table 1. Oligonucleotide primers used for sequencing 
Exon 1: PK-1F: 5’-cct ttt ctc ttc tct gtc tcc c-3’
PK-1R: 5’-ggc tcc tag ttt tca ccc tca t-3’
Exon 2: PK-2F: 5’-ctg cag aac tga tcc cca gcc-3’
PK-2R: 5’-ccc tgt agc ttg acc cat ccc-3’
Exon 3: PK-3F: 5’-cat ggg gag gaa ggg cag gt-3’
PK-3R: 5’-acc aat agg ccc tgt gtg gct-3’
Exon 4: PK-4F: 5’-ttg cct ctc atg ttc tgg ggg-3’
PK-4R: 5’-tgg cca gga cct cga ggc at-3’
Exon 5: PK-5F: 5’-ggc cac ctt ccc ctg aaa cc-3’
PK-5R: 5’-ttt ccg gcc ctg gcc cag c-3’
Exon 6: PK-6F: 5’-tcc ggg gct cag aac tca cat-3’
PK-6R: 5’-agg aga agg gaa tgt gcc cag-3’
Exon 7: PK-7F: 5’-gca act gtg ccc cgt cct ca-3’
PK-7R: 5’-gtg atg ggg aat agc gac agg-3’
Exon 8: PK-8F: 5’-cca tca cct ttc ttc tcc tgc-3’
PK-8R: 5’-ttc acc cac agg tgt ccc taa-3’
Exon 9: PK-9F: 5’-agt cac agt gtg agt cct ac-3’
PK-9R: 5’-tat gga agg gat ttg gtt cc-3’
Exon 10: PK-10F: 5’-ttc cat acc cca gtg ccc ctt-3’
PK-10R: 5’-acc cct gac cca aag ctc cat-3’
Exon 11: PK-11F: 5’-cac agc ttg tta gtg aca cct g-3’
PK-11R: 5’-gct cct gat aca aat ggt agg a g-3’
Exon 12: PK-12F: 5’-gtg tga gcc acc aca cct gtc-3’
PKr-6: 5’-GTG TGG GCT GGA GAA CGT AGA-3’
Nucleotides in lower case are located in intron. Nucleotides in uppercase are located in exon.
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rTth DNA polymerase XL was added. Cycles were as follows: 1 minute at 94°C, 10 minutes
at 64°C, and 10 minutes at 72°C. After cycle no. 19, the extension time was increased with
15 seconds per cycle for a total of 30 cycles.
The amplified XL-PCR product was used as template in nested PCRs in which each exon
and introns 1, 5, and 8, including the intron-exon bounderies, were amplified. Exon 1 was
amplified directly from genomic DNA using primers PK-1F and PK-1R (Table 1). The
reaction mixture in 100 µL volume contained 10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl,
1.5 mmol/L MgCl2, 0.01% (wt/vol) gelatine, 0.2 mmol/L of each dNTP, 1 mmol/L of each
primer, 1 µL XL-PCR product, and 2.5 U AmpliTaq DNA polymerase. All reagents were
obtained from Perkin-Elmer. The samples were subjected to 30 cycles of amplification with
denaturation at 94°C for 45 seconds (5 minutes at 95°C in the first cycle), annealing at 64°C
for 45 seconds, and extension at 72°C for 45 seconds, followed by an elongated extension
time of 7 minutes after the last cycle. Negative controls, without added DNA, were included
in each run to exclude amplification of contaminating DNA. 
Reverse transcription-PCR (RT-PCR) was performed as described.12 cDNA synthesis was
initiated with random hexamers. cDNA was amplified with primers PKr-5 (exon 8: 5’-GGT
GAG CGA CGG CAT CAT GG-3’) and CDPK-9 (exon 9: 5’-CGC ATG CTG CAT CTT
CAC CGC-3’) for detection of the nt 1091 mutation. For the detection of the nt 1529
mutation, primers CDPK-11 (exon 11: 5’-CTC AGC CCA GCT TCT GTC TCG-3’) and
PKr-6 were used. PCR conditions were as described under nested-PCR. Normal human liver
RNA was included as positive control.12 These products were used for direct DNA
sequencing. For all RNA samples amplified in a RT-PCR we routinely included a control
where the reverse transcription step was omitted. 
Sequencing of PCR products
Automated sequencing was performed with the ABI Prism Dye Terminator Cycle
Sequencing Ready Reaction Kit (Perkin-Elmer/Applied Biosystems, Foster City, CA),
according to the instructions, and sequence reactions were analyzed on a Perkin-
Elmer/Applied Biosystems ABI 310 Genetic Analyzer.
Restriction endonuclease digestion
All mutations in DNA and RNA and the polymorphisms in DNA were confirmed and
characterized using restriction endonuclease digestion when applicable. To confirm the 1091
mutation detected by sequencing, we amplified a 264-bp fragment containing exon 8 from
genomic DNA using primers PK-8F and PK-8R (Table1). The fragment contains three
restriction sites for Cac8I (GCN/NGC), yielding fragments of 4, 22, 83, and 155 bps. The
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1091 G/A mutation removes two sites simultaneously (fragments of 22 bp and 242 bp). For
confirmation of the nt 1529 mutation, we amplified exon 11, with primers PK-11F and PK-
11R (fragment of 330 bp). The mutation creates a restriction site for StyI (C/CWWGG),
producing fragments of 190 and 140 bp. The same enzymes were used for confirmation of
the mutations in RNA. Primers used for RT-PCR were as mentioned above in “Polymerase
chain reaction (PCR) procedures.”
To detect the polymorphism at nt 1705 (A/C),14 we amplified a fragment using primers PK-
12F and PKr-6 (235 bp). BspHI (T/CATGA) will only cleave this product, when an adenine
is present (132 bp and 103 bp).
The nt 1738 (C/T) (this study, Van Solinge et al.,15 and Bianchi et al.16) polymorphism was
detected using BseRI [GAGGAG(N)10 / and (N)8CTCCTC], only cleaving a fragment
amplified with primers PK-12F and PKr-6 if a thymine is present at this position (182 bp and
53 bp). The polymorphism at nt +51 in intron 5 (C/T) (this study, Fujii et al.,17 and
Baronciani et al.18) was detected by sequencing intron 5, because no useful restriction
enzyme recognition sites are present. 
The trinucleotide ATT repeat in intron 1119 was amplified with 4,7,2’,7’-tetrachloro-6-
carboxy-fluorescein (TET)-labeled primers JHATT19 and PK-TNR-R4 and examined with
the GeneScan short denatured module on the ABI 310 Genetic Analyzer and by sequencing
the fragments.
Protein studies
Enzyme assays and the heat stability assay of PK were performed according to the methods
of Beutler.20 The antibody consumption assay was performed essentially as described
earlier.21 Oligomerization in the presence and absence of 10 mmol/L fructose-1,6-
diphosphate (FDP) was studied by gel filtration experiments on a Sephacryl S-200 superfine
column (Pharmacia, Uppsala, Sweden) using lactate dehydrogenase (130 kDa) as an internal
standard.22
Molecular modelling
Coordinates of the x-ray crystal structure of the M1 muscle type PK from Felis domesticus,
obtained from the Brookhaven Data Bank as 1PKM (submitted by Allen and Muirhead),
were used as a scaffold for the construction of a model of HRPK. Initially, the corrected
cDNA sequence of the human PKLR-gene7,23 was aligned with the sequences derived from
both 1PKM (Allen and Muirhead) and 1PKN9 structures, using the Alignment of Multiple
Protein Sequences (AMPS) program, as described.24 This resulted in the alignment as shown
in Figure 1.
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Figure 1 (color version, addendum page 166). Alignment of muscle-type pyruvate kinase from Felis
domesticus (1PKM) and Oryctolagus cuniculus (1PKN) with R-type PK from human (HRPK). The
alignment was generated with AMPS, as described in the Materials and Methods and drawn with the
program ALSCRIPT.35 Amino acids that are completely conserved among the three PKs are shown
with yellow letters in boxes shaded with magenta. Only residues of human R-type PK (56-574)
corresponding to 1PKM (12-530) are shown. The secondary structure elements, α-helixes and β-
strands, assigned to 1PKM are shown above the sequences as cylinders and filled arrows, respectively.
The domain organization of PK is represented by filled arrows right under the secondary structure
elements. Color code: the N-terminal domain N is yellow; the catalytic domain A is blue, domain B is
orange, and the C-terminal twisted αβ-type domain C is pink. The numbers above the sequences are in
accordance with the numbering in 1PKM, whereas the numbers beneath the sequences refer to the
codon numbering of HRPK. The red-filled triangle indicates the position of residue 364 (glycine to
aspartic acid mutation), and the green filled triangle indicates the position of residue 510 (arginine to
glutamine mutation).
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After alignment of the sequences, the HRPK was constructed from 1PKM with the program
package from Biosym Technologies (San Diego, CA) in the following way: (1) the
coordinates of 1PKM were read into the program INSIGHTII, (2) followed by alignment of
the sequence of 1PKM with the HRPK sequence according to Figure 1 using the program
HOMOLOGY and (3) transferring of 1PKM coordinates to HRPK. (4) The raw model of
HRPK was modified to eliminate close Van der Waals contacts. (5) The adjusted model of
HRPK was then subjected for minimization in the program DISCOVER for 6,000 iterations
with the steepest descendants algorithm assuming a pH of 7.0, essentially as described.25 The
minimized model of HRPK was used for inspection of the mutations described in this study.
Results
Pyruvate kinase mutations
The proband was a compound heterozygote with a novel G1091 to A mutation in exon 8 and
a second mutation (G1529 to A) in exon 11 on the other allele of the PKLR gene (Figure 2A,
only G1091 to A shown). The G1091 to A mutation results in the substitution of a conserved
glycine by an aspartate at codon 364, whereas the G1529 to A mutation leads to the
substitution of a conserved arginine residue with glutamine at codon 510. The latter is a well-
known and common mutation among non-gypsy whites.4,26 The G1091 to A mutation was
also present in the mother, whereas the G1529 to A mutation was detected in his father.
Analysis of the PKLR gene of the second husband showed that he was a heterozygote carrier
nt 1091 Exon 8 Intron 8A nt 1091 Exon 8 Exon 9B
Figure 2. Detection of the nucleotide G1091 to A mutation in exon 8 of the human PKLR gene and RNA
of the proband by sequencing. (A) DNA; (B) RNA.
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of the G1091 to A mutation. Analysis of DNA obtained from liver coupes showed that the
deceased baby was a G1091 to A homozygote (data not shown). The pedigree and mutation
analysis of the family are shown in Figure 3. The second Danish family also exhibited the
G1091 to A and G1529 to A mutations. The daughter and son were both compound heterozygotes
and the 1091 mutation was inherited from the father, whereas the mother was carrier of the
1529 mutation. RT-PCR analysis of RNA followed by sequencing and restriction enzyme
analysis indicated that both mutated alleles were expressed (Figure 2B, only G1091 to A shown).
The prevalence of the two mutations was determined by screening 100 normal controls for
the G1091 to A and G1529 to A mutations. None was detected, indicating that the G1091 to A
and G1529 to A allele frequency is less than 1:200.
Polymorphisms
A C/T polymorphic site was identified in exon 12, at position 1738, 13 nucleotides
downstream of the translation termination codon.15,16 Estimated from 100 chromosomes of
unrelated individuals, the allelic frequency was as follows: C-alleles, 0.26; T-alleles, 0.74.
Observed homozygosity for C/C was 0.04, for C/T was 0.43, and for T/T was 0.53. In
addition, the polymorphism in intron 5 at nt +5117,18 was used to determine the haplotypes
of our patients.
Using four polymorphisms, we performed DNA haplotype analysis. The 1529 mutation was
linked to IVS-5-T, 14 ATT repeats in intron 11, nt 1705-C, and nt 1738-T. The 1091 mutation
Figure 3. Pedigree of family 1. Filled areas denote the nt 1091 mutation. Shaded areas denote the nt
1529 mutation. *Proband.
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was linked to IVS-5-C, 12 ATT repeats in intron 11, nt 1705-A, and nt 1738-C, in all patients
(Table 2).
Enzyme activities
RBC PK activity of the proband in family I as well as the affected children in family II was
low, but detectable (Table 2). However, although blood samples were taken shortly before
blood transfusion, it cannot be excluded that the activity in the patients was, at least partly,
originating from the presence of residual donor cells. To evaluate the mean cell age of the
RBC population, the cell age-dependent enzymes hexokinase and glucose-6-phosphate
dehydrogenase were measured too. The largely increased activities of these enzymes indicate
a very young mean cell population and emphasize the extent of the PK deficiency.
Unfortunately, no blood samples were available from the deceased daughter in family I nor
from the affected son in family II. As expected, the proband’s heterozygous parents have low
PK activities. The second husband as well as the father in family II are heterozygous too.
Altough the mother in family II is a carrier of the G1529 to A mutation, her PK activity was
not significantly lowered.
Protein studies
Biochemical studies at the protein level were hampered by the low PK activity and the
potential presence of donor RBCs in the patients. It could not be excluded that the residual
enzyme activity in the proband was originating mainly from donor cells. Yet, we decided to
characterize the enzyme from patient and heterozygotes. However, we were unable to detect
any significant aberrations. First, the expression of inactive enzyme protein was assayed by
performing an antibody comsumption assay. The amount of immuno-reactive material
consumed by a fixed enzyme activity appeared to be normal in all cases. However, in the
patient, a minor part of the activity could not be precipitated with the antibody for R-type
PK, suggesting the presence of PK isoforms that are not recognized by the antibody (data not
shown). In severe PK deficiency, the compensatory presence of M2-type PK has been shown
in some cases.27 However, no enzyme activity could be precipitated with antibody against
M2-type PK. In another set of experiments, the heat stability of the enzyme was investigated,
but no labile enzyme could be detected. The allosteric properties of the enzyme were
investigated by studying the effects of FDP on the activity at low phosphoenolpyruvate
concentrations. Again, the enzyme from patient and heterozygotes behaved completely
normal. Also, the extent of tetramerization in presence and absence of FDP was studied by
gel filtration experiments, but no signs of altered subunit interactions were observed (results
not shown).
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Because of the limitations as described above, these results did not allow any conclusions on
the expression of mutant enzyme at the protein level.
Molecular modelling
Alignment of cat M1PK, rabbit M1PK, and human RBC PK (HRPK) shows that HRPK is
approximately 70% similar to the two enzymes (Figure 1). Like cat and rabbit M1PK, HRPK
may therefore be divided into four domains. Residues 42-85 form the N-terminal domain.
Residues 86-159 and 263-431 form domain A, a classic α/β-barrel, that comprises the
catalytic site. The residues that comprise domain B span from codons 160 to 262 and loop
out from the end of the third β-strand in domain A. Finally, the C-terminal C-domain from
residues 432 to 574 forms an open twisted αβ-type domain. The mutated Gly364 is located
in the A-domain, whereas Arg510 is situated in the C-domain. Both amino acids are
conserved in cat and rabbit M1PK (Figure 1), yeast, rat LPK, chicken MPK,8 mouse RPK,28
Figure 4 (color version, addendum
page 167). Cα-ribbon trace of the model
of human R-type PK monomer. The
color code is as for Figure 1: the N-
terminal domain N is yellow; catalytic
domain A is blue, domain B is orange,
and the C-terminal twisted αβ-type
domain C is pink. The positions of the
amino acids 364 (G1091 to A mutation)
and 510 (G1529 to A mutation) are
indicated by red and green color,
respectively. The active site bound
pyruvate molecule taken from 1PKN9 is
represented by pink space filling.
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and dog RPK.29 In  Bacillus stearothermophilus the glycine 364 is conserved, whereas
arginine 510 is not.30
Figure 4 shows the Cα-ribbon trace of the model of human RBC PK. Placement of the
mutations in this model shows that the mutations are both located at the interface of domains
A and C. Glycine 364 is situated in the loop connecting Aα6 and Aβ7, whereas Arg510
connects Cα4 and Cβ3. Please note that the substituted amino acids in the HRPK are not
located in cis in vivo because mutations are present on separate alleles. Therefore, Figure 4
only indicates the position of the mutated codons.  We then configured the mutated codons
into the model and made a close-up view of areas around the respective parts of the PK
monomer, as shown in Figure 5. The Gly364 to Asp mutation in domain A is situated close
to glutamine at position 482 and to Arg486 in domain C of the monomer. Asp364 is not
involved in any salt bridge formation to Arg486, but it forms a hydrogen bond to the
backbone carbonyl of Gln482. The glutamine for arginine substitution at position 510 leads
to the formation of two hydrogen bonds (Thr88 and Ala399), whereas the wild-type has only
one hydrogen bond to Ala399.
Figure 5 (color version, addendum page 168). Close-up view of areas around the amino acids 364
(A) and 510 (B). Residues in close contact with the mutated residues, translated from codons 364 and
510, are shown with side chains, whereas the residues further apart are shown in Cα-ribbon trace
representation as in Figure 4. The color code is as for Figure 1. (A) and (B) are shown with the mutated
aspartic acid and glutamine replacing the wild-type glycine and arginine, respectively. Hydrogen bonds
less than 3.0 Å are shown as white lines.
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Discussion
Patients with clinically apparent PK deficiency are rare in the Western-European population.
Although calculating the probability of the events as they happened to the first Danish family
will be difficult, we think this is a very rare and unlucky event indeed. Not only did the son from
the first marriage inherit both affected alleles, but in addition the mother remarried with a carrier
of PK-deficiency and the daughter born from this marriage again inherited two affected alleles,
which proved fatal. The appearance of a second unrelated Danish family at the same time, again
with two affected siblings and identical mutations is coincidental, but raises questions
concerning the prevalence of these mutations in Denmark. Although the nt 1529 mutation
represents 45% of the diseased alleles in non-gypsy whites4,26 and probably is the most
prevalent mutation in Western-Europe,31,32 both mutations were not detected in a control group
of 100 healthy individuals. 
Within the two families, the G1091 to A mutation was present in the heterozygous, homozygous,
and compound heterozygous form. No other sequence variants were found in the patients
heterozygous for the G1091 to A mutation other than the polymorphisms (vide infra). Patients in
the two families who are heterozygous for the G1091 to A mutation all have decreased PK
activity. When the nt 1091 mutation is inherited with the nt 1529 mutation on the other allele,
severe PK deficiency and clinical symptoms occur (proband and two siblings in family 2). The
patient with the nt 1091 mutation present on both alleles was clinically severely affected, PK-
deficient, and died. Thus, the G-to-A change at position nt 1091 correlates with the disease. In
addition, the substituted amino acids are phylogenetically conserved, indicating that they are
important for the function of the enzyme. Taking all these findings into consideration, we
conclude that the G-to-A change at position nt 1091 causes PK deficiency.
We used four polymorphisms to study the haplotype of the described mutations.15-18 In
accordance with previous studies, the nt 1529 mutation is linked to nt 1705-C and 14 ATT
repeats in intron 11, supporting the theory of a common ancestor gene for this mutation. We find
that the nt 1529 is linked to nt 1738-T and a thymine at nt 51 in intron 5, substantiating this
hypothesis. The nt 1091 mutation was linked in all affected individuals to nt 1705-A, nt 1738-
C, 12 ATT repeats, and a cytosine at nt 51 in intron 5.
Enzymatic studies and gelfiltration experiments of PK from our patients did not demonstrate any
abnormality other than the reduced activity. There may be several reasons for this. First, it is
possible that the mutant enzymes do not differ in their kinetic properties. Many mutations
present in compound heterozygous or homozygous form have reduced activity, but normal
responses in kinetic studies.4 Interestingly, even identical mutations can exhibit different kinetic
profiles. Moreover, the tetrameric structure of PK makes interpretation of gel filtration data
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difficult, because several hybrid proteins can be present. Secondly, interference of donor cells in
the compound heterozygous patients, differences in enzymatic behaviour in vivo and in vitro,
unstability of mutant enzymes, and overexpression of M2PK might influence results.27,33
To obtain more insight in the pathogenesis of the nt 1091 and nt 1529 mutations, we constructed
the three-dimensional model of human RBC PK, using the known crystal structure of cat PKM
as scaffold. Previous studies in other species have indicated that the precise conformation of the
area of the molecule that is mutated in this study may be critical, not only in respect to proper
alignment of residues in the active site, but also for allosteric transitions and binding of ADP and
FDP.8,30 Walker et al.30 have proposed the existense of two pockets at the interface of domains
A and C: the Arg42-pocket (in humans Arg86) that is important for ADP binding and the residue
466-pocket (in humans Arg510), which is possibly important for binding of a second allosteric
activator. These pockets are divided by the fourth α helix of domain C (Cα4), which is bound
by hydrogen bonds and salt bridges to domain A by connection from Ala399 (in domain A) to
Arg510 (in domain C), Asp400 (domain A) to Arg488 (domain C), and Asn113 (domain A) to
Val506 in domain C (human numbering). In this way, a critical conformation of the interface
between domains A and C is specified. The area around Gly364 is spacious and the insertion of
the aspartate is not likely to disrupt the structure of PK by a simple sterical effect. However,
aspartate comes in close contact with glutamine 482, and a salt bridge that would disrupt the
crucial interaction between Arg488 and Asp400 is likely to be established (Figure 5A). In a
similar manner, substitution of Arg510 with glutamine reduces the conformational freedom
between domains A and C, because an extra connection between these domains is created by
formation of a salt bridge to Thr88. Probably the salt bridge from Gln510 to Ala399 will be
intact, but structural changes caused by the hydrogen bond to Thr88 will affect the energy
balance in this area and influence allosteric transitions (Figure 5B). Moreover, Thr88 is close to
Arg86, which is the proposed ADP binding residue.
We propose that the Gly364 to Asp and Arg510 to Gln mutations affect the interdomain structure
between domains A and C and that the function of both the Arg86 and Arg510 pockets might be
affected. Since transition from the T-state to the high-affinity R-state of PK requires rotation of
all subunits in the tetramer by flexible hinges,34 the formation or breakage of intersubunit
contacts could restrict the conformation of the active site as well.
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Abstract
Mutations encoding class I glucose-6-phosphate dehydrogenase (G6PD) variants are
associated with chronic nonspherocytic hemolytic anemia (CNSHA), the most severe
phenotypic expression of G6PD deficiency. These mutations frequently affect the G6PD
dimer interface that is essential for enzymatic activity. We detected two de novo missense
mutations concerning residues located close together in the dimer interface in two patients
with severe G6PD deficiency. A novel c.1225C>T missense mutation was identified in a
male neonate who presented with hemolysis and severe hyperbilirubinemia and the predicted
Pro409Ser substitution constituted a novel class I variant, designated G6PD Utrecht. G6PD
deficiency in the second patient was due to the once previously reported class I variant G6PD
Sumaré (Val431Gly). Structural analysis revealed that the mutated residues Pro409 and
Val431, located on different subunits, interact directly across the subunit interface and
perturb formation of the G6PD dimer upon mutation. Favism and mild chronic hemolysis
characterized the phenotype of the patient with G6PD Sumaré which contrasts with the more
severe clinical picture of the patient with G6PD Utrecht and, in addition, that of the patient
orginally described with G6PD Sumaré. We postulate that this G6PD variant is at the
crossing between class I and class II G6PD deficiency and its ultimate phenotypic expression
is either aggravated or ameliorated by other (extra)genetic factors.
Introduction
Chronic nonspherocytic hemolytic anemia (CNSHA) is the most severe phenotypic
expression of glucose-6-phosphate dehydrogenase (G6PD) deficiency1 (OMIM#305900).
Because G6PD’s principal role in the red blood cell is to provide reductive potential in the
form of NADPH to protect the cell against oxidative stress,2 the CNSHA phenotype results
from a continuous, severe lack of reducing power. This feature distinguishes class I G6PD
variants from other deficient G6PD variants (classes II to IV)3 which are associated with
episodes of oxidative stress evoked by infections or drugs, resulting in acute hemolytic
anemia. The residual G6PD activity of class I variants is variable, ranging from activities as
high as 35% of normal, to severely reduced or even undetectable enzyme activity.4 Some
residual enzyme activity is believed to be present, however, because total lack of G6PD has
been shown to be a lethal condition at an early stage in embryonic development.5 The
deficiency is more pronounced in red blood cells, when compared to other cells, because of
the long life span of the erythrocyte after the loss of capacity of protein synthesis.6
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Most mutations underlying class I variants are located in and around exon 10 of the G6PD
gene (G6PD on chromosome Xq28). The homology model of human G6PD based on the
crystal structure of Leuconostoc mesenteroides7 and, more recently, the crystal structure of
human G6PD8 itself shows that the corresponding amino acids are located close to the dimer
interface and the structural NADP, indicating that integrity of these regions is important for
enzyme stability and in vivo activity. 
We studied two patients with severe G6PD deficiency and identified two G6PD variants that
both resulted from a de novo mutation. One of the mutations was novel whereas the other is
reported here for the second time. The affected amino acids, located and interacting with one
another at the dimer interface, were, in contrast to the literature, associated with distinct
phenotypic expression upon mutation. 
Materials and methods
Informed consent was obtained from all subjects.
Case report: patient 1
A male baby was born at 37 weeks of gestation with a birth weight of 2330 g. He was the
second baby of Dutch Caucasian nonconsanguineous parents. The family history was
negative for anemia. The mother has blood group B Rhesus-negative. Therefore, she received
anti-D gammaglobulins at 30 weeks of gestation. On the first day of life, total serum bilirubin
rose to 167 µmol/L (reference value 0–1 day: <100 µmol/L) and intense phototherapy
commenced. Initially, hemoglobin was 16.3 g/dL on day 1 (reference value 1–3 days:
13.4–21.6 g/dL) but decreased to 12.0 g/dL on the second day of life with a reticulocytosis
of 235‰ (reference value <2 days: 30–60‰). Because the baby’s blood group was O
Rhesus-positive, the working diagnosis at that moment was hemolysis due to anti-D
antibodies despite a negative Coombs’ test. On day 5 he received a blood transfusion. The
highest bilirubin level was 212 µmol/L on day 3 (reference value 3–5 days: <200 µmol/L).
At discharge (day 9) his hemoglobin was 14.9 g/dL (reference value 0–3 months: 9.4–13.4
g/dL). 
On follow up (age: 7 weeks) he was pale but not jaundiced. He was breast-fed and received
25 µg of vitamin K once daily. Hemoglobin was 8.0 g/dL, reticulocytes 140‰ (reference
value: 0–20‰) and serum iron 13 µmol/L (reference value: 10–32 µmol/L). As the anti-D
antibodies should have disappeared after 7 weeks, he was started on iron supplements with
130
De novo missense mutations in G6PD 
the working diagnosis of iron deficiency anemia due to hemolysis. At age 9 weeks, the blood
hemoglobin was 6.7 g/dL, reticulocytes were 218‰ (Table 1) and total serum bilirubin was
43 µmol/L (reference value: 3–21 µmol/L). The iron supplements were withdrawn. At this
point he was diagnosed with hemolytic anemia due to severe G6PD deficiency (see Results
and discussion). To date at age three years, the boy has experienced numerous hemolytic
episodes, mostly triggered by infections, complicating his chronic hemolysis, frequently
requiring blood transfusion.
Case report: patient 2
This boy is the second son of Caucasian nonconsanguineous Dutch parents born at 41 weeks
of gestation with a normal hemoglobin (17.7 g/dL) and without signs of neonatal jaundice
(bilirubin: 134 mmol/L on the fourth day). From the age of 1 month he was treated with
ferrousfumarate for anemia (hemoglobin 8.5 g/dL) for a period of 2 months. The further
history is uneventful. 
At the age of 29 months, he presented with an episode of severe hemolysis 3 days after eating
fava beans for the first time: hemoglobin 6,7 g/dL (reference value: 11.8–14.4 g/dL); lactate
dehydrogenase (LD), 4142 U/L (reference value: 470–900 U/L); reticulocytes, 140‰.
Further analysis led to the diagnosis of G6PD deficiency (see Results and discussion).
During the following year, he was mildly jaundiced one more time during an episode of
gastroenteritis, for which his parents sought no medical attention. Hemoglobin was between
9.3 and 9.9 g/dL with 47–65‰ reticulocytes and LD 748–802 U/L, all suggestive of mild
ongoing hemolysis. 
Biochemical analysis 
G6PD activity and activity measurements of the red blood cell age-related enzymes pyruvate
kinase (PK) and hexokinase (HK) were determined according to standardized procedures.9
Molecular analysis
DNA was isolated from peripheral white blood cells and exons 2–13 of G6PD of the patients
were amplified by PCR according to previously described methods.10 DNA sequence
analysis was performed as described11 with the appropriate primers. Screening of a normal
control population (n = 50) for the novel c.1225C>T mutation was performed by MspI
digestion, a recognition site of which is abolished by the mutation. cDNA nucleotide and
amino acid numbering starts at the initiator methionine and sequence variations are described
according to the mutation nomenclature system.12
Genotyping the dinucleotide (TA) insertion polymorphism in the UDP-
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glucuronosyltransferase 1 (UGT1) promoter was modified from the method described by
Monaghan et al.13 6-FAM labeled sense primers were used for amplification and fluorescent
PCR products were analyzed on the ABI 310 Genetic Analyzer (Applied Biosystems, Foster
City, CA) using GeneScan 3.1 software. 
Molecular modeling
The mutated residues Ser409 and Gly431 were modeled using the program O14 and
coordinates from the crystal structure of human G6PD (protein data bank entry 1QKI). 
Results and Discussion
Severe G6PD deficiency was diagnosed in both patients based on low to undetectable G6PD
activity. To rule out possible contamination with donor erythrocytes (patient 1) and to
establish glycolytic enzyme activities after recovery from hemolytic crisis (patient 2),
repeated measurements of G6PD, HK, and PK activities were performed at age 7 and 41
months, respectively. These measurements showed undetectable G6PD activity, despite a
high reticulocyte count, and elevated activity of HK and PK, consistent with a young red cell
population (Table 1). The undetectable residual enzymatic activity hampered further
enzymatic characterization. Glycolytic enzyme activities of the patient’s relatives were all
within normal range (Table 1).
Table 1. Glycolytic enzyme activities of patients 1 and 2
Patient 1 Father Mother Brother Reference
Age at diagnosis 9 weeksa
Follow-up 7 months
PK (U/gHb) 26.9 22.4 8.4 16.7 14.2 6.9–14.5
HK  (U/gHb) 7.70 5.91 1.42 1.66 1.46 1.02–1.58
G6PD (U/gHb) 2.3 <1.0 10.6 10.6 11.0 7.1–11.5
hemoglobin (g/dL) 6.7 8.5 9.4–13.4
reticulocytes (‰) 218 135 0–20
Patient 2 Father Mother Brother Reference
Age at diagnosis 29 months
Follow-up (age) 41 months
PK (U/gHb) 27.1 28.4 NA 12.2 13.0 6.9–14.5
HK (U/gHb) 5.63 3.77 ND 1.29 1.02–1.58
G6PD (U/gHb) <1.0 <1.0 9.6 11.6 7.1–11.5
hemoglobin (g/dL) 6.7 9.3 9.4–13.4
reticulocytes (‰) 140 62 0–20
a Eight weeks following transfusion. NA, Not available; ND, Not determined.
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We established the G6PD genotypes by DNA sequence analysis of the complete coding
region. Regarding patient 1, we detected a novel hemizygous cytosine to thymine
substitution at nt 1225 (c.1225C>T) in exon 10 (Figure 1A) coding for serine instead of the
highly conserved proline at residue 409.15 No other mutations were detected in G6PD.
Screening of a control population by MspI digestion, of which a recognition sequence is
abolished by this mutation, failed to detect the 1225T allele. The severe clinical phenotype
of chronic hemolysis is consistent with class I G6PD deficiency3 and we designated this
novel variant G6PD Utrecht. Regarding patient 2, DNA analysis revealed a hemizygous
thymine to guanine substitution at nt 1292 in exon 11 (c.1292T>G) (Figure 1B). This
mutation encodes the once previously reported class I G6PD variant Sumaré (Val431Gly).16
Neither mutation was encountered during subsequent DNA analysis of exons 10 and 11 in
any of the, respective, relatives, notably the mothers (Figures 1A and B). Because we could
confirm the parent–child relationship by parental DNA testing (data not shown), we inferred
the occurence of a de novo mutational event in both patients. Moreover, this most likely
occurred in early embryogenesis or in the maternal germline because buccal-cell DNA
patient 2
mother
c.1292T>G; Val431Gly
G6PD Sumaré
B.
patient 1
mother
c.1225C>T; Pro409Ser
G6PD Utrecht
A.
Figure 1. (A) DNA sequence analysis of G6PD of patient 1 (top) shows the novel hemizygous cytosine
to thymine substitution (arrow) at nt 1225 in exon 10 of G6PD. This substitution is absent in G6PD of
the mother (bottom), indicating a de novo missense mutation. The mutation predicts a proline to serine
substitution at residue 409 in G6PD (G6PD Utrecht). (B) DNA sequence analysis of G6PD of patient
2 (top) revealed a hemizygous thymine to guanine substitution at nt 1292 in exon 11 (Val431Gly, G6PD
Sumaré). This substitution is absent in the mother (bottom), indicating a de novo mutation.
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samples from both patients also demonstrated hemizygosity for the respective mutations
(data not shown). To our knowledge, this adds two G6PD variants that have arisen de novo
to the five previously reported in class I G6PD deficiency.17-21
The severe clinical phenotype in patient 1, in particular with regard to the
hyperbilirubinemia, in the immediate perinatal period was unusual because excessively
increased hemolysis, especially in the first few days of life, does not constitute the cardinal
factor in the pathogenesis of hyperbilirubinemia in G6PD-deficient neonates.22 The presence
of a dinucleotide (TA) insertion polymorphism23 in the promoter of the gene that codes for
UDP glucuronosyltransferase 1 (UGT1), the enzyme that catalyzes bilirubin conjugation by
the liver, however, is known to be actively involved in the pathogenesis of G6PD deficiency
associated neonatal hyperbilirubinemia.24 One dinucleotide insertion increases the incidence
of hyperbilirubinemia from 9.7% in G6PD-deficient neonates homozygous for the normal
promoter (TA6/TA6), to 31.6% in those heterozygous (TA6/TA7), and 50% in those
homozygous (TA7/TA7) for this polymorphism.24,25 Indeed, we detected this polymorphism
in the heterozygous state in our patient (Figure 2A).
Nearly half of the mutations encoding class I G6PD variants directly affect the subunit
interface of the G6PD dimer.8 Structural analysis of the crystal structure of human G6PD8
reveals that residues Pro409 (mutated in patient 1) and Val431 (mutated in patient 2) are also
A. B.(TA)6
(TA)7
(TA)6 / (TA)6
patient 1 patient 2
Figure 2. Dinucleotide (TA) insertion polymorphism in the UDP-glucuronosyltransferase 1 (UGT1)
promoter was determined by detection of fluorescent PCR products. Patient 1 was heterozygous for one
dinucleotide insertion (TA6/TA7) (panel A) whereas patient 2 was homozygous for the wild-type
promoter (TA6/TA6) (panel B).
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involved in interactions among the subunits of the G6PD dimer (Figure 3). Pro409 is located
in a loop that connects β strands M and N that act as a scaffold for the interface and NADP-
binding residues.8,26 The Pro409-containing loop is involved in numerous interactions with
the other subunit, specifically with residues from helices f, f’, l, and m, and residues from a
loop that connects helices l and m. This latter loop contains the mutated residue Val431.
Thus, Pro409 and Val431, located on different subunits, interact directly in the subunit
interface. Pro409 makes inter-subunit contacts with Tyr424, Tyr428, and Val431 and
mutation to serine would disrupt some of these contacts. Likewise, inter-subunit contacts of
Val431 with Pro409 are likely to be disrupted upon mutation of Val431 to glycine. Moreover,
the Pro409Ser and Val431Gly mutations both introduce a residue that allows for greater main
chain flexibility, which could destabilize subunit interactions. The critical nature of the
conformation of the Pro409-containing loop is further illustrated by the effect of mutations
of the adjacent residue Gly410. Mutations of Gly410 to alanine,27 cysteine,28 or aspartate29
all lead to class I deficiency. In conclusion, mutations Pro409Ser and Val431Gly could
weaken dimer interactions, compromising the stability and enzymatic activity of G6PD. The
subsequent lack of NADPH leads to CNSHA, although the different phenotypes in both
patients point out the importance of both the position as well as the nature of amino acid
replacement with regard to the extent of chronic hemolysis.
The mild phenotype of G6PD Sumaré, as expressed in patient 2, also differed from the
Figure 3 (color version, addendum page 168). Ribbon representation of a G6PD dimer with green
spheres indicating the position of Pro409 and magenta spheres indicating the position of Val431.
Subunits A and B are colored red and blue, respectively. The structural NADP molecules are shown in
dark blue ball-and-stick representation. Dashed rectangles depict the two regions in the G6PD dimer
interface disrupted by the Pro409Ser and Val431Gly substitutions. Note that although residues Pro409
and Val431 are located close together, they in fact reside on different subunits. (Inset) Close-up view
of the vicinity of Pro409 (here shown on subunit A) and Val431 (subunit B) with selected residues
shown in ball-and-stick (oxygen, red; nitrogen, blue; carbon, black). The carbon atoms of the mutated
residues are shown in green (Ser409) and magenta (Gly431). The mutations were modeled using the
program O.14 The figure was generated from the atomic coordinates of protein data bank entry 1QKI8
using computer programs Molscript35 and Raster3D.36
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clinical picture of the only other patient carrying this variant to date.16 Saad et al.16 originally
identified G6PD Sumaré in a 22-year-old white male of unknown origin from southeastern
Brazil who displayed persistent chronic jaundice since birth, splenomegaly, mild chronic
anemia (Hb 13.0 g/dL), and reticulocytosis (140‰).16 This patient’s daughter, compound
heterozygous for G6PD Sumaré and the common G6PD A– variant, had jaundice at birth and
mild chronic hemolysis whereas several respiratory infections did not evoke hemolytic
crises.30 In contrast, neonatal jaundice was absent in our patient and, in fact, he had been
clinically normal until he presented with favism at the age of 29 months. Only then was he
diagnosed with mild chronic hemolysis due to severe G6PD deficiency. 
The vast majority of cases of favism occur in individuals carrying the severely deficient, non-
CNSHA, class II G6PD variants. However, favism as the first clinical symptom of class I
G6PD deficiency has been described before, namely, in association with G6PD Tokyo
(Glu416Lys).31 G6PD Tokyo was exclusively associated with CNSHA in three unrelated
Polish G6PD-deficient families, whereas in a fourth, unrelated, family three members
presented with favism during childhood and only further observation confirmed CNSHA in
these patients.31 From a structural point of view, only a few mutations causing class II G6PD
deficiency affect residues in the G6PD dimer interface. Strikingly, however, one of these
concerns another, recently described substitution of residue 431: Val431Met, G6PD
Surabaya.32 This variant was discovered in an 18-year-old male following an episode of
acute hemolytic attack but without chronic hemolysis.32 This is intriguing because alternate
substitutions of the same amino acid at the G6PD dimer interface are seldomly associated
with distinct phenotypic expression.1,8 In fact, the only example, to our knowledge, involves
the substitution of Glu398 by Lys in class I variant G6PD Puerto Limon33 whereas
substitution of Glu398 with Gly characterizes class II variant G6PD Anadia.27
In conclusion, Val431 is located in a region of the G6PD dimer interface crucial for
enzymatic activity as illustrated by the severe CNSHA phenotype of G6PD Utrecht.
Substitution of Val431 by Gly, however, places G6PD Sumaré at the crossing between class
I and class II G6PD deficiency. Consequently, phenotypic expression in the two reported
patients with G6PD Sumaré is either aggravated or ameliorated by other factors. These
factors may be environmental or genetic, either linked or unlinked to the G6PD gene.34 With
regard to the difference in neonatal jaundice associated with the inheritance of G6PD
Sumaré, as discussed above, the co-inheritance of the UGT1 promoter polymorphism
represents one such factor. Our patient was homozygous for the normal promoter (TA6/TA6,
Figure 2B) whereas, unfortunately, the UGT1 promoter genotype of the original patient is
unknown. 
Understanding genotype to phenotype interactions is important in counseling patients with
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G6PD deficiency. As illustrated by our study, these interactions are complex and dependent
on many factors. Describing these mutations and the associated phenotypes is important in
order to widen our knowledge of G6PD deficiency.
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Abstract
Hexokinase deficiency is a rare autosomal recessive disease with a clinical phenotype of
severe hemolysis. We report a novel homozygous missense mutation in exon 15
(c.2039C>G, HK [hexokinase] Utrecht) of HK1, the gene that encodes red blood cell-
specific hexokinase-R, in a patient previously diagnosed with hexokinase deficiency. The
Thr680Ser substitution predicted by this mutation affects a highly conserved residue in the
enzyme’s active site that interacts with phosphate moieties of adenosine disphosphate,
adenosine triphosphate (ATP), and inhibitor glucose-6-phosphate. We correlated the
molecular data to the severe clinical phenotype of the patient by means of altered
enzymatic properties of partially purified hexokinase from the patient, notably with
respect to Mg2+-ATP binding. These kinetic properties contradict those obtained from a
recombinant mutant brain hexokinase-I with the same Thr680Ser substitution. This
contradiction thereby stresses the valuable contribution of studying patients with
hexokinase deficiency to achieve a better understanding of hexokinase’s key role in
glycolysis.
Introduction
Hexokinase (HK) catalyses the phosphorylation of glucose to glucose-6-phosphate (G6P)
using adenosine triphosphate (ATP) as a phosphoryl donor. HK-I is the predominant HK
isozyme in tissues that depend strongly on glucose use for their physiological functioning,
such as brain, muscle and erythrocytes. HK-I displays unique regulatory properties in its
sensitivity to inhibition by physiological levels of the product G6P and, moreover, relief of
this inhibition by inorganic phosphate (Pi).1 The recent determination of structures for
human2 and rat3 HK-I has provided substantial insight into ligand binding sites and
subsequent modes of interaction.2-7
Erythrocytes contain a specific subtype of HK-I (HKr)8 that is encoded by the HK-I gene.9
Erythroid-specific transcriptional control results in a unique red blood cell-specific cDNA
that differs from HK-I cDNA at the 5’-end.10-12 Hexokinase deficiency is a rare disease with
nonspherocytic hemolytic anemia as the predominant clinical feature. Seventeen families
with hexokinase deficiency have been described to date13 and only one patient has been
characterized at the cDNA level.14 We now report on the molecular defect underlying
hexokinase deficiency in a previously reported Dutch family.15
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Study Design
Patient Z62 was born from a consanguineous marriage, that is, from first cousins, and was
originally reported in 1983.15 She presented with neonatal jaundice and transfusion-
dependent hemolysis. Residual HK activity in the patient’s erythrocytes, platelets, and
lymphocytes was about 25% of normal,15 in agreement with a generalized HK deficiency
caused by a mutation in HK1. DNA was isolated from peripheral white blood cells according
to standardized procedures. The erythroid-specific promoter, red blood-cell specific exon 1,
and exons 2 to 18 of HK1 of the patient and a healthy control subject were amplified by
polymerase chain reaction (PCR) (primer sequences available on request). cDNA nucleotide
and amino acid numbering starts at the HK-I start codon, and sequence variations are
described according to the mutation nomenclature system.16 DNA sequence analysis was
performed with the appropriate primers as described.17
Results and discussion
DNA sequence analysis of HK1 of the patient and a control subject revealed several base
changes compared with the reference sequences (GenBank AF016349-016365) (Table 1).
Base variations for which both the patient and control subject were homozygous could
represent either sequence discrepancies or polymorphisms. The c.78G>C and
IVS15+27C>T are postulated dimorphic changes for Leu25 and an intronic polymorphism,
respectively. The c.2039C>G missense mutation in exon 15, however, was a likely candidate
Table 1. DNA sequence variations in HK1.
Control subject patient Z62
–426_–424insGa (G)4 (G)4
IVS1+66C>Gb G/G G/G
IVS1+85C>G G/G G/G
Exon 2, c.78G>C (Leu25) G/C C/C
IVS12+31G>A A/A A/A
Exon 15, c.2039C>G (Thr680Ser) C/C G/G
IVS15+27C>T C/T C/C
IVS17+41T>C C/C C/C
a Relative to the HKr initiator methionine (GenBank AF029306); b relative to HKr exon 1
(GenBank AF016349).
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to cause hexokinase deficiency because the consequent Thr680Ser substitution it encodes
affects a critical residue in the active site2,3,7,18 that is, moreover, evolutionary conserved
(Figure 1). Subsequent screening of the patient’s family for c.2039C>G affirmed
cosegregation of this mutation with lowered HK activity (Figure 2) whereas in a healthy
control population (n = 50), this mutation was not encountered (not shown). We designated
the variant HK found in this family HK Utrecht. 
Structural changes due to a conservative threonine-to-serine substitution are likely to be
limited since serine can form the same hydrogen bonds as threonine. However, the
consequent removal of the methyl group could affect hydrogen bond formation by increasing
         ↓
Homo sapiens, HK-I(c) TCEVGLIVGTGSNACYMEE
Mus musculus, HK-I(c) SCEIGLIVGTGSNACYMEE
Rattus norvegicus, HK-I(c) TCEIGLIVGTGTNACYMEE
Bos Taurus, HK-I(c) TCEVGLIVGTGSNACYMEE
Xenopus laevis, HK-I NCEIGLIVGTGSNACYMEE
Cyprinus carpio, HK-I(c) TCEVGLIAGTGSNACYMEE
Homo sapiens, HK-II(c) HCEVGLIVGTGSNACYMEE
Homo sapiens, HK-III(c) RCEIGLIVGTGTNACYMEE
Homo sapiens, HK-IV QCEVGMIVGTGCNACYMEE
Rattus norvegicus, HK-IV QCEVGMIVGTGCNACYMEE
Sparus aurata, HK-IV SCEVGMIVGTGCNACYMEE
Drosophila melanogaster, HK-I NCKIGLIVGTGANACYMER
Drosophila melanogaster, HK-II DCRVGVIVGTGCNACYVED
Caenorhabditis elegans SCQIGVIVGTGTNACYMER
Schistosoma mansoni KCAVGLIVGTGTNVAYIED
Plasmodium falciparum PCYIGIILGTGSNGCYYEP
Entamoeba histolytica           SCGMGLIFGTGTNGCYIEK
Haemonchus contortus SCQIGVIVGTGTNACYMEK
Trypanosoma brucei EVQVGVIIGTGSNACYFET
Toxoplasma gondii ECRVGLIIGTGFNACYVEP
Schizosaccharomyces pombe, HK-I GTEIGVIFGTGCNACYIEK
Saccharomyces cerevisiae, HK-PI ETKMGVIFGTGVNGAFYDV
Saccharomyces cerevisiae, HK-PII ETKMGVIFGTGVNGAYYDV
Tuber borchii TTRIGCIFGTGCNAAYMET
Kluyveromyces lactis QTKMGIIIGTGVNGAYYDV
Debaryomyces occidentalis EAKMGLFSGTGCNGAYYDV
Yarrowia lipolytica QIKLGNIFGTGVNAAYYEK
Treponema pallidum SSYVGFILGTGMNSAYLEP
Nicotiana tabacum DVAVAVILGTGTNAAYVER
Spinacia oleracea DVIAAVILGTGTNAAYVER
Thr680
Figure 1. Conservation of Thr680. Amino acid alignment of the region surrounding human HK-I
residue Thr680 among 30 hexokinases. Where applicable, specific isozymes are denoted.  Conserved
residues compared with human HK-I are in shaded gray. The “c” in parentheses refers to the C-terminal
domain of HK.
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the rotational freedom of the side chain or, alternatively, by introducing a water molecule at
the site previously occupied by the methyl group. Small conformational changes could thus
have a significant effect on catalysis, because enzymes typically require a delicate balance of
interactions for optimal activity.
In view of its central position in the active site (Figure 3), Thr680 has been proposed to
hydrogen bond to the β- and γ-phosphoryl group of ATP during catalysis.7 Thus, altered
binding of phosphate-containing ligands is likely an important factor in deficient enzyme
function. Indeed, enzymatic properties of partially purified mutant red cell HK from the
Figure 2. Cosegregation of the novel c.2039C>G (Thr680Ser) missense mutation with lowered
HK activity. In the family pedigree chart, individuals heterozygous or homozygous for the c.2039C>G
mutation are indicated by half-filled and filled symbols, respectively. Symbols represent the
corresponding family members in the bottom part of the figure. Lanes in the agarose gel for each family
member are directly below the symbol for that individual. The agarose gel below shows a 301-bp PCR
product encompassing exon 15, which was amplified from genomic DNA and subjected to AciI
digestion. c.2039C>G creates an additional restriction site upon the two normally present in this
fragment. Thus, digestion of the wild-type allele results in fragments of 14, 221, and 66 bp, whereas
the extra AciI recognition sequence yields additional fragments of 34 and 187 bp. Digestion fragments
are indicated by arrows on the right (14 and 34 bp fragments are not shown). Homozygosity for
c.2039C>G is confirmed in patient Z62. The patient’s father (Z32), mother (H37), sisters (Z53 and
Z66),15 and daughter N84 were all heterozygous, whereas sister Z56 didn’t carry the mutation. All
family members heterozygous for the Thr680Ser substitution displayed reduced HK activity in their
red blood cells, ranging from 0.64–0.89 U/gHb (reference value: 1.34 ± 0.42 U/gHb).15 HK activity for
sister Z56 was 1.22 U/gHb. *indicates Z62; M, marker; NC, healthy control.
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patient showed near normal affinity for glucose15 but a 2-fold decrease in affinity for Mg2+-
ATP and a markedly (3- to 9-fold) decreased affinity for inhibitor glucose-1,6,-
diphosphate.15 Surprisingly, these results contradict with kinetic data obtained from a
recombinant human brain HK-I Thr680Ser mutant as expressed in Escherichia coli.18 The
kcat value of this mutant decreased only 2.5-fold and was, in fact, characterized solely by a
slightly higher affinity for glucose, whereas the Km(ATP), Ki(ATP), and Ki for the G6P
analog 1-5-anhydroglucitol-6-phosphate were similar when compared to wild-type HK-I.18
These unexpected discrepancies must be attributed either to the different sources of the
enzyme, that is, E. coli versus human red blood cells, or to the different N-terminal ends of
HKr and HK-I. It highlights the differences in fate and function of mutant enzyme in vivo as
underscored by a recent case of glucose-6-phosphate dehydrogenase deficiency.19
The 2-fold higher Km for Mg2+-ATP15 reflects a relatively modest effect of the Thr680Ser
Figure 3. Thr680 is a critical residue in the active site of HK (color version, addendum page 169).
Schematic drawing of the active site of HK-I shows Thr680, bound glucose, and adenosine diphosphate
(ADP) in ball-and-stick representation (atom coloring: carbon black; oxygen, red; nitrogen, blue; and
phosphor, magenta). The carbon atom that is absent in the Thr680Ser mutant is colored gray. Illustrated
is the central position occupied by Thr680 in the active site where it is located at the tip of a loop and
makes a hydrogen bond with the α-phosphoryl group of ADP. This figure was generated from the
atomic coordinates of the HK-I ADP/glucose complex7 (protein data bank entry 1DGK) using
computer programs Molscript22 and Raster3D.23
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substitution on ATP binding to the active site. This change in Km may not affect in vitro HK
activity, which is measured at excess Mg2+-ATP (5 mM),20 but may have a significant effect
in vivo because intracellular ATP concentrations are much lower (0.6 mM)21 and similar to
the Km. In the study conducted by Ouwerkerk et al21, blood from patient Z62 was used to
measure intracellular Mg2+-ATP concentrations in oxygenated and deoxygenated red blood
cells. In oxygenated red blood cells, Mg2+-ATP concentrations were slightly higher in the
patient (1.04 mM) when compared with the healthy control (0.61 mM) and equal to the
reticulocyte control (1.11 mM).21 Likewise, in deoxygenated red blood cells comparable
Mg2+-ATP concentrations were measured in the patient (0.57 mM) and healthy control (0.62
mM),21 which, in fact, denotes a strongly decreased Mg2+-ATP concentration, when
compared to a reticulocyte control (1.79 mM)21 and considering the high degree of
reticulocytosis (40–50%) in the patient. Therefore, we postulate that at physiological
concentations of Mg2+-ATP, the 2-fold increase in Km for Mg2+-ATP results in a significantly
decreased HK activity in the patient’s red blood cells, which is reinforced by deoxygenation.
These considerations are in agreement with the severe clinical phenotype as observed in
patient Z62 and even true if HK is expressed and maintained at a normal level. The residual
(in vitro) activity of 25%, however, suggests an additional effect on either protein expression
or enzyme stability. 
The identification of a homozygous c.2039C>G (Thr680Ser) missense mutation in patient
Z62 places previously determined enzymatic properties of the mutant enzyme into
perspective and stresses the valuable contribution of studying patients with HK deficiency
toward a better understanding of the key role played by HK in the glycolytic pathway and,
in particular, in red cell metabolism.
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Summary, general discussion, and future prospects
The clinical hallmark of the patients described in this thesis is chronic hemolysis. Regardless
of the kind of underlying inherited enzymopathy, the here described deficiencies of
hexokinase (HK), pyruvate kinase (PK), and glucose-6-phosphate dehydrogenase (G6PD)
ultimately resulted, albeit to a various extent, in shortened red blood cell survival because
“metabolically defective red blood cells are old before their time, and suffer from metabolic
progeria” (Valentine W.N. and Paglia D.E. Blood Cells. 1980; 6: 819-829). All three
mentioned enzymes are key enzymes of the Embden-Meyerhof Pathway (HK and PK) and
the Hexose Monophosphate Shunt (G6PD). The underlying mechanisms by which these
deficiencies cause hemolysis, however, are distinct. The main cause of hemolysis in either
HK or PK deficieny is a depletion of the cellular ATP content whereas the G6PD-deficient
erythrocyte is more susceptible to oxidative damage. To induce a clinically significant
hemolysis, red blood cell enzyme function must be significantly impaired under
physiological conditions. Thus, in compound heterozygous patients overt hemolysis assures
that, at least, one gene product is severely defective. The focus of this thesis was to identify
the molecular mechanisms by which inherited enzymopathies lead to impaired enzyme
function. This constitutes the primary basis of the associated hemolytic disease. The
molecular defects underlying the above-mentioned enzyme deficiencies were found to affect
correct human gene expression (chapter 1) either at the level of transcriptional regulation
(chapter 2), pre-mRNA processing (chapter 3), or protein structure (chapters 4 and 5) and
function (chapters 6 and 7).
Enzymopathy due to defects at the level of transcriptional regulation
In chapter 2 we described a severely PK-deficient patient. In reticulocyte RNA from this
patient we detected a monoallelic pattern of gene expression. This led to the identification of
a novel transcriptional regulatory element in the erythroid-specific promoter of PKLR. RNA
from the patient demonstrated sole expression of the paternal c.1529G>A missense PKLR
allele. On the DNA level, however, the boy was heterozygous for this missense mutation.
Moreover, 3 novel in cis DNA sequence variations were identified on the maternal allele in
the erythroid-specific promoter of PKLR: –324T>A, –248delT, and –83G>C. We established
the functional consequences of each individual mutation using in vitro transfection assays in
K562 cell line. Hence, we demonstrated that –324T>A was a non-functional mutation
whereas –248delT represented a non-functional polymorphism. This polymorphism had
previously been associated with PK deficiency by others because it disrupts a binding site for
the erythroid-specific transcription factor GATA-1. We clearly demonstrated, however, that
the concerning GATA-1 binding site was non-functional. The –83G>C mutation caused
effective downregulation of the PKLR promoter, thereby explaining the pattern of
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monoallelic gene expression of the in trans allele. Systematic mutagenesis of the region
surrounding nt –83 disclosed the presence of a novel cis-regulatory element, which we
designated PKR-RE1. To confirm that this novel element was actively involved in DNA-
protein interaction we performed electrophoretic mobility shift assay using K562 nuclear
extract. These experiments demonstrated in vitro DNA-protein interaction at the core of
PKR-RE1, involving an as-yet-unidentified trans-acting factor. Because no known protein is
known to recognize the PKR-RE1 motif, we concluded that PKR-RE1 may be involved in a
novel mechanism of erythroid-specific trans activation, mediating the effects of factors
necessary for regulation of PK gene expression during red cell differentation and maturation.
The monoallelic expression of the 1529A allele rendered this particular patient ‘pseudo-
homozygous’ for c.1529G>A, a missense mutation that predicts the substitution of arginine
by glutamine at residue 510. It was, therefore, reasonable to assume that the PK-deficient
phenotype, i.e. severe, transfusion-dependent hemolytic anemia, of the patient described in
chapter 2 could be attributed to the sole synthesis of the Arg510Gln PK-R variant. As
demonstrated in chapter 5, the introduction of a glutamine residue at position 510 in the A/C
domain interface causes reduced conformational freedom between these two domains. This
may explain the very low activity and striking instability that is usually associated with this
common PK-deficient variant. It is of interest that the severe clinical picture of the ‘pseudo-
homozygous’ patient in chapter 2 was remarkably different from that of patient MB86,
described in chapter 4. The latter, mildly affected patient was homozygous for the
c.1529G>A mutation and had never been transfusion-dependent. This may indicate that in
spite of the envoked structural perturbation, some residual enzymatic function is still
maintained in the Arg510Gln PK-R variant. Thus, the amount of residual enzymatic activity
would be higher in the homozygous patient because about twice the amount of aberrant
protein is synthesized from the two defective alleles whereas in the ‘pseudo-homozygous’
patient only one allele is actively involved in protein synthesis. 
Chapter 2 emphasizes the need for an as-complete-as-possible molecular characterization in
general. Molecular diagnostic approaches that are confined to the protein coding region of
the gene or use only cDNA transcribed from a patient’s RNA, in this case would either have
missed the transcriptional mutant or misdiagnosed the patient as homozygous for the
c.1529G>A missense mutation.  
Enzymopathy due to defects at the level of pre-mRNA processing
The synthesis of only one species of mutant PK, in spite of a compound heterozygous
genotype, was also demonstrated in another patient with severe PK deficiency. In this case
the production of mutant Arg479His PK-R was due to aberrant processing of PKLR pre-
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mRNA. This patient, described in chapter 3, was compound heterozygous for two mutations
which were both likely to affect correct splicing. One novel mutation abolished the invariant
dinucleotide of intron 5 (IVS5+1G>A) whereas the other mutation (c.1436G>A) altered the
exonic consensus sequence of IVS10 and, in addition, encoded an arginine to histidine
substitution at residue 479. A novel approach was employed to study the effects of both
mutations on pre-mRNA processing. The main feature of this approach constituted the use
of ex vivo produced nucleated erythroid cells from the patient as a source of RNA. This
approach allowed for a more profound analysis of the effects on pre-mRNA processing, as
demonstrated by the detection of multiple aberrant transcripts, associated with both
mutations but also, for the first time, in wild-type PKLR pre-mRNA. As anticipated, one of
the predominant transcripts associated with the IVS5+1G>A mutation lacked the upstream
exon 5. Unexpected, however, was the identification of the second major transcript
associated with this mutation. This nonsense transcript lacked both exons 5 and 6 (see
below). No functional protein was expected nor detected (by Western blotting) from either
transcript, which rendered the IVS5+1A allele de facto a null allele. The c.1436G>A
mutation in this patient was mainly associated with a strong reduction in transcript levels
although the majority of these transcripts were normally spliced. Such a strong reduction of
transcripts may be the reflection of increased instability of the major part of mutant
transcripts derived from the 1436A allele. However, because the processes of transcriptional
regulation and pre-mRNA processing are intimately related, an additional effect of the
c.1436G>A mutation on transcription cannot be excluded. Altogether, the PK-deficient
phenotype in this patient could mainly be attributed to the presence of strongly reduced
amounts of  Arg479His PK-R. We confirmed this by Western blot. The sole presence of
Arg479His PK-R in this patient enabled a direct comparison with the crystal structure and
enzymatic properties of the same recombinant PK variant as expressed in Escherichia coli.
The structural data were in agreement with our own observations but a striking difference
was noted with regard to the heat stability of both mutant PK variants. We had demonstrated
that the patient’s PK showed reduced thermal stability in vitro. This was in agreement with
a remarkable sensitivity to heat displayed by the patient during febrile episodes or even
prolonged exposure to sunlight. These two observations suggested a decreased stability of
the Arg479His PK tetramer. The recombinant Arg479His PK variant, however, showed
nearly unaffected thermal stability. This discrepany resembles a similar contradiction
between enzymatic properties of mutant human enzyme and its recombinant analog
observed in a case of hexokinase deficiency (chapter 7) and will be further discussed below
(Enzymopathy due to defects at the protein level – protein function). It emphasized,
however, that knowledge obtained from recombinant (mutant) enzymes should be interpreted
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with care when applied to their human analogs.
As mentioned above, the composition of one transcript identified in the patient described in
chapter 3 was quite unusual. During pre-mRNA processing, two consecutive exons (exons
5 and 6) had been simultaneously skipped from the pre-mRNA transcribed from the allele
with the IVS5+1G>A mutation. These two events were likely related and led us to propose
a mechanism in which correct processing of exon 6 in wild-type PKLR pre-mRNA depends
on the presence of exon 5 in the primary transcript. In other words, in wild type PKLR pre-
mRNA, exon 5 contains regulatory splicing elements necessary for proper processing of
exon 6. It is obvious that due to a mutation at the intron 5 donor splice site and the
subsequent removal of the entire exon 5, the putative regulatory elements were automatically
skipped from the pre-mRNA, leading to inefficient inclusion of the sixth exon. The presence
of a splice enhancer element in PKLR exon 5 automatically implies that other base changes
in this exon, for example the missense mutations as described in chapter 4, may be capable
of disturbing correct pre-mRNA processing. For further discussion, see Future prospects.
Enzymopathy due to defects at the protein level – protein structure
The major molecular defect underlying the hereditary enzymopathies are single-base
changes that predict the substitution of a structurally and functionally important amino acid.
This is especially true in case of PK and G6PD deficiency (chapter 1) and our results
obtained from a large group of patients with PK deficiency, described in chapter 4, are in
agreement with this observation of missense mutations being predominant. The 28 patients
studied and reported in chapter 4 originated from 26 different families. We identified 24
different alleles associated with PK deficiency and 14 of these mutations were novel. Of the
24 mutant allels, 20 carried a missense mutation (83%), including 12 novel ones. This is
slightly higher than the global distribution of missense mutations which is approximately
70% (chapter 1). The four remaining mutations were nonsense mutations (two mutations,
including one novel) or predicted to affect pre-mRNA processing (two mutations, including
one novel). The frequently detected c.331G>A mutation was of particular interest. This
mutation predicts the unfavorable subsitution of glycine by arginine at residue 111 (PK
Utrecht) and was identified in five unrelated Dutch families. This meant that the novel
c.331G>A mutation constituted a major cause of PK deficiency in The Netherlands. More
specific, together with the common mutations c.1456C>T and c.1529G>A, c.331G>A
accounted for nearly 50% of mutant PKLR alleles in The Netherlands. When applied to
diagnostic procedures, we recommend that an efficient initial screening for PKLR mutations
in Dutch PK-deficient patients should include these 3 mutations.
Ideally, the effects of missense mutations on protein structure and function should be
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examined using purified mutant PK from the patient. However, apart from the practical
limitations, a mutant enzyme purified from red blood cells of the patient may be unstable or
lack enzymatic activity, thereby hampering further biochemical characterization. The variant
G6PD Utrecht described in chapter 6 is an illustration of the latter. Furthermore, in case of
PK deficiency most patients are compound heterozygous. Hence, when both genes are
actively producing a mutant monomer, five different tetrameric forms can be assembled. This
limits the value of biochemical characterization considerably. An alternative approach
comprises the expression of the recombinant mutant enzyme. In that case, especially with
regard to the evaluation of enzymatic properties, chapters 3 and 7 have demonstrated that
significant differences in enzymatic behaviour may be observed when comparing
recombinant human enzymes with enzymes obtained from the patient. An initial approach to
elucidate the mechanism by which amino acid substitutions may lead to impaired enzymatic
function involves the evaluation of the concerning residue and the interactions in which it is
involved in the three-dimensional model of the crystal structure. The tetrameric crystal
structure of human erythrocyte R-state PK has recently been elucidated and we used this
model in chapter 4 to study the consequences of the novel amino acid changes on structure
and function of PK. By doing so we obtained additional structural support to affirm the
association of the respective mutations with PK deficiency. The effects of some mutations
were quite clear because they concerned the substitution of amino acids buried in the
hydrophobic core of the protein. Others altered the conformation of the B domain near the
active site or directly affected the ATP binding site. Provided that stable protein is
synthesized, these mutations may significantly alter PK enzymatic activity. Because the
allosteric regulation of PK is considered to be regulated by interdomain and intersubunit
interactions (chapter 1), a group of mutations that affected those regions were of particular
interest. One of these amino acid changes altered the C/C’ subunit interface, Arg569Gln,
whereas three mutations predicted a disruption of the A/A’ subunit interface: Arg337Trp,
Gly358Glu, and Arg385Lys. More specific, the mutations regarding residues Arg337 and
Arg385 may disrupt the formation of salt bridges, crucial for the T- to R-state allosteric
transition of the tetrameric enzym. Again, provided that stable PK monomers are
synthesized. The Gly358Glu substitution was the only mutation that could be directly
correlated to the patient’s phenotype because of homozygosity of this patient for the
causative c.1073G>A mutation. The patient was severely affected and transfusion-
dependent, thereby confirming the detrimental effects of this mutation at the A/A’ subunit
interface. Unfortunately, further biochemical characterization of enzymatic properties of this
mutant PK was not possible because the, Syrian, patient was not available for further study.
Our investigations reported in chapter 4 confirmed the association of the common
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c.1456C>T mutation with, in general, mild clinical expression of PK deficiency. This
mutation encodes a PK-R variant characterized by an arginine to tryptophan substitution at
residue 486 in the A/C subdomain interface. In this critical region of PK, replacing Arg486
with tryptophan is an amino acid change with potentially dramatic consequences.
Interestingly, in the three-dimensional model, a neighbouring residue of Arg486 is Gly364.
While the drastic Arg486Trp change causes little structural perturbation and, consequently,
leaves the enzymatic properties nearly unaffected, a similar drastic amino acid substitution
at residue 364 (Gly364Asp) caused severe PK deficiency and ultimately led to death in a
homozygous patient (chapter 5). This illustrates that the impairment of enzymatic function
is strongly dependent not only on the location of the replaced amino acid but also on the
amino acid with which it is replaced. A similar example is described in chapter 6 and
concerns two different G6PD variants that are both characterized by a perturbation of the
same critical region of the dimeric enzyme (see below). In chapter 5, the above-mentioned
mutation that predicted the Gly364Asp substitution concerned a novel c.1091G>A mutation,
identified in the homozygous state in the deceased patient. Because, at that time, the human
crystal structure had not yet been elucidated, the predicted structure of human R-state PK-R
was developed based on the homologous crystal structures of R-like muscle PK from cat and
rabbit. A detailed structural analysis was made of the effects of this mutation by molecular
modeling of aspartate at residue 364 of the PK monomer. We were able to demonstrate that,
located at the A/C domain interface, aspartate at residue 364 in the A domain interacts with
the backbone carbonyl of Gln482 of the C domain and introduces an alternative inter-domain
salt bridge with Arg488. As a result, the critical conformation of the A/C interface is
disrupted. Our results regarding the inter-domain interactions at the A/C interface being
critical for stability of the protein as well as the deleterious effect of the Gly364Asp
substitution were recently confirmed by the elucidation of the crystal structure of human
Gly364Asp PK-R (Valentini G. et al. Journal of Biological Chemistry. 2002; 17: 23807-
23814). The homozygous patient described above was the first child from the mother’s
second marriage. The mother had the misfortune to re-marry a second husband who was,
again, heterozygous for PK deficiency. Her first husband was also heterozygous and the child
born from this first marriage was compound heterozygous for the c.1091G>A and the
c.1529G>A mutations. This child was severely affected and required a blood transfusion
every three months at the time this study was conducted. He showed clinical symptoms that
were comparable with the clinical symptoms of two other patients from a second family who
were also compound heterozygous for the same combination of mutations in PKLR (chapter
5). A comparison of these PK deficiency-associated phenotypes may lead to the conclusion
that the co-inheritance of the 1529A allele confers some residual enzyme stability or
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function that is lost upon inheritance of two 1091A alleles. This is in agreement with the
beneficial ‘additive effect’ of the Arg510Gln PK-R variant as proposed above. 
Enzymopathy due to defects at the protein level – protein function
Dramatic changes in the enzyme’s structure brought about by significant structural
perturbation are obviously also likely to result in altered enzymatic activity, most frequently
in a negative manner. The location and interactions of the affected amino acid, as well as the
nature of the introduced substitution are important determinants for the resulting molecular
perturbation and its impact on protein function. This has been mentioned above with regard
to two drastic substitutions in PK (Gly364Asp and Arg486Trp) that led to differently
impaired enzyme function, and is further illustrated by the study described in chapter 6. In
this study, two patients with severe G6PD deficiency were investigated at the molecular
level. One patient suffered from severe chronic hemolytic anemia whereas in the other
patient only low level, subclinical, chronic hemolysis could be detected. Molecular analysis
revealed that both patients carried a variant G6PD gene on their X-chromosomes. The
respective mutations had arisen de novo, either in early embryonic development or in the
maternal germline. The amino acid substitutions Pro409Ser (G6PD Utrecht) and Val431Gly,
predicted by the mutations, both affected the G6PD dimer interface. Formation of the G6PD
dimer is crucial for G6PD enzymatic activity and nearly all mutations that affect the dimer
interface cause the most severe form of G6PD deficiency, the one that is associated with
chronic nonspherocytic hemolytic anemia (class I G6PD deficiency) (chapter 1). We studied
the two mutations in the three-dimensional model of human G6PD. This revealed that
Pro409 and Val431 were also located in the dimer interface and moreover, being located on
different subunits, interacted directly across the subunit interface. It was shown that Pro409
makes inter-subunit contacts with Tyr424, Tyr428, and Val431, and that mutation to serine
would disrupt some of these contacts. Likewise, inter-subunit contacts of Val431 with Pro409
were likely to be disrupted upon mutation of Val431 to glycine. Moreover, the Pro409Ser and
Val431Gly mutations both introduced a residue that allows for greater main chain flexibility,
which could destabilize subunit interactions. We concluded that both the Pro409Ser and
Val431Gly substitutions could weaken dimer interactions, thereby compromising the
stability and enzymatic activity of G6PD. On one hand, these observations, when combined
with the different phenotypes of both patients, pointed out the importance of both the
position as well as the nature of amino acid replacement with regard to the extent of chronic
hemolysis. On the other hand, however, they also clearly demonstrated that the ultimate
outcome of identical amino acid substitutions with regard to the clinical phenotype is not
solely dependent on the amino acid substitution itself because the phenotype of the patient
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with the Val431Gly substitution described in chapter 6, differed markedly from the only
other patient described to date that carried this G6PD variant. This other patient displayed
persistent chronic jaundice since birth, splenomegaly, mild chronic anemia, and
reticulocytosis. In contrast, the patient we described showed no neonatal jaundice and had
been clinically normal until he presented with favism at age 29 months. Therefore, like the
observed differences in expression of the Arg510Gln PK-R variant (chapters 2 and 4), we
concluded that the clinical picture also depended on other, genetic, factors.  
Chapter 6 demonstrates that differences in chronic hemolysis exist among patients with
different class I G6PD variants and even among patients with the same G6PD variant. This
underscores the need for a re-evaluation of the G6PD deficiency classification system
(chapter 1) which is based on residual G6PD enzymatic activity and clinical features. 
The homozygous PK-deficient patient in chapter 5 died of severely impaired enyzme
function caused by a dramatic perturbation of a critical inter-domain interface. The G6PD-
deficient patients described in chapter 6 displayed different phenotypes upon a drastic
molecular perturbation of the G6PD subunit interface. In chapter 7 we showed that also
subtle alterations in crucial areas of the enzyme can cause a severe impairment of enzyme
function in vivo, leading to chronic hemolysis. The patient described in chapter 7 had been
diagnosed with severe HK deficiency 20 years ago and we recently elucidated the molecular
basis underlying this rare case of HK deficiency. Previously, the enzymatic properties of
purified mutant HK from the patient had been biochemically characterized and had revealed
a two-fold decrease in affinity for Mg2+-ATP and a markedly (3- to 9-fold) decreased affinity
for inhibitor glucose-1,6,-diphosphate. We could easily correlate these features to the now
established molecular defect in the homozygous patient. We detected a novel c.2039C>G
missense mutation which predicted the substitution of active site residue Thr680 by serine
(HK Utrecht). Although structural changes due to this conservative substitution were likely
to be limited, structural analysis using the three-dimensional model of human HK1 displayed
a central position of the absolutely conserved Thr680 in the active site. In the active site,
Thr680 interacts with phosphate moieties of ADP/ATP and glucose-6-phosphate. Hence, the
removal of a methyl group upon mutation from threonine to serine could cause small
conformational changes, resulting in altered binding of phosphate-containing ligands and
illustrating the delicate balance of interactions that enzymes typically require for optimal
activity. The only 2-fold higher Km for Mg2+-ATP reflected the relatively modest effect of
the Thr680Ser substitution on ATP binding to the active site. We anticipated a more
significant effect in vivo, however, because of the severe clinical picture of the patient. A
plausible explanation was provided by intracellular Mg2+-ATP concentrations of the patient,
as measured in previous studies. These concentrations were much lower in vivo, and close to
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the Km, than the excess Mg2+-ATP concentrations used for HK activity measurements in
vitro. We postulated that at physiological concentrations of Mg2+-ATP, the two-fold increase
in Km for Mg2+-ATP results in significantly decreased HK activity in the patient’s red blood
cells.
Strikingly, again the enzymatic properties of the human red blood cell HK contradicted with
published kinetic data obtained from a recombinant human brain HK (HK-I) that harboured
the same mutation. The recombinant mutant HK was characterized solely by a slightly
higher affinity for glucose, whereas the Km(ATP), and Ki(G6P) were unaffected. These
unexpected discrepancies in kinetic behaviour between human mutant red blood cell HK and
recombinant mutant HK-I may be attributed to the different sources of the respective
enzyme, i.e. Escherichia coli versus human red blood cells. An alternative explanation,
however, may be provided by the differences in N-terminal ends of red blood cell HK and
HK-I. Human red blood cell HK and HK-I are transcribed from the same gene and both
proteins are identical except for their N-terminal ends. Similarly, human PK-R and PK-L are
transcribed from the same gene and both proteins are identical except for a unique peptide
that is only present at the N-terminal end of PK-R. The differences in enzymatic properties
between the two HK mutants is reminiscent of similar discrepancies between two Arg479His
PK-R mutants as observed in chapter 3. In this case, to avoid partial proteolysis of the
recombinant enzyme, a truncated mutant PK-R was produced. This protein lacked 49 amino
acids from its N-terminal end, including the erythroid-specific peptide. Although in vitro
enzymatic activity was essentially unaffected in case of the truncated PK-R (de facto PK-L),
the observed discrepancies between two otherwise identical proteins might point at a
functional role for the erythroid-specific N-terminal peptides of HK and PK in vivo.  
It has been suggested that in PK, structure and function are so finely tuned that even
moderate molecular alterations may significantly perturb cell metabolism. Among the single
amino acid changes described in chapter 4, one was postulated to cause little, if any,
structural perturbation. This concerned a conservative leucine to valine substitution at the
surface of the protein. The underlying mutation, c.814C>G (Leu272Val), was detected by
chance in a asymptomatic individual who, moreover, displayed normal PK enzymatic
activity. Enzymatic activities as determined under artificial conditions in the laboratory, may
not always truely reflect the behaviour of aberrant enzymes in vivo, and the Leu272Val PK-
R variant may cause a very mild form of PK deficiency. The individual carrying this variant
originated from an African country, Ghana, and in this area of the world, (severe) PK
deficiency is very rare. Interestingly, very recently it was reported that PK deficieny in mice
protects against malaria (Min-Oo, G. et al. Nature Genetics. 2003; 35: 357-362). The defense
mechanism itself remains unclear but the PK-deficient mice displayed splenomegaly,
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constitutive reticulocytosis, and were resistant against Plasmodium chabaudi infection.
Thus, PK deficiency contributes to the complex genetic control mechanism in humans that
controls the susceptibility of infection with Plasmodium species as well as the ultimate
outcome of the disease. It is therefore tempting to speculate that the Leu272Val substitution,
as identified in the Ghanese individual, represents a PK-R variant which is characterized by
only slightly modified enzymatic properties, such that cellular survival is ensured but
infection with Plasmodium species is withstood. Perhaps this is achieved in conjunction with
other alleles that alter red blood cell metabolism and that have been retained by positive
selection in areas of the world where malaria is an endemic disease. These other alleles
include sickle-cell anemia, β-thalassemia, and G6PD deficiency.  
It is worth noting that the PK deficiency itself in the malaria-resistant mice could be
attributed to a single Ile90Asn amino acid substitution, which was encoded by the c.269T>A
missense mutation. Coincidentally, we had identified the same missense mutation in two,
related, compound heterozygous patients with severe PK deficiency, described in chapter 4.
Future prospects
Several aspects of the studies conducted in this thesis may be the subject of future research.
Of considerable interest is the identification of PKR-RE1, a novel transcriptional regulatory
element in the erythroid-specific promoter of PKLR, described in chapter 2. Electrophoretic
mobility shift assay has demonstrated the binding of a trans-acting factor to this element and
transfection experiments have demonstrated its functional importance. Obviously, a major
aim for further study will be the identification of the putative transcription factor. Thus far,
the core binding motif resembles no known transcription factor binding elements. This could
imply that a novel trans-acting factor is involved or, alternatively, a known factor with yet
unrecognized binding properties. The putative transcription factor has been demonstrated to
play a crucial role in PKLR erythroid-specific transcription but may do so also in other,
erythroid, genes. Future research should, therefore, consider a broad perspective and include
other, erythroid-specific, promoters.  
Discussing the putative aberrant effects of enzyme function is based upon the assumption
that the respective protein is actually synthesized and stable enough in vivo to allow dimer
(G6PD) or tetramer (PK) assembly. However, numerous examples are available in the
literature that show that mutants proteins can be unstable. For a comprehensive
understanding of the effect of a mutation, the quantitative determination of (mutant) protein
would be of surplus value. Another important factor to consider in this respect is the,
additional, effect that mutations may have on pre-mRNA processing. Such putative effects
on RNA splicing have always been a major focus in our research and, if possible, the
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appropriate experiments have always been conducted to exclude any such additional effect
(chapters 5 and 7). Regarding the results of the RNA experiments conducted in chapter 3,
we hypothesized the presence of an exonic splice enhancer element (ESE) in PKLR exon 5,
required for the efficient inclusion of exon 6 in wild-type PKLR pre-mRNA. Future
experiments using recombinant constructs and in vitro splicing assays may aim to confirm
and identify the putative ESE(s) in PKLR exon 5, and the exact sequence motif(s) it
comprises. The importance of considering additional effects on pre-mRNA processing is
underscored by the recent general appreciation of the role of ESEs in constitutive splicing.
Because ESEs constitute degenerate sequence motifs that may be spread throughout the
exon, their important functional role implies that every other mutation that does not directly
disrupt any splice site consensus sequence may still be a candidate mutation to affect correct
pre-mRNA processing. In fact, the number of missense and synonomous mutations that does
so is increasing. Because RNA was unavailable from most patients described in chapter 7,
additional effects on pre-mRNA processing have not been taken into account. Especially
with regard to amino acid substitutions Val134Asp, Ala154Thr, and Gly165Val which are
predicted by missense mutations in PKLR exon 5, it should be excluded that the identified
mutations do not cause additional effects on pre-mRNA processing. Considering the fact that
ESEs may be present in many, if not all, human exons, a comprehensive approach to
investigate the mechanism of disease should include RNA analysis.
The sophisticated allosteric mode of regulation of PK complicates the evaluation of the effect
of molecular pertubation on the enzyme’s structure and function. A limitation in this respect
is the often-mentioned fact that no T-state and R-state crystal structures are available from
the same species. The latter would enable a more profound analysis of the effects of the
appropriate mutations in both the T- and R-state enzymes, like for instance the amino acid
substitutions Arg337Trp and Arg385Lys described in chapter 4. The recent elucidation of
the crystal structure of R-state human erythrocyte PK has significantly contributed to a better
understanding of the structure and function of PK. It would be of even greater benefit to the
scientific community if both human crystal structures would become available.
In Africa, (severe) PK deficiency is very rare but malaria is an endemic disease. The recent
report that PK deficiency in mice protects against malaria combined with the identification
of a novel, putatively mild, Leu272Val PK-R variant in an individual from Ghana (chapter
4) may indicate that the two are connected. The c.814C>G mutation (Leu272Val) was not
detected in a Caucasian normal control population and it will be of interest to screen a
representative African control population. This may resolve the question whether the African
PKLR 814G allele is either very rare, or a polymorphic variant that has remained undetected
because of only subtle effects on enzymatic activity. 
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Twice, discrepancies were observed between the enzymatic properties of mutant enzymes
(PK and HK) obtained either from the patient’s enzyme or from a recombinant enzyme
(chapters 3 and 7). These differences may be attributed to the different sources of the
enzyme but it is intriguing that both recombinant enzymes lacked the erythroid-specific N-
terminal peptide. This may indicate that the N-terminal peptide has a functional role in vivo
and future studies may be directed towards the elucidation of this putative role.
The only cure available to patients with an inherited enzymopathy is bone marrow
transplantation. This is only rarely performed because of its negative side effects. Instead,
blood transfusion is the therapy of choice to alleviate the anemia and to protect patients from
fatal hemolysis. With regard to PK, the PK-M2 isozyme is gradually replaced by the red
blood cell-specific PK-R isozyme during erythroid differentiation and maturation (chapter
1). Persistent PK-M2 expression throughout erythroid maturation might be able to
compensate, in part, for a defective PK-R isozyme and thereby ameliorate the hemolysis.
Patients with sickle-cell anemia display a similar amelioration of clinical symptoms due to
persistent expression of fetal hemoglobin (HbF). In certain PK-deficient patients, a persistent
expression of PK-M2 has been detected but the beneficial effect is unclear. Also, the reason
why this ‘compensation’ occurs in some patients but not in others is unknown. From a
therapeutical point of view it might be worth to first resolve these questions, followed, if
appropriate, by a detailed analysis of the transcriptional control mechanisms that drives PK-
M2 expression throughout erythroid differentiation and maturation. Eventually, this may
lead to clues regarding the means to upregulate PK-M2 expression in patients with severe PK
deficiency.  
Concluding remarks
The variety of clinical features associated with the various enzymopathies, regardless of the
underlying molecular mechanism, have unequivocally made clear that the phenotype of
hereditary red blood cell enzymopathies, and perhaps genetic disease in general, is not solely
dependent on the molecular properties of mutant proteins but rather reflects a complex
interplay between physiological, environmental and other (genetic) factors. Putative
phenotypic modifiers include differences in genetic background, concomitant functional
polymorphisms of other glycolytic enzymes (many enzymes are regulated by their product
or other metabolites), post-translational modification, ineffective erythropoiesis, and
different splenic function.
It was the focus of this thesis, as a first step towards a better understanding of the correlation
between genotype and phenotype, to identify the molecular basis of disease in hereditary
human red blood cell enzymopathies. In summary, the investigated mutations cause disease
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by means of a variety of mechanisms and they affect several aspects of gene expression.
They may either abolish gene expression completely (chapter 2), or lead to aberrant RNA
splicing events (chapter 3). Once a mutant enzyme is synthesized it may be unstable because
of significant structural perturbation (chapters 4 and 5), or unable to assemble its proper
active conformation (chapter 6). Even subtle changes may still significantly impair an
enzyme’s function, especially at physiological conditions (chapter 7). It is not even
excluded and far from unlikely that some mutations exert their effect via multiple of these
molecular mechanisms. With regard to the patients described in this thesis we are far from
understanding the factors that contribute to their complex phenotypes but, hopefully, we have
shed that much light on the underlying molecular mechanisms of disease so that we can state:
“That is why the patient is ill”.
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Chapter 4, Figure 1. PK monomer with depicted positions of the substituted amino acids
described in this study. The figure highlights one PK subunit in the tetrameric structure. The residues
affected by the novel missense mutations are shown as red spheres. The A domain is colored blue. The
B (top) and C domains (bottom) are colored green. The N-terminal domain is colored light-blue. The
substrate analog phosphoglycolate and the allosteric effector fructose-1,6-diphosphate are colored
purple and drawn in ball-and-stick mode in their binding pockets in the A and C domains, respectively.
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Chapter 4, Figure 2. Modeling of the
Gly111Arg substitution. Ribbon drawing of
the neighborhood of the Gly111Arg substitution
with selected residues shown in ball-and-stick.
The modeled conformation of Arg111 is
depicted with magenta carbon atoms. Arginine
side chains can adopt several orientations, but
only one is shown. In all possible conformations
of Arg111, sterical clashes or unfavorable
charge interactions would occur between its
side chain and one or more of the neighboring
residues depicted.
Chapter 4, Figure 3. Structural role of Arg337 and Arg385. Arg337 is located close to the
substrate-binding site in the A domain (blue) and forms a salt bridge with Asp390 of the same subunit.
Arg385, located in the A domain of an opposing subunit (gray), forms a salt bridge with Asp221 of the
B domain (green). In the crystal structure, the substrate binding site is occupied by the substrate analog
phosphoglycolate drawn in purple ball-and-stick representation. Mutation Arg337Trp would cause
severe sterical hindrance and abolish charge interactions. The more conservative mutation of
Arg385Lys would not cause sterical hindrance and would retain in part the potential for hydrogen
bonding and charge interactions. Due to their position close in domain and subunit interfaces close to
the active site these mutations will likely affect catalysis and allosteric regulation.
166
Addendum ‘Color Figures’
167
Addendum ‘Color Figures’
Chapter 5, Figure 1. Alignment of muscle-type pyruvate kinase from Felis domesticus (1PKM)
and Oryctolagus cuniculus (1PKN) with R-type PK from human (HRPK). The alignment was
generated with AMPS, as described in the Materials and Methods and drawn with the program
ALSCRIPT.35 Amino acids that are completely conserved among the three PKs are shown with yellow
letters in boxes shaded with magenta. Only residues of human R-type PK (56-574) corresponding to
1PKM (12-530) are shown. The secondary structure elements, α-helixes and β-strands, assigned to
1PKM are shown above the sequences as cylinders and filled arrows, respectively. The domain
organization of PK is represented by filled arrows right under the secondary structure elements. Color
code: the N-terminal domain N is yellow; the catalytic domain A is blue, domain B is orange, and the
C-terminal twisted αβ-type domain C is pink. The numbers above the sequences are in accordance with
the numbering in 1PKM, whereas the numbers beneath the sequences refer to the codon numbering of
HRPK. The red-filled triangle indicates the position of residue 364 (glycine to aspartic acid mutation),
and the green filled triangle indicates the position of residue 510 (arginine to glutamine mutation).
Chapter 5, Figure 4.
Cα-ribbon trace of the model of
human R-type PK monomer. The
color code is as for Figure 1: the N-
terminal domain N is yellow;
catalytic domain A is blue, domain
B is orange, and the C-terminal
twisted αβ-type domain C is pink.
The positions of the amino acids
364 (G1091 to A mutation) and 510
(G1529 to A mutation) are indicated
by red and green color, respectively.
The active site bound pyruvate
molecule taken from 1PKN9 is
represented by pink space filling.
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Chapter 5, Figure 5.
Close-up view of areas around the amino acids 364 (A) and 510 (B). Residues in close contact with the
mutated residues, translated from codons 364 and 510, are shown with side chains, whereas the
residues further apart are shown in Cα-ribbon trace representation as in Figure 4. The color code is as
for Figure 1. (A) and (B) are shown with the mutated aspartic acid and glutamine replacing the wild-
type glycine and arginine, respectively. Hydrogen bonds less than 3.0 Å are shown as white lines.
Chapter 6, Figure 3. Ribbon representation of a G6PD dimer with green spheres indicating the
position of Pro409 and magenta spheres indicating the position of Val431. Subunits A and B are
colored red and blue, respectively. The structural NADP molecules are shown in dark blue ball-and-
stick representation. Dashed rectangles depict the two regions in the G6PD dimer interface disrupted
by the Pro409Ser and Val431Gly substitutions. Note that although residues Pro409 and Val431 are
located close together, they in fact reside on different subunits. (Inset) Close-up view of the vicinity of
Pro409 (here shown on subunit A) and Val431 (subunit B) with selected residues shown in ball-and-
stick (oxygen, red; nitrogen, blue; carbon, black). The carbon atoms of the mutated residues are shown
in green (Ser409) and magenta (Gly431). The mutations were modeled using the program O.14 The
figure was generated from the atomic coordinates of protein data bank entry 1QKI8 using computer
programs Molscript35 and Raster3D.36
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Chapter 7, Figure 3. Thr680 is a critical residue in the active site of HK. Schematic drawing
of the active site of HK-I shows Thr680, bound glucose, and adenosine diphosphate (ADP) in ball-and-
stick representation (atom coloring: carbon black; oxygen, red; nitrogen, blue; and phosphor, magenta).
The carbon atom that is absent in the Thr680Ser mutant is colored gray. Illustrated is the central
position occupied by Thr680 in the active site where it is located at the tip of a loop and makes a
hydrogen bond with the α-phosphoryl group of ADP. This figure was generated from the atomic
coordinates of the HK-I ADP/glucose complex7 (protein data bank entry 1DGK) using computer
programs Molscript22 and Raster3D.23
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Inleiding
Vanaf het moment dat de volwassen rode bloedcel het beenmerg verlaat is hij optimaal in
staat om zuurstof te binden, te transporteren, en af te geven aan de weefsels. Dit is de
belangrijkste taak van de erythrocyt gedurende zijn ongeveer 120-dagen durende verblijf in
de bloedbaan. De biconcave vorm van de rode bloedcel is zeer geschikt voor het uitwisselen
van zuurstof en kooldioxide. Aangezien dit laatste tot in de kleinste microcapilairen
plaatsvindt, moet de erythrocyt in staat zijn om sterk van vorm te veranderen. Dit is
mogelijk door het ontbreken van een kern en cytoplasmatische organellen, en dus de
mogelijkheid tot eiwitsynthese.
De rode bloedcel gebruikt energie voor een aantal cellulaire processen die van vitaal belang
zijn. Dit zijn onder meer (1) het in stand houden van de glycolyse; (2) het in stand houden
van de electrolytische gradiënt tussen plasma en het cytoplasma van de rode bloedcel; (3)
de synthese van glutathion; (4) purine en pyrimidine metabolisme; (5) het in een
gereduceerde, functionele, staat houden van hemoglobine; (6) het beschermen van metabole
enzymen, hemoglobine, en membraan eiwitten tegen oxidatieve schade; en (7) het in stand
houden van de fosfolipiden asymetrie van de erythrocytaire celmembraan. Omdat kern en
mitochondrieën ontbreken, is de volwassen rode bloedcel niet in staat om energie te
genereren via de oxidatieve Krebs Cyclus. Daarom is hij voor het genereren van energie in
de vorm van adenosine trifosfaat (ATP), en reducerend vermogen in de vorm van purine
nucleotiden: gereduceerd nicotinamide adenine dinucleotide (NADH) en nicotinamide
adenine dinucleotide fosfaat (NADPH), volledig afhankelijk van de anaerobe omzetting van
glucose via de Embden-Meyerhof route (glycolyse) en de oxidatieve Hexose Monofosfaat
Shunt. 
Bij de hierboven beschreven metabole routes en processen zijn vele enzymen betrokken.
Enzymopathieën van de rode bloedcel tasten uiteindelijk de cellulaire integriteit van de rode
bloedcel aan en verkorten diens levensduur. Aldus leiden zij tot een hemolytische anemie.
Het overgrote deel van deze enzymopathieën is erfelijk. Om een klinisch relevante
hemolyse te veroorzaken moet de functie van de erythrocyt onder fysiologische
omstandigheden aanzienlijk zijn verminderd. Klinisch gezien kunnen de erythrocytaire
enzymopathieën in twee groepen worden ingedeeld. De eerste groep betreft deficiënties van
enzymen van de glycolyse, en enzymen betrokken bij het purine en pyrimidine
metabolisme. Deze stoornissen resulteren uiteindelijk in een tekort aan ATP, hetgeen
aanleiding geeft tot een chronisch hemolytische anemie. De meest voorkomende oorzaak
van een dergelijke anemie is een deficiëntie van pyruvaat kinase (PK). De tweede groep
heeft betrekking op stoornissen in de Hexose Monofosfaat Shunt, welke de hoeveelheid
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gereduceerd glutathion constant houdt. De enzymopathieën van deze groep zijn
geassocieerd met een periodieke hemolyse, geïnduceerd door oxidatieve stress,
medicijngebruik, of infecties. De meest voorkomende oorzaak in deze groep zijn
deficiënties van glucose-6-fosfaat dehydrogenase (G6PD).
In het algemeen geldt dat de mate van hemolyse wordt bepaald door het relatieve belang
van het aangedane enzym, maar ook door de veranderde eigenschappen van een mutant
enzym met betrekking tot functie of stabiliteit (of beide). Daarnaast speelt de mogelijkheid
tot compensatie van een enzymdeficiëntie door overexpressie van een isoenzym, of het
gebruik van alternatieve metabole routes eveneens een rol in het uiteindelijke fenotype van
patiënten met een erfelijke hemolytische anemie. 
Doel van het onderzoek
Het fenotype van patiënten met erfelijke enzymopathieën van de rode bloedcel is zeer
variabel. Een van de doelstellingen van de laboratoriumgeneeskunde is om het verband vast
te stellen tussen het genotype van een patiënt en diens fenotype. Daartoe is het kennen van
de moleculaire pathogenese van essentieel belang. Het is immers de basis van de ermee
samenhangende hemolytische anemie. Dit betekent dat naast het identificeren van de
oorzakelijke mutatie op DNA-niveau, de betrokken moleculaire mechanismen via welke
deze aanleiding geeft tot een verminderde enzymfunctie in kaart moeten worden gebracht.
Deze kunnen zich op verschillende niveau’s in genexpressie afspelen; transcriptie, vorming
van een correct mRNA, translatie, en eiwit. Het combineren van de genetische informatie
met klinische, biochemische, en structurele data resulteert in een beter begrip van de
moleculaire pathogenese en draagt zo bij aan het antwoord op de vraag: “Waarom is de
patiënt ziek?”.
Samenvatting en conclusies
De in dit onderzoek beschreven enzymopathieën van de rode bloedcel betreffen deficiënties
van HK, PK, en G6PD. Deze drie enzymen zijn allen belangrijke regulator enzymen van de
glycolyse (HK en PK) en de Hexose Monofosfaat Shunt (G6PD). De onderzochte mutaties
in het DNA beïnvloedden de expressie van het betreffende gen op het niveau van de regulatie
van transcriptie (hoofdstuk 2), het vormen van een correct mRNA (hoofdstuk 3), of de
structuur (hoofdstukken 4 en 5) en functie (hoofdstukken 6 en 7) van het eiwit.
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Erythrocytaire enzymopathie ten gevolge van verstoorde regulatie van transcriptie
In hoofdstuk 2 wordt een ernstig PK-deficiënte patiënt beschreven. Uit RNA-analyse bleek
dat bij deze patiënt slechts het paternale allel tot expressie kwam waarop een puntmutatie
(c.1529G>A) aanwezig was. Op DNA-niveau was deze patiënt echter heterozygoot voor
deze mutatie. Daarnaast bleek hij eveneens heterozygoot voor drie mutaties in cis op het
maternale allel; –324T>A, –248delT, en –83G>C. Deze laatste drie mutaties waren niet
eerder beschreven. 
Met behulp van in vitro transfectie studies in K562 cellen werd het effect van elke mutatie,
afzonderlijk en gezamenlijk, onderzocht. –324T>A bleek een niet-functionele mutatie en
–248delT een niet-functioneel polymorfisme. De –83G>C mutatie daarentegen was in staat
de promoter activiteit drastisch te reduceren. Dit verklaarde de expressie van enkel het
paternale, in trans, allel. Mutagenese van de nucleotiden in de directe nabijheid van
nucleotide –83 toonde vervolgens de aanwezigheid aan van een onbekend, functioneel
transcriptie regulator element in de erythroid-specifieke promoter van het PKLR gen: PKR-
RE1. Met behulp van Electrophoretic Mobility Shift Assay met K562 nucleair extract werd
bevestigd dat er ook DNA–eiwit interactie plaatsheeft op dit element, waarbij een onbekend
eiwit blijkt te binden aan PKR-RE1. Van geen van de bekende eiwitten is bekend dat zij
binden aan het bindingsmotief van PKR-RE1. Daarom concluderen wij dat dit regulator
element mogelijk betrokken is bij een nieuw mechanisme van erythroïd-specifieke trans
activatie.
Feitelijk was bovenstaande patiënt ‘pseudo-homozygoot’ voor de c.1529G>A puntmutatie,
welke codeert voor een arginine naar glutamine aminozuur substitutie op positie 510
(Arg510Gln). Dus bepaald dit mutante PK voor een belangrijk deel het PK-deficiënte
fenotype. Zoals beschreven in hoofdstuk 5, veroorzaakt de Arg510Gln verandering een
drastische afname van de vrijheid in conformatie tussen het A- en het C-domein. Dit
verklaart de zeer lage enzymatische activiteit en de instabiliteit welke deze PK variant vaak
kenmerkt. Het is opvallend dat het ernstige klinische beeld van de patiënt zoals beschreven
in hoofdstuk 2 aanmerkelijk verschilde van dat van patiënt MB86, beschreven in hoofdstuk
4. Deze patiënt was daadwerkelijk homozygoot voor c.1529G>A, vertoonde een zeer mild
klinisch beeld en was niet transfusie-afhankelijk. Wellicht duidt dit verschil erop dat er
ondanks de drastische structurele veranderingen nog steeds een bepaalde mate van
enzymatische activiteit bestaat in de Arg510Gln PK variant. Deze restactiviteit zou dan
uiteraard, ongeveer tweemaal, hoger uitkomen in de homozygote patiënt dan in de ‘pseudo
homozygote’ patiënt.
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Erythrocytaire enzymopathie ten gevolge van defect mRNA
De aanwezigheid van slechts één mutant PK, ondanks heterozygotie voor de onderliggende
mutatie op DNA-niveau, bleek ook bij een andere patiënt met een ernstige PK-deficiëntie. In
dit geval bleek het enig aanwezige PK een variant te zijn met een Arg479His substitutie.
Deze patiënt, beschreven in hoofdstuk 3, was dubbel heterozygoot voor twee puntmutaties
die beiden zeer waarschijnlijk een negatief effect zouden hebben op de vorming van een
correct mRNA. De eerste, niet eerder beschreven, mutatie veranderde de invariante
dinucleotide aan het 5’-einde van intron 5 (IVS5+1G>A). De andere mutatie bevond zich in
exon 10 (c.1436G>A) en veranderde de ‘splice site’ consensus sequentie aan het 5’-einde
van intron 10. Deze laatste mutatie codeerde daarnaast eveneens voor de Arg479His
substitutie. Om het effect van beide mutaties op pre-mRNA niveau te bestuderen werd
gebruik gemaakt van een ex vivo benadering. Hierbij werden uit perifeer bloed van de patiënt
kernhoudende erythroïde cellen gekweekt waaruit vervolgens RNA werd geïsoleerd. Dat
deze benadering een toegevoegde waarde had bleek uit het feit dat er meerdere afwijkende
transcripten konden worden aangetoond die elk afzonderlijk het gevolg waren van een van
beide mutaties. Bij een aanzienlijk deel van de transcripten was, ten gevolge van de
IVS5+1G>A mutatie, exon 5 niet geïncludeerd. Daarnaast bleek dat naast exon 5, ook exon
6 in een groot deel van de transcripten ontbrak (zie onder). Omdat van deze beide
transcripten geen eiwit werd verwacht noch aangetoond met behulp van Western Blot, was
het IVS5+1A allel in feite een nul-allel.
De c.1436G>A mutatie bij deze patiënt bleek voornamelijk geassocieerd met een sterke
afname van het aantal transcripten. Van het merendeel hiervan waren de introns echter op een
correcte wijze verwijderd. Deze mRNA’s codeerden dus voor een kleine hoeveelheid
Arg479His PK, hetgeen het fenotype van deze patiënt bepaalde. De recent gepubliceerde
kristal-structuur van recombinant humaan Arg479His PK bevestigde onze bevindingen voor
wat betreft het geringe effect van de mutatie op de stabiliteit van de PK monomeer.
Opvallend was echter dat recombinant Arg479His PK niet temperatuur-gevoelig bleek
terwijl het PK van de patiënt dat wel was; zowel in vitro als in vivo bleek het PK van de
patiënt zeer gevoelig voor een verhoging van de temperatuur. Dit laatste uitte zich door een
toename van de hemolyse tijdens perioden met koorts maar ook, bijvoorbeeld, na een lang
verblijf in de (warmte van) de zon. Een dergelijke tegenstrijdigheid in enzymatische
eigenschappen tussen mutante enzymen van, respectievelijk, recombinante en menselijke
herkomst werd eveneens geconstateerd in hoofdstuk 7 en zal later verder worden besproken
(zie Erythrocytaire enzymopathie ten gevolge van verstoorde eiwitfunctie). Het benadrukt
dat enzymatische eigenschappen van recombinante (mutante) enzymen met de nodige
voorzichtigheid dienen te worden geïnterpreteerd. 
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Zoals hierboven vermeld was de samenstelling van één transcript vrij opmerkelijk. In dit
transcript ontbrak als gevolg van de IVS5+1G>A mutatie niet alleen exon 5 maar bovendien
bleek ook het naastgelegen exon 6 uit het pre-mRNA te zijn verwijderd. Het was aannemelijk
dat het ontbreken van beide exons verband hield met elkaar. Wij postuleren een mechanisme
waarbij het efficiënt includeren van exon 6 in wild-type PKLR mRNA afhankelijk is van de
aanwezigheid van exon 5 in het primaire transcript. Met andere woorden, in exon 5 bevinden
zich splice-regulator elementen die noodzakelijk zijn voor een efficiënte inclusie van exon 6
in PKLR mRNA. Omdat de IVS5+1G>A mutatie tot exclusie van exon 5 leidt, worden deze
splice-regulator elementen daarmee automatisch eveneens verwijderd uit dit pre-mRNA. Dit
geeft vervolgens weer aanleiding tot een inefficiënte inclusie van exon 6. De mogelijke
aanwezigheid van dergelijke splice-regulator elementen betekent dat andere (punt)mutaties
in exon 5 die coderen voor een aminozuur substitutie (hoofdstuk 4) mogelijk eveneens tot
een defect mRNA leiden.
Erythrocytaire enzymopathie ten gevolge van verstoorde eiwitstructuur
De belangrijkste genetische oorzaak van erfelijke enzymopathieën van de rode bloedcel
vormen puntmutaties die coderen voor een substitutie van structureel en functioneel
belangrijke aminozuren. Onze resultaten aangaande een grote group patiënten met PK
deficiëntie is daarmee in overeenstemming. In hoofdstuk 4 beschrijven we een genetisch
onderzoek onder 28 patiënten die afkomstig waren uit 26 niet-gerelateerde families. We
identificeerden 24 verschillende mutaties die geassocieerd waren met PK deficiëntie.
Hiervan waren er 14 niet eerder beschreven. Twintig van de 24 verschillende mutaties (83%)
waren puntmutaties die coderen voor een aminozuur substitutie, waaronder een niet eerder
beschreven c.331G>A mutatie. Deze puntmutatie codeert voor een arginine in plaats van
glycine op positie 111 (PK Utrecht) en in vijf niet-gerelateerde Nederlandse families bleek
deze mutatie voor te komen. Samen met de eveneens frequent voorkomende c.1456C>T en
c.1529G>A mutaties was de c.331G>A mutatie daarom een van de belangrijkste oorzaken
van PK deficiëntie in Nederland.
Om meer inzicht te krijgen in het effect van bepaalde aminozuur substituties op de structuur
en functie van PK hebben wij in hoofdstuk 4 de locatie en interacties van het desbetreffende
aminozuur in de drie-dimensionale structuur van humaan wild-type rode bloedcel-PK
bestudeerd. In een aantal gevallen bleek de substitutie het hydrofobe binnenste van het eiwit
ernstig te verstoren. Andere aminozuur substituties hadden betrekking op het B-domein en
de ATP-bindingsplaats. Aangezien beiden deel uitmaken van het actieve centrum van PK
zullen mutaties in dit gebied tot een verlies aan enzymatische activiteit leiden. Een bepaalde
groep puntmutaties in het bijzonder betrof substituties van aminozuren die zich bevinden op
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het scheidingsvlak tussen twee subunits in de PK tetrameer. Samen met de inter-domein
interacties zijn inter-subunit interacties verantwoordelijk voor de allostere regulatie van PK.
Een van deze aminozuur substituties betrof een verstoring van C/C’ subunit interacties
(Arg569Gln) terwijl drie andere mutaties een verandering van A/A’ subunit interacties tot
gevolg hadden (Arg337Trp, Gly358Glu, en Arg385Lys). Met name Arg337Trp en
Arg385Lys verhinderen zeer waarschijnlijk de vorming van een zoutbrug die van cruciaal
belang is voor de allostere transitie van PK.
Onze resultaten uit hoofdstuk 4 bevestigden eveneens het mild klinische beeld zoals dat over
het algemeen wordt waargenomen bij patiënten met de veel voorkomende c.1456C>T
(Arg486Trp) mutatie. Arg486 bevindt zich op het scheidingsvlak tussen het A- en C-domein
binnen de PK monomeer. Op ditzelfde scheidingsvlak bevindt zich Gly364. Het is opvallend
dat de Arg486Trp substitutie nauwelijks effect heeft op de enzymatische eigenschappen van
PK, terwijl eenzelfde drastische substitutie van een nabijgelegen aminozuur (Gly364Asp)
wel een ernstige PK deficiëntie tot gevolg heeft en in een homozygote patient zelfs tot de
dood heeft geleid. De Gly364Asp substitutie werd gecodeerd door een niet eerder
beschreven c.1091G>A puntmutatie. Omdat op het moment van dit deel van het onderzoek
de kristalstruktuur van humaan rode bloedcel-PK nog niet bekend was ontwikkelden wij een
theoretisch drie-dimensionaal model dat was gebaseerd op de kristalstructuur van spier-PK.
Aan de hand van dit model bleek dat een aspartaat op positie 364 de interactie tussen het A-
en C-domein ernstig verstoorde door het creëren van een extra zoutbrug. Zeer recent werden
deze bevindingen bevestigd middels de kristalstructuur van humaan Gly364Asp PK. Eerder
genoemde homozygote patiënt was het eerste kind uit het tweede huwelijk van haar moeder.
Deze had uit haar eerste huwelijk een kind dat dubbel heterozygoot was voor twee PKLR
mutaties, c.1091G>A en c.1529G>A. Dit kind vertoonde een ernstig fenotype en was
transfusie-afhankelijk. Wederom wekte het verschil in fenotype de suggestie dat de
overerving van het c.1529G>A allel wellicht nog enige enzymatische activiteit met zich
meebracht daar waar homozygotie voor het c.1091G>A allel lethaal was (zie Erythrocytaire
enzymopathie ten gevolge van verstoorde regulatie van transcriptie).
Erythrocytaire enzymopathie ten gevolge van verstoorde eiwitfunctie
Uit het bovenstaande mag worden geconcludeerd dat naast de positie en de interacties van
een aminozuur ook de aard van het aminozuur waarmee het wordt vervangen een belangrijke
rol speelt in het uiteindelijke effect van dergelijke puntmutaties. Dit bleek ook het geval bij
twee patiënten met G6PD deficiëntie, beschreven in hoofdstuk 6. Terwijl de ene patiënt zich
kenmerkte zich door een ernstige chronische hemolytische anemie, vertoonde de andere
slechts een milde, subklinische, chronische hemolyse. Beide patiënten waren hemizygoot
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voor een de novo mutatie in G6PD. De mutaties codeerden voor een niet eerder beschreven
Pro409Ser (G6PD Utrecht) en Val431Gly substitutie in G6PD. G6PD is enzymatisch actief
in dimere vorm en zowel Pro409 als Val431 bevinden zich op het scheidingsvlak tussen twee
G6PD monomeren. Vrijwel alle mutaties die het proces van dimerisatie verstoren leiden tot
de klinisch meest ernstige vorm van G6PD deficiëntie. Deze klasse I G6PD deficiënties
worden gekenmerkt door een chronische hemolyse. Beide aminozuur substituties werden
bestudeerd aan de hand van het drie-dimensionale model van de kristalstruktuur van humaan
G6PD. Dit liet zien dat aminozuren Pro409 en Val431 zich niet alleen bevinden op
voornoemd scheidingsvlak maar dat ze daarnaast ook interactie met elkaar aangaan in wild-
type G6PD. Zowel Pro409Ser als Val431Gly verstoren de interacties tussen twee G6PD
monomeren waardoor de stabiliteit en enzymatische activiteit van G6PD ernstig wordt
verminderd. Gezien de fenotypische verschillen toont dit, aan de ene kant, wederom het
belang aan van de locatie en aard van aminozuur substitutie. Aan de andere kant laten deze
resultaten ook zien dat het fenotype niet alleen afhankelijk is van de aminozuur substitutie
omdat het (milde) fenotype van de patiënt met de Val431Gly G6PD variant sterk verschilde
van dat van de enig andere patiënt die tot nu toe is beschreven met deze G6PD variant. Deze
patiënt vertoonde vanaf geboorte een chronische icterus, milde chronische anemie,
reticulocytose, en splenomegalie. De door ons beschreven patiënt vertoonde geen neonatale
icterus en had geen klinische verschijnselen tot hij 29 maanden oud was en zich toen
presenteerde met favisme. Het fenotype wordt dus door meerdere, al dan niet genetische
factoren, (mede) bepaald.
Zowel in hoofdstuk 5 als in hoofdstuk 6 bleek het veelal ernstige fenotype het gevolg van
een drastische aminozuur substitutie die een cruciaal deel van het eiwit betrof. Dat ook een
subtiele verandering tot een ernstig verlies aan in vivo activiteit kan leiden, hetgeen
uiteindelijk resulteerd in een ernstige chronische hemolyse, wordt beschreven in hoofdstuk
7. Bij een patiënt waarbij meer dan 20 jaar geleden de, zeldzame, diagnose HK deficiëntie
werd gesteld, hebben wij de oorzakelijke mutatie in het DNA geïdentificeerd. Het betrof een
niet eerder beschreven puntmutatie (c.2039C>G) waardoor threonine op positie 680 wordt
vervangen door serine (HK Utrecht). Dit is een zeer conservatieve verandering van een echter
evolutionair zeer geconserveerd aminozuur. Aan de hand van het drie-dimensionale model
van de kristalstructuur van humaan HK blijkt dat Thr680 zich centraal in het actieve centrum
van HK bevindt en daar interacties aangaat met fosfaatgroepen van ADP/ATP en glucose-6-
fosfaat. Deze resultaten correleerden goed met eerder bepaalde enzymatische eigenschappen
van partieel gezuiverd mutant HK van de patiënt. Het mutante HK van de patiënt kenmerkte
zich namelijk door een tweevoudig verlaagde affiniteit voor Mg2+-ATP, en een aanzienlijk
verlaagde affiniteit voor de allostere remmer glucose-1,6-difosfaat. Waarschijnlijk betekent
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het verlies van een methyl-groep een kleine verandering van de conformatie hetgeen
resulteert in een veranderde binding van fosfaat-groep dragende liganden. 
De tweevoudig verlaagde affiniteit voor Mg2+-ATP impliceerde een relatief gering effect op
ATP binding. Dit was in tegenspraak met het ernstige klinisch beeld waardoor de suggestie
werd gewekt dat het in vivo effect van de mutatie ernstiger is. Daarom vergeleken we eerder
bij deze patiënt bepaalde intracellulaire Mg2+-ATP concentraties. Deze concentraties waren
vele malen lager in vivo, en vrijwel gelijk aan de Km, dan de Mg2+-ATP concentraties zoals
die worden gebruikt bij in vitro activiteits bepalingen. Het is daarom zeer waarschijnlijk dat
een tweevoudig verlaagde affiniteit voor Mg2+-ATP bij fysiologische concentraties een veel
ernstiger effect zal hebben op de enzymatische activiteit van HK.
De resultaten uit hoofdstuk 7 duidden, net als in hoofdstuk 3, op een verschil in
enzymatische eigenschappen tussen, in dit geval, partieel gezuiverd HK van de patiënt en
recombinant geproduceerd HK-I met dezelfde mutatie. Het recombinante Thr680Ser HK-I
kenmerkte zich door een normale Km(ATP) en Ki(glucose-6-fosfaat). Mogelijk worden deze
opvallende verschillen veroorzaakt door de verschillende bronnen waaruit het enzym werd
geïsoleerd (humane rode bloedcellen versus Escherichia coli). Het is echter ook mogelijk dat
het verschil in N-terminus tussen rode bloedcel-HK en HK-I hierbij een rol speelt. Zowel
rode bloedcel-HK als HK-I worden door hetzelfde gen gecodeerd maar alleen rode bloedcel-
HK bezit een uniek peptide aan het N-terminale uiteinde. Dit vertoont opvallende
overeenkomsten met de weefsel-specifieke expressie van rode bloedcel-PK en lever-PK door
PKLR. Ook rode bloedcel-PK bezit daardoor een uniek peptide aan de N-terminus. Het
verschil in enzymatische eigenschappen tussen beide mutante HK’s doet denken aan
eenzelfde verschil in eigenschappen tussen de twee mutante PK’s met een Arg479His
substitutie (hoofdstuk 3). Hierbij speelt het rode bloedcel-specifieke peptide mogelijk een
rol omdat ook in het geval van PK dit peptide bij het recombinant mutante enzym ontbrak.
Ondanks een normale in vitro enzymatische activiteit van beide recombinant geproduceerde
‘rode bloedcel-enzymen’ suggereren de waargenomen verschillen bij beide enzymen een
mogelijk functionele rol voor het rode bloedcel-specifieke peptide in vivo.
De erfelijke enzymopathieën van de rode bloedcel leiden tot een grote diversiteit in
fenotypen. De onderliggende moleculaire pathogenese blijkt slechts voor een deel
verantwoordelijk voor het fenotype en naast de afwijkende eigenschappen van een mutant
enzym spelen overige fysiologische-, genetische-, en omgevingsfactoren een rol. In dit
onderzoek is de moleculaire pathogenese van een aantal erfelijke enzymopathieën van de
rode bloedcel in kaart gebracht om zodoende een beter inzicht te krijgen in de
genotype–fenotype relatie. Samenvattend blijkt dat de onderzochte mutaties op verschillende
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manieren bepaalde aspecten van gen-expressie verstoren. Gen expressie kan volledig worden
geblokkeerd (hoofdstuk 2) of er wordt enkel afwijkend mRNA gesynthetiseerd (hoofdstuk
3). Wanneer een mutant eiwit toch tot expressie komt kan het instabiel zijn door ernstige
verstoringen van de structuur (hoofdstukken 4 en 5) of niet in staat zijn om zijn juiste
conformatie aan te nemen (hoofdstuk 6). Ook subtiele veranderingen blijken echter een
sterke verlaging van de enzymactiviteit te kunnen veroorzaken, met name onder
fysiologische omstandigheden (hoofdstuk 7). Het is niet uitgesloten en zelfs waarschijnlijk
dat sommige mutaties via meerdere moleculaire mechanismen hun uiteindelijke effect
sorteren. Met betrekking tot het complexe fenotype van de patiënten zoals beschreven in dit
proefschrift is er dan ook nog veel onderzoek nodig om tot een beter begrip van de
genotype–fenotype relatie te komen. Hopelijk heeft het onderzoek zoals beschreven in dit
proefschrift echter wel een dusdanig licht geworpen op de onderliggende moleculaire
pathogenese van de onderzochte enzymopathieën van de rode bloedcel dat we kunnen
zeggen: “daarom is de patiënt ziek”.
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Bijna promovendus-af, dat is toch even wennen. Een mooi moment om even pas op de plaats
te maken en nu eens even niet-wetenschappelijk, dat is op dit moment ook even wennen, de
afgelopen jaren (impact-factor 8.3) in herinnering te roepen en terug te denken aan de
mensen zonder wie dit boekje er niet zo uit had gezien. 
Allereerst een woord van dank aan mijn promotoren, Prof. Dr. J.J.M. Marx en Prof. Dr. W.W.
van Solinge, en co-promoter Dr. G. Rijksen. Beste Jo, ook al lag de dagelijkse begeleiding
niet in jouw handen, je toonde immer een frisse en ter zake doende interesse in ons
onderzoek en dat is door mij altijd zeer gewaardeerd. Beste Wouter, onze samenwerking
begon vlak voordat jij jouw proefschrift ging verdedigen. Nu ik, 11 jaar later, op het punt sta
datzelfde te doen en jij daarbij als mijn promoter aanwezig zal zijn is dat uiteraard een
speciaal moment voor mij. Het is voor een groot deel aan jou te danken dat ik uiteindelijk in
de wetenschap terecht ben gekomen en ik ben je daar nog altijd bijzonder dankbaar voor. Ik
heb veel van je geleerd en door de jaren heen heb jij mij met een nimmer aflatend
enthousiasme altijd weer weten te motiveren en, af en toe, te (re-)activeren (doe dat nou maar
gewoon!). Ik ben erg blij dat jij in mij je vertrouwen voor de toekomst hebt gesteld door mij
als onderzoeker aan te stellen. Het worden mooie jaren waarin ‘science never sleeps’,
beloofd!
Beste Gert, mister HK, dankzij jouw kennis heeft de ‘medische enzymologie’ nu ook voor
mij iets minder geheimen. Het is met name de manier waarop jij resultaten vaak in het juiste
perspectief wist te plaatsen en jouw originele ideeën die van belangrijke invloed op dit werk
zijn geweest. Bedankt ook voor het geven van een stukje zelfvertrouwen, ik had me geen
betere co-promoter kunnen wensen.
De vrouwelijke kant van de Rode Bloedcel Pathologie Onderzoeksgroep, ofwel Annet,
Brigitte, en Karen. Sfeermaker en paranimf Annet, na jouw transfer van Crucell naar ons aan
de andere kant van het raam (sorry nog John), ben je ook meteen niet meer weg te denken
geweest. Met jouw jeugdig enthousiasme heb je je altijd met heel je hart voor ‘de zaak’ in
het algemeen en die van mij in het bijzonder ingezet. Ik kan je daarvoor niet genoeg
bedanken! En ook al hebben we tegenwoordig ieder ons eigen epje, ik ben blij dat we
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voorlopig nog niet van je af zijn want ‘het is goed zo’. Brigitte en Karen, wordt het F1 of
toch I(mpossible)T(o)F(ind)? Pak ‘m, desnoods met de decoupeerzaag.
Meiden, bedankt voor jullie interesse, steun, en voor de gezelligheid op het lab. Maak mijn
labtafel nu maar weer vrij!
Eric Huizinga van de afdeling Kristallografie. Beste Eric, drie hoofdstukken in dit
proefschrift zijn in nauwe samenwerking met jou tot stand gekomen. Heel veel dank
daarvoor want het is de inhoud ervan zeker ten goede gekomen. Je hebt ongetwijfeld veel
geduld met me moeten hebben (iedere keer als ik ADP zie...) maar ik heb daardoor wel
ontzettend veel van je geleerd. Sterker nog, door jou ben ik het kijken naar en werken met
structuren ook nog leuk gaan vinden.
The Danish Connection at Rigshospitalet, Finn Nielsen, Claus Nerlov, and Joan
Christiansen, Kaere Finn, I don’t think that I have ever been more ‘radiant’ than I was in your
lab. It’s been fun and such a pleasure working with you throughout all these years, especially
with regard to Chapter 2. We will definitely continue our stimulating collaboration. Kaere
Claus, thanks a lot for your time and advices. We finally know how to reproduce the EMSA.
Kaere Joan, many thanks for helping me out in the lab at Rigshospitalet, for me sitting there
(looking good), for picking me up at the airport, for showing me Copenhagen, for serious
conversations, and a thousand laughs. I hope you will get a chance to see the tulips.
Adri Thomas van de afdeling Ontwikkelingsbiologie. Beste Adri, ongeveer een jaar geleden
vroeg ik je om hulp bij het isoleren van polysomen. Dat verliep voorspoedig (los van wat
fenol in je oog), net als onze samenwerking. Jij bent een all-round wetenschapper met een
flinke dosis humor. En ook al is een discussie voeren met jou af en toe net topsport, ik heb
ervan genoten en geleerd. Hoofdstuk 3 is mede daarom ook jouw verdienste en wat mij
betreft het begin van nog veel meer.
Prof. Ernest Beutler (Scripps Research Institute, La Jolla), it’s been a real privilege to have
been working with you on Chapter 2.
Voor met name het klinische deel van dit onderzoek ben ik bijzonder veel dank verschuldigd
aan Arjenne Kors en Ingrid Prins, en aan Karel Nieuwenhuis (dubbel bedankt!) van de
afdeling Hematologie. 
Verder dank aan alle klinici dankzij wie de deadline voor Hoofdstuk 4 toch nog werd
gehaald. P. Joosten (Medisch Centrum Leeuwarden), M. Karagiorga en V. Berdoukas
(‘Aghia Sophia’ Children’s Hospital, Athens), L.E. de Bruyne en R.J.Th. Ouwendijk (Ikazia
Ziekenhuis), A.H.P.M. Essink, E. de Vries, T. van Ditzhuijsen, en N. van Widdershoven
(Jeroen Bosch Ziekenhuis), K. Schmiegelow (Rigshospitalet, Copenhagen), A.A. van
Loosdrecht (VU Medisch Centrum), R. Tamminga (Academisch Ziekenhuis Groningen), G.
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van Waveren (Boven IJ Ziekenhuis), en P. Wijermans (Leyenburg Ziekenhuis). Een speciaal
woord van dank gaat in dit kader uit naar Tanja van Maanen (Westfries Gasthuis) voor haar zeer
gewaardeerde medewerking die verder reikt dan Hoofdstuk 4. 
Een groot deel van dit onderzoek zou uiteraard niet mogelijk zijn geweest zonder de dikwijls
bijzonder bereidwillige medewerking van de patiënten en hun familie. Allemaal enorm bedankt! 
Lab Speciële Haematologie oftewel Bep, Gerda, Jeanne, Lucy, Margriet, Marlène, (Walk On)
Paul, Yke, en Wietske. Heel veel dank voor het bepalen van al die enzym activiteiten (natuurlijk
waren ze altijd net de vorige dag gedaan), hitte-instabiliteits testen, het isoleren van DNA’tjes,
het opbergen en het prompt weer opzoeken daarvan. Jullie zullen wel eens een zucht geslaakt
hebben als ik daar weer bedremmeld stond met een buis, een formulier, een DNA cupje, een
rapport, kortom: een vraag. Nu dit achter de rug is ga ik me echt op ZIS en jullie SPYT-bestand
storten want “ik durf het nu echt bijna niet meer te vragen”.
Mijn kamermaten Mark en Thomas. ‘Three is a crowd’ is dus niet altijd waar, dat blijkt maar
weer. Bedankt voor het delen van een werkplek zonder planten, maar met mooie kasten; met
hele lelijke ‘desktop pictures’ maar ook met hele mooie (!); waar mensen elkaars verhalen
aanhoren (of doen alsof) maar waar ook een serene rust kan heersen; waar mensen elkaar wel
eens (letterlijk) buitensluiten maar niet in hokjes plaatsen; met weinig chagrijn en altijd een fikse
dosis humor. Nog wel een goede raad van deze senior roommate: Mark, nooit meer boerenkool
en Thomas, nooit meer tabellen in ‘Word’, want dat trek ik niet.
Bedankt, alle mensen van lab I, II, en III van de Hematologie waarmee en waartussen ik de
afgelopen vier jaar op een prettige manier heb vertoefd. De mensen van lab III wil ik in het
bijzonder bedanken voor hun gastvrijheid ten tijde dat onze onderzoeksgroep feitelijk een
eenmans fractie was: Jan-Willem, Gertie, Irlando, Suzanne, Gijsbert, Christine, Erik, Marjolein,
Kurt, Ingrid, Els, het werd op het laatst wellicht allemaal een beetje druk maar bovenal was het
gezellig en ik was met plezier bij jullie. Irlando en Suzanne, you’re next!
Jasper, onze samenwerking heeft zich niet vertaald naar dit boekje maar doet het niettemin goed
op mijn CV. Bedankt en succes in Zwolle (CU in bla bla).
Leden van de Promotie Commissie, Prof. Dr. Ph. G. de Groot, Prof. Dr. G. E. J. Staal, Prof. Dr.
D. Roos, Prof. Dr. R. M. Liskamp, en Dr. F. C. Nielsen, bedankt voor jullie interesse en
belangstelling.
Uit het oog maar zeker niet uit het hart, bedankt Rob Kraaijenhagen en Brenda van der Meijden
want in (toen nog) Ziekenhuis Eemland is het tenslotte allemaal begonnen. 
Mijn goede vriendin Diane. We kennen elkaar al meer dan 25 jaar en zulke vriendschappen
moet je koesteren. Ik ben dan ook bijzonder blij dat jij als paranimf naast mij wilt komen
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staan. Ik weet dat je je bijzonder goed zult voorbereiden, dus misschien schuif ik je wel een
vraagje toe.
Lieve papa en mama, ik hoop dat jullie met het lezen van dit boekje een beetje zullen
begrijpen wat mij de afgelopen jaren heeft beziggehouden. Ik weet in ieder geval zeker dat
ik dit nooit had kunnen doen zonder jullie liefde en steun. Bedankt voor het komen uit een
goed nest!
Lieve Noah en Aron, jullie zijn zonder twijfel het mooiste resultaat ooit en ook zonder twijfel
heb ik met name de laatste maanden veel te weinig tijd voor jullie gehad. Maar nu is het
boekje eindelijk af (nog nul bladzijden!), dus haal de tennisrackets, de voetbal, de kleine
treintjes, de lego, de auto’s, de vlieger, en alles wat ik nog moet lijmen maar tevoorschijn,
papa gaat met jullie aan de bak.
Tot slot, lieve Petra (ITPeetje). Jij bewijst des te meer dat je promoveren zeker niet alleen
doet. Als jij niet al die tijd steeds onvoorwaardelijk achter me was blijven staan, mij boven
achter de computer alle tijd en rust gunde terwijl jij beneden de boel draaiende hield, was dit
boekje er nooit gekomen. Het zegt heel veel over jou, want alleen jij maakt het verschil!
Salut!
Richard
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De auteur van dit proefschrift werd geboren op 1 juni 1966 te Nijkerk. Na het behalen van
het VWO diploma aan de Rooms Katholieke Scholengemeenschap “Eemland College
Noord” in 1984, werd in datzelfde jaar begonnen met de studie Sociale Geografie aan de
Universiteit Utrecht. In 1985 werd deze studie verruild voor de Medische
Laboratoriumopleiding aan de Hogeschool Utrecht. Na het behalen van het  diploma werd in
1989 een aanstelling verkregen bij Algemeen Christelijk Ziekenhuis Eemland te Amersfoort.
Van 1993 tot 1999 was de auteur daar werkzaam als specieel analist op het gebied van de
bijzondere hematologie en moleculaire diagnostiek. Als assistent in opleiding in het
Universitair Medisch Centrum Utrecht werd onder leiding van Prof. Dr. W. W. van Solinge
en Prof. Dr. J. J. M. Marx in de periode januari 2000 tot december 2003 het onderzoek
verricht dat in dit proefschrift is beschreven. Momenteel is de auteur werkzaam als
onderzoeker bij de Rode Bloedcel Pathologie Onderzoeksgroep binnen het Centraal
Diagnostisch Laboratorium van het Universitair Medisch Centrum Utrecht. 
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